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living	 organisms	 including	 the	 human	malaria	 parasite	Plasmodium	 falciparum.	While	
the	parasite	has	the	capacity	to	generate	CoA	from	pantothenate,	it	cannot	produce	this	
nutrient	 de	 novo,	 and	 as	 a	 result	 depends	 on	 external	 supplies.	 Processes	 in	 the	 CoA	
metabolic	pathway	have	been	 identified	as	possible	 targets	 for	drug	development	and	
pantothenate	 analogues	 as	 agents	 that	 can	 interfere	 with	 those	 processes	 to	 block	
parasite	development.	
	
In	 this	 dissertation	 it	 is	 shown	 that	 the	 class	 of	 pantothenate	 analogues	 known	 as	N‐
substituted	 pantothenamides	 (PanAms)	 and	 N‐substituted	 pantoyltauramides,	 inhibit	
the	growth	of	intraerythrocytic‐stage	P.	falciparum	parasites	at	sub‐	and	low	micromolar	
concentrations	 respectively.	 In	 both	 cases,	 the	 compounds	 inhibited	 parasite	
proliferation	through	 inhibition	of	pantothenate‐dependent	processes.	 It	 is	also	shown	
that	 the	 antiplasmodial	 potency	 of	 PanAms	 can	 be	 strengthened	 through	 structural	
modifications	 rendering	 the	 compounds	 less	 susceptible	 to	 degradation	 by	 enzymes	




the	 compounds	 serving	 as	 alternative	 substrates	 for	 pantothenate	 kinase	 (PanK),	 the	












in	 feitlik	 alle	 lewende	 organismes,	 insluitend	 die	 malaria	 parasiet	 Plasmodium	
falciparum	wat	in	die	mens	voorkom.	Die	parasiet	het	die	kapasiteit	om	KoA	te	genereer	
vanaf	 pantotenaat,	maar	 kan	 dié	 spesifieke	 voedingstof	 nie	de	novo	 produseer	 nie	 en	
moet	gevolglik	op	eksterne	bronne	staatmaak.	Prosesse	in	die	KoA	metaboliese	padweg	




gesubstitueerde	 pantoteenamiede	 (PanAms)	 en	N‐gesubstitueerde	 pantoïeltauramiede	
inhibeer	 die	 groei	 van	 eritrositiese‐fase	 P.	 falciparum	 by	 sub‐	 en	 lae	 mikromolare	
konsentrasies	onderskeidelik.	In	beide	gevalle	inhibeer	die	verbindings	die	verspreiding	
van	parasiete	deur	pantotenaat‐afhanklike	prosesse	te	inhibeer.	Dit	is	ook	bewys	dat	die	
antiplasmodiale	werking	 van	PanAms	versterk	 kan	word	deur	middel	 van	 strukturele	
veranderinge	 wat	 die	 verbindings	 minder	 vatbaar	 maak	 vir	 afbraak	 deur	 ensieme	
bekend	 as	 panteteinases,	 wat	 natuurlik	 en	 alomteenwoordig	 in	 soogdiere	 voorkom,	
veral	in	serum.	
	
Ten	 slotte	 is	 dit	 ook	 getoon	 dat	 die	 antiplasmodiale	 werking	 wat	 PanAms	 toon	
veroorsaak	 word	 deur	 as	 alternatiewe	 substrate	 vir	 pantotenaatkinase	 (PanK),	 die	
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Malaria	(also	known	as	paludism,	“chills	and	fever”,	marsh	 fever,	or	 jungle	 fever),	or	a	
disease	 resembling	 it,	 was	 first	 reported	 over	 4,000	 years	 [1].	 In	 2700	 BC,	 several	
characteristic	symptoms	of	the	disease	were	described	in	the	Nei	Ching,	an	ancient	book	
of	Medicine	 edited	by	 the	 “Yellow	Emperor”	Huangdi	 of	 China.	 By	 the	4th	 Century	BC,	
malaria	was	widely	recognised	in	Greece	where	it	was	responsible	for	many	deaths	[1].	
On	a	worldwide	basis,	the	disease	has	probably	been	the	most	serious	ailment	affecting	









When	 Charles	 Laveran	 first	 saw	 malaria	 parasites	 in	 the	 erythrocytes	 of	 a	 patient	
suffering	from	the	disease	in	Constantine,	Algeria,	then	a	French	territory	in	1880,	little	
was	 known	 about	 their	 transmission	 [1‐3].	 In	 1897,	 Ronald	 Ross	 discovered	 malaria	
parasites	in	the	gut	of	a	mosquito	that	had	been	feeding	on	a	patient	suffering	from	the	
disease.	 Later,	 using	a	bird	malaria	model,	 he	demonstrated	 the	 role	of	mosquitoes	 in	
transmitting	 the	 parasites.	 By	 9th	 of	 July	 1898	 Ross	 had	 established	 that	 mosquitoes	
served	 as	 intermediate	 hosts;	 the	 malaria	 parasites	 developed	 in	 the	 gastrointestinal	
tract	 of	 the	 insect	 before	 migrating	 to	 the	 salivary	 glands	 from	 where	 they	 were	
transmitted	to	the	next	vertebrate	victim	during	succeeding	blood	meals	[1,	3].	








Organisation	 (WHO)	 estimates	 that	 219	 million	 clinical	 cases	 of	 the	 disease	 were	
reported	 in	 2010,	 resulting	 in	 approximately	 660	 000	 deaths	 [4].	 Other	 studies	 using	
different	 prediction	 tools	 incorporating	 documented	 and	 non‐documented	 deaths	
estimate	 that	 the	 number	 of	 malaria	 victims	 is	 higher,	 and	 may	 have	 reached	 1.24	
million	 [5].	 The	 disease	 burden	 is	 particularly	 severe	 in	 sub‐Saharan	 Africa,	 where	
approximately	 90%	 of	 fatalities	 occur	 [4,	 6].	 Children	 and	 pregnant	 women	 —	
particularly	 during	 their	 first	 pregnancy	—	are	 amongst	 the	most	 affected	 [5].	 In	 this	
region	 of	 the	 African	 continent,	 one	 child	 dies	 from	 malaria	 every	 minute,	 while	
gestational	malaria	is	responsible	for	up	to	200	000	infant	deaths	each	year	[6].	Asia	and	
Latin	 America	 are	 also	 affected,	 and	 to	 a	 lesser	 extent,	 the	 Middle	 East	 and	Western	
Europe	[7].	
	

















in	 the	 Greater	Mekong	 sub‐region	 (Cambodia,	 Lao,	Myanmar,	 Thailand,	 Viet	 Nam	 and	
China:	Yunnan	Province	and	Guangxi	Zhuang	Autonomous	Region)	in	Southeast	Asia	are	
highly	 affected,	 while	 several	 adjacent	 cities	 are	 essentially	 malaria	 free	 [12,	 13].	 In	





The	 five	 species	of	malaria	parasites	 that	 infect	humans	naturally,	 i.e.	P.	 falciparum,	P.	
vivax,	 P.	 malariae,	 P.	 ovale	 and	 P.	 knowlesi,	 exhibit	 some	 differences	 in	 their	
developmental	stages.	However,	the	life	cycle	of	all	of	them	include	asexual	and	sexual	











(at	 this	 stage	 called	 sporozoites)	 contained	 in	 its	 salivary	 glands	 into	 the	 peripheral	
blood	of	the	victim	[14,	15].	After	approximately	30	minutes,	the	sporozoites	initiate	the	
so‐called	 liver	 stage	 as	 they	 reach	 the	 liver	 and	 penetrate	 its	 parenchyma	 cells	
(hepatocytes).	 It	 is	here	where	 they	develop	 for	between	5‐10	days	depending	on	 the	
Plasmodium	 species.	 As	 the	 parasites	multiply	 in	 the	 hepatocytes,	 the	 liver	 cells	 swell	




After	 invading	 the	 RBC,	 the	 merozoites	 enter	 a	 period	 of	 low	 metabolic	 activity	 for	
around	15	hours	[17];	during	this	time,	the	parasite	is	often	called	“ring	stage”	due	to	its	
ring‐shaped	 appearance	 under	 light	 microscopy.	 Following	 the	 apparently	 dormant	
period,	 the	parasite	 initiates	 a	 vigorous	metabolic	 phase,	 feeding	on	haemoglobin	 and	
inducing	biochemical	changes	within	the	RBC	while	developing	through	the	trophozoite	
stage	 and	 into	 the	 schizont	 stage,	 which	 is	 reached	 approximately	 36	 hours	 post‐
invasion.	 During	 the	 next	 12	 hours	 the	 schizont	matures	 and	 divides,	 completing	 the	
intraerythrocytic	stage	with	the	rupture	of	the	RBC	and	release	of	around	20	daughter	
merozoites,	within	 approximately	 48	 hours	 post‐invasion	 in	 the	 case	 of	P.	 falciparum,	
the	most	virulent	malaria	parasite,	and	the	one	most	prevalent	in	the	African	continent	
[16,	18‐20].	






Once	 the	 newly	 formed	 merozoites	 are	 released	 from	 the	 ruptured	 RBC,	 most	 are	
destroyed	 by	 the	 host	 immune	 system,	 however	 the	 few	 that	 survive	 go	 on	 to	 infect	
fresh	RBCs	and	reinitiate	the	intraerythrocytic	cycle.	It	is	important	to	note	that,	for	the	
parasite	 to	 complete	 its	 life	 cycle	 in	 the	 mosquito,	 after	 several	 cycles	 of	 asexual	
replication	 –	 due	 to	 not	 yet	 very	 well	 understood	 triggers	 –	 a	 subset	 of	 the	
intraerythrocytic	merozoites	do	not	undergo	 schizogony	 (development	 into	 schizonts)	
but	 alternatively	 differentiate	 into	 male	 (microgametocyte)	 and	 female	
(macrogametocyte)	sexual	forms	[16,	19]	(figure	1.2).	
	
After	 invading	 the	 hepatocytes	 some	 sporozoites	 do	 not	 develop	 into	 merozoites.		
Instead	 they	 remain	 dormant	 (hypnozoite	 stage)	 for	 weeks,	 months	 or	 even	 years,	





As	 gametocytes	 (transmission	 stage)	 in	 RBCs	 are	 ingested	 by	 female	 Anopheles	
mosquitoes	 during	 a	 blood	meal,	 the	membrane	of	 the	 erythrocyte	 ruptures	 releasing	
the	sexual	 forms	of	 the	parasite.	 In	 the	mid	gut	of	 the	mosquito,	 the	microgametocyte	
fuses	with	the	macrogametocyte	to	form	a	zygote.	The	zygote	then	differentiates	into	a	
motile	form	called	an	ookinete.	After	18‐24	hours,	the	ookinete	penetrates	the	mosquito	
midgut	 wall	 where	 it	 matures	 into	 a	 sporozoite‐filled	 oocyst.	 The	 oocyst	 then	 bursts	
releasing	up	to	10	000	sporozoites,	which	move	to	the	lumen	of	the	mosquito’s	salivary	
glands	where	they	remain	viable	during	the	whole	lifespan	of	the	mosquito	and	ready	to	
be	 injected	and	 initiate	 a	new	 infection	on	 the	next	 victim.	Depending	on	 the	parasite	










Figure	1.2	 –	Plasmodium	 falciparum	 life	 cycle	 comprising	mosquito	 stage,	 liver	 stage	 and	 the	




Practically	 all,	 except	 cerebral	 malaria,	 clinical	 signs	 and	 symptoms	 of	 malaria	 are	
associated	with	the	intraerythrocytic	stage	of	the	parasite’s	life	cycle.	During	this	stage,	
the	 synchronous	 burst	 of	 RBCs	 and	 release	 of	merozoites	 as	well	 as	 the	 discharge	 of	
massive	 amounts	 of	 metabolic	 waste	 (including	 haemozoin,	 also	 called	 the	 malaria	


















inappropriate	 treatment	or	when	 infections	are	 complicated	by	major	organ,	blood	or	
metabolic	 impairments.	 In	 such	 cases	 the	 clinical	 manifestations	 of	 the	 disease	 may	
include	 acute	 severe	 anaemia	 [22]	 and	 haemoglobinuria	 as	 a	 result	 of	 massive	
haemolysis,	 impaired	haematopoesis	 [23],	 coagulopathies	 [24,	 25],	 hypotension,	 acute	
respiratory	distress	syndrome	[25],	acute	renal	failure	[25,	26],	jaundice,	hypoglycaemia	





At	 present,	 the	 control	 of	 malaria	 relies	 essentially	 on	 reducing	 the	 contact	 between	




The	 control	 of	mosquitoes	 is	 achieved	mainly	 through	 spraying	 of	 insecticides	 on	 the	
interior	 walls	 of	 homes	 (indoor	 residual	 spraying	 (IRS))	 as	 well	 as	 use	 of	 insecticide	
treated	bed	nets	(ITN)	and	garments.	Other	strategies	for	vector	control	include	the	less	












Intensive	 research	 in	 vaccine	 development	 is	 ongoing	 in	 different	 parts	 of	 the	world.	
Several	 vaccine	 candidates	 are	 in	 different	 stages	 of	 development,	 with	 the	 first	
recombinant	P.	falciparum	vaccine,	RTS,S/AS01	currently	in	Phase	III	clinical	trials	[27].	
	
Reports	of	 the	vaccine	 tested	 in	Africa	 indicate	 that	 its	efficacy	has	been	43.6%	 in	 the	
first	 year	 but	 was	 ‐0.4%	 in	 the	 fourth	 year.	 Overall,	 the	 vaccine	 was	 effective	 in	
decreasing	clinical	malaria	in	children	only	by	16.8%	over	a	four	year	period	[28].	More	
efficacious	 vaccines	 that	 can	 be	 used	 to	 prevent	 clinical	 disease	 caused	 by	 the	 most	
dangerous	malaria	parasites	(P.	falciparum	and	P.	vivax)	are	desperately	needed,	as	well	
as	 support	 for	 eradication	 efforts	 through	 induction	 of	 immunity	 that	 blocks	 parasite	
transmission.	
	
As	discussed	by	Birkett	et	al.	 [28],	 the	 challenges	 in	malaria	 vaccine	development	 are	
related	 to	 (i)	 the	 lack	of	well‐characterized	 target	 immunogens	 and	 the	 inexistence	of	
clear	 correlates	 of	 protection	 allowing	 the	 development	 of	 a	 vaccine	 directed	 to	 all	
stages	of	the	life	cycle	of	the	most	important	Plasmodium	parasites;	(ii)	a	limited	amount	
of	effective	and	secure	delivery	systems	that	induce	robust	protective	immunity;	(iii)	the	
need	 for	 vaccines	 designed	 to	 provide	 “herd	 protection”	 by	 targeting	 sexual	 stage	














A	number	of	 antimalarial	drugs	have	been	used,	 the	vast	majority	of	which	 target	 the	
clinically	 important	 intraerythrocytic	 stage	 of	 the	 parasite.	 The	most	 commonly	 used	
compounds	 belong	 to	 three	 major	 classes	 including	 quinolines,	 antifolates	 and	




Quinine,	 the	 historic	 representative	 of	 the	 antimalarial	 quinolines,	 is	 an	 alkaloid	
extracted	from	the	bark	of	the	Cinchona	tree.	It	was	the	first	effective	medicine	used	for	
treating	malaria	caused	by	P.	falciparum.	Quinine	(1,	figure	1.3)	was	the	antimalarial	of	
choice	until	 the	1940s	when	more	active	and	 less	 toxic	synthetic	analogues,	several	of	




the	 mainstay	 antimalarial	 compound	 for	 several	 decades.	 It	 is	 considered	 one	 of	 the	
most	 successful	 antimalarial	 drugs	 ever	 prepared,	 bearing	 in	 mind	 its	 low	 synthetic	
costs,	chemical	stability,	ease	of	administration	and	safety	[31].	CQ	interferes	with	haem	






(derived	 from	 haemoglobin	 digestion)	 detoxification	 in	 Plasmodium	 parasites.	 The	
compound	increases	the	intravesicular	pH	[32,	33]	in	parasitized	erythrocytes	and	binds	
to	haem,	thus	preventing	its	bio	crystallization	and	conversion	into	non‐toxic	haemozoin	
crystals,	 which	 then	 results	 in	 an	 accumulation	 of	 cytotoxic	 haem,	 eventually	





in	P.	 falciparum	and,	 to	a	 lesser	degree,	P.	vivax	developing	resistance	 to	 the	drug	[36,	
37]	(Figure	1.6).	Plasmodium	 falciparum	 resistance	has	been	reported	practically	 in	all	
endemic	 countries	 [37‐40],	 resulting	 in	 recommendations	 for	 its	 discontinued	 use	 as	




Single	 nucleotide	 polymorphisms	 (SNPs)	 in	 the	 genes	 encoding	 the	 P.	 falciparum	 CQ	
resistance	 transporter	 (PfCRT)	 and	multidrug	 resistance	 transporter	 1	 (PfMDR)	 have	
been	 linked	 to	 reduced	 parasite	 susceptibility	 to	 CQ,	 other	 4‐aminoquinolines	 and	












[46‐48].	 Newer	 8‐aminoquinolines	 such	 as	 tafenoquine	 (6)	 and	 also	 combinations	 of	
bulaquin	(7)	and	chloroquine	(2)	are	currently	undergoing	clinical	trials	[48,	49],	while	
pamaquine	 (8)	 was	 discontinued	 many	 years	 ago	 due	 to	 toxicity	 issues	 [50].	 It	 is	
expected	 that	 the	 new	 chemotherapies	 under	 development	 should	 become	 available	
soon	 and	 contribute	 to	 expanding	 the	 limited,	 yet	 most	 wanted	 repertoire	 of	
gametocidal	 drugs.	 These	 will	 play	 the	 important	 role	 of	 blocking	 transmission	 of	













Antifolate	 antimalarials	 are	 compounds	 that	 impair	 the	metabolism	 of	 the	 vitamin	 B9	
(folate),	 an	 essential	 pathway	 for	 the	 survival	 of	 malaria	 parasites.	 The	 compounds	
selectively	target	the	asexual	stage	of	Plasmodium	parasites	by	impairing	the	production	
of	 pyrimidine	 nucleotides	 which	 are	 required	 as	 building	 blocks	 for	 the	 synthesis	 of	
deoxyribonucleic	 acid	 (DNA)	 [51].	 Proguanil	 (9,	 figure	 1.4),	 the	 precursor	 of	 the	
antiplasmodially	active	metabolite	cycloguanil	(10),	is	a	triazine	chloroguanide	that	was	
introduced	 into	 clinical	 use	 in	 the	 1940s	 following	 the	 development	 of	 resistance	 of	





Sulfadoxine	 (14,	 figure	 1.4),	 a	 sulfonamide	 antibiotic,	 is	 structurally	 related	 to	 p‐
aminobenzoic	 acid	 (PABA)	 and	 competitively	 inhibits	 another	 key	metabolic	 enzyme,	








was	 reported	 soon	 after	 their	 introduction	 into	 clinical	 use	 (Figure	 1.6),	 this	 class	 of	
compounds,	particularly	the	combination	of	pyrimethamine	(11)	with	sulfadoxine	(14)	







CQ‐resistant	malaria	 in	 several	 sub‐Saharan	African	 countries	until	 the	1990s	 [38,	55,	
56].	 Since	 then,	 alternative	 antimalarial	 antifolates	 have	 been	 used,	 including	 the	
combination	 of	 chlorproguanil	 (12)	 with	 dapsone	 (13)	 (also	 known	 as	 LapDap®).	
However,	 similar	 to	 some	 aminoquinolines,	 this	 combination	 was	 withdrawn	 after	
concerns	with	 safety	 in	 glucose‐6‐phosphate	dehydrogenase	 (G6PD)	deficient	patients	
[56‐58].	
	
New	 antifolate	 chemotherapies	 including	 the	 Medicines	 for	 Malaria	 Venture	 (MMV)’s	
P218,	 which	 is	 effective	 against	 both	 CQ‐	 and	 pyrimethamine‐resistant	 as	 well	 as	
sensitive	 parasites,	 are	 currently	 under	 development	 [59].	 The	 combination	 of	
antifolates	with	compounds	acting	on	different	targets	is	regarded	as	showing	potential	




             	
Figure	1.4	–	Structures	of	selected	antifolate	antimalarial	drugs.	
	







Endoperoxides	are	a	 class	of	 antimalarial	 compounds	of	which	artemisinin	 (15,	 figure	
1.5),	 also	 known	 as	 qinghaosu,	 is	 the	 prototype.	 These	 compounds	 are	 currently	 the	
mainstays	of	antimalarial	treatment.	
	
Artemisinin	 and	 its	 derivatives	 artemether	 (ATH;	 16),	 artesunate	 (17)	 and	
dihydroartemisinin	 (DHA;	18),	 collectively	 called	 artemisinins,	 have	 a	 potent	 and	 fast	
acting	activity	against	the	early	and	mature	intraerythrocytic	stages	of	P.	vivax	as	well	as	













released	 from	the	haem	during	haemoglobin	digestion	 through	 the	direct	 reduction	of	
the	 endoperoxide	 bond	 of	 artemisinins.	 The	 generated	 reactive	 oxygen	 species	 (ROS)	
then	 damage	 the	 parasites’	 food	 vacuole	membrane	 and	 affect	mitochondrial	 electron	
transport	functions,	eventually	resulting	in	parasite	death	[65,	66].	It	is	also	thought	that	






the	 antimalarial	 activity	 of	 artemisinins	may	 result	 from	 the	 disrupted	 cellular	 redox	
cycling	 [67,	 68].	 Indeed,	 artemisinin	 activity	 depends	 on	 haemoglobin	 digestion	 [69],	
which	is	in	accordance	to	the	drug’s	specificity	and	efficacy	against	other	haemoglobin‐
degrading	 microorganisms	 [70].	 Other	 theories	 suggest	 that	 artemisinin	 oxidizes	
parasite	Flavin	Adenine	Dinucleotide	 (FADH2)	 and	parasite	 redox‐active	 flavoenzymes	
[71]	 or	 it	 is	 activated	 by	 reduction	 in	 the	 parasite	mitochondria	 [72],	 both	 processes	
resulting	 in	parasite	death	due	to	 increase	 in	ROS.	Still	other	postulations	suggest	 that	
artemisinin	 inhibits	 a	 homologue	 of	 the	 sarcoendoplasmic	 reticulum	 Ca2+‐ATPase	
(SERCA)	 in	 P.	 Falciparum	 [73].	 Furthermore,	 pharmacologically	 active	 metabolites	 of	











Studies	 using	microarray	 and	 biochemical	 analyses	 revealed	 that	P.	 falciparum	MDR1	
and	 CRT	 gene	 amplification,	 polymorphisms	 at	 codons	 241,	 86,	 and	 76	 of	 PFE0775C,	
elevation	 of	 the	 antioxidant	 defence	 network,	 and	 increased	 expression	 of	 many	
chaperones,	are	involved	in	the	mechanisms	of	parasite	resistance	to	DHA	and	ATH	[67,	
78,	 79].	 The	 identification	 of	 these	 elements	 can	 facilitate	 the	 discovery	 of	 new	
antimalarial	compounds	that	target	them	or	other	elements	of	the	specific	biochemical	






pathways	 involved.	 Promising	 new	 compounds	 may	 be	 able	 to	 prevent	 P.	 falciparum	
from	entering	an	inactive	stage	altogether,	or	greatly	prolong	the	time	at	which	parasites	
recrudesce	in	vitro	after	artemisinin	exposure.	One	clinical	trial	showed	that	increasing	
the	 daily	 dose	 of	 artemisinin	 from	 4	 mg/Kg	 to	 6‐8	 mg/kg	 was	 not	 effective	 as	 a	
treatment	option	since	the	dose	range	did	not	accelerate	the	clearance	of	parasites	from	
blood	 circulation	 and	 was	 associated	 with	 increased	 toxicity	 including	 temporary	





and	 combinations	 of	 artemisinins	 with	 other	 antimalarial	 compounds	 including	
mefloquine,	 doxycycline	 or	 sulfadoxine/pyrimethamine	 (usually	 called	 artemisinin‐
based	combination	therapy,	or	simply	ACT),	remain	effective	and	are	recommended	as	




protocols	 for	 preparation	 of	 artemisinin,	 the	 sole,	 still	 largely	 effective,	 compound	
currently	in	clinical	use,	have	been	developed	[82‐84],	the	main	source	continues	to	be	













implementation	 of	 strategies	 to	 (i)	 extend	 the	 useful	 life	 span	 of	 artemisinin,	 and	 (ii)	
generate	 novel	 combination	 therapies	 not	 based	 on	 currently	 used	 drugs,	 and	
combinations	 that	 target	 essential	 parasite	 pathways	 and	 biological	 processes	 not	
explored	by	the	existing	compounds. 
           
Figure	1.5	–	Structures	of	selected	sesquiterpene	endoperoxide	antimalarial	drugs.	



























identified	 targets	 as	well	 as	 existing	 pharmacophores	 (defined	 as	 ensembles	 of	 steric	
and	 electronic	 features	 that	 are	 necessary	 to	 ensure	 the	 optimal	 intermolecular	




to	 develop	 new	 chemotherapies.	 Among	 other	 examples,	 this	 approach	 has	 been	
explored	 to	 produce	 combinations	 of	 Amodiaquine/Sulfadoxine/Pyrimethamine	 [87];	
Amodiaquine/Artesunate	 [88];	 Chlorproguanil/Dapsone	 [89]	 and	 more	 recently,	 to	




Figure	 1.7	 –Structure	 of	 lumefantrine	 (19),	 a	 compound	 used	 in	 combination	 with	 other	
chemotherapeutics	 for	 improved	 antimalarial	 activity	 of	 formulations	 including	 Coartem®	 or	
Riamet®.	
	
Natural	 products,	 mainly	 derived	 from	 plants,	 constitute	 another	 approach	 for	
developing	 antimalarial	 chemotherapies	 [91].	 Screening	of	 natural	 products	 known	 to	
possess	antipyretic	and	other	pharmacological	properties	can	be	 the	starting	point	 for	






medicinal	 chemistry	endeavours	 [92,	93].	Natural	products	are	 the	sources	of	 the	 two	




Using	drugs	 that	 have	been	developed	 for	 other	 diseases	 is	 also	 a	possibility	 that	 has	
been	 explored	 for	 antimalarial	 drug	 development.	 Such	 drugs	might	 be	 active	 against	
malaria	parasites	by	acting	against	orthologs	of	their	targets	 in	other	systems,	or	their	
antiplasmodial	 activity	may	 be	 through	 different	mechanisms	 [29].	 Exploring	 such	 an	
approach	 has	 the	 advantage	 of	 making	 use	 of	 compounds	 —	 regardless	 of	 their	
mechanism	 of	 action	 —	 that	 have	 already	 been	 developed	 and	 approved	 for	 use	 in	
humans,	 which	 translates	 into	 reduced	 costs	 of	 development	 and	 less	 time	 spent	 in	
product	development	prior	to	introduction	into	the	market	[29].	This	approach	can	also	
make	use	of	inexpensive	drugs,	particularly	after	production	restrictions	associated	for	




“resistance	 reverser”	 compounds	 is	 another	 approach	 used	 in	 antimalarial	 drug	
development.	 A	 number	 of	 clinically	 used	 drugs,	 including	 the	 antihypertensive	
verapamil	(20,	figure	1.5)	[96,	97]	and	the	antidepressant	desipramine	(21)	[98],	have	
been	 shown	 to	 reverse	 the	 resistance	 of	 P.	 falciparum	 parasites	 to	 CQ,	 opening	 the	
possibility	 of	 co‐administration	 of	 CQ	 with	 resistance	 modulators	 for	 antimalarial	
treatment.	
	










It	 is	 important	 to	note	 that	 the	use	of	 a	 single	 resistance	 reverser	drug	often	requires	
administration	of	extremely	high	concentrations	of	the	compound	in	order	to	achieve	a	
positive	 effect.	 However,	 when	 combinations	 of	 resistance	 modulators	 including	
verapamil,	 desipramine	 and	 trifluoperazine	 (22,	 figure	 1.7)	 are	 applied,	 clinically	




activity	 is	 probably	 the	mostly	 exploited	 approach	 in	 antimalarial	 drug	 development.	
Under	 this	 strategy	 (as	 well	 as	 the	 ones	 discussed	 previously),	 knowledge	 of	 the	
mechanism	 of	 action	 or	 the	 biological	 target(s)	 of	 the	 compound	 is	 not	 necessarily	
required.	 This	 approach	 has	 successfully	 been	 applied,	 for	 example,	 to	 prepare	more	
effective	 quinine	 analogues	 including	 CQ	 (2),	 amodiaquine	 (3),	 primaquine	 (5),	 and	
mefloquine	 (4)	 (Figure	 1.3)	 and	 also	 to	 prepare	 more	 effective	 antifolates	 and	






artemisinins,	 based	 on	 the	 chemical	 structures	 of	 their	 parent	 compounds	
pyrimethamine	(11)	and	artemisinin	(15),	respectively	[101‐103].	
	
It	 is	 known	 that	 antimalarial	 drugs	 are	 based	 on	 only	 about	 30	 different	 chemical	
scaffolds	of	which	only	around	10	are	clinically	useful	[103].	 In	addition	to	the	 limited	
diversity	of	scaffolds,	the	drawbacks	of	chemical	modifications	of	existing	compounds	—	
particularly	 those	 to	 which	 parasites	 have	 developed	 resistance	 —	 are	 that	 such	







Possibly	 the	 most	 innovative	 and	 also	 challenging	 approach	 in	 antimalarial	 drug	
development	is	identifying	new	targets	and	then	designing	compounds	that	act	on	such	
targets.	 Nevertheless,	 the	 readily	 accessible	 TDR	 ‐	 Targets	 Database	 website	
(http://tdrtargets.org)	 that	 integrates	 genomic	 information	 with	 functional	 data	
(including,	 for	 example,	 data	 on	 gene	 expression,	 phylogeny	 and	 essentiality,	 that	 has	
been	 collected	 from	 various	 sources),	 associated	 with	 our	 current	 knowledge	 of	 the	
parasite	 biology	 and	 biochemistry	 and	 the	 availability	 of	 technologies	 for	 genetic	
manipulation,	 constitute	 some	 of	 the	 necessary	 tools	 for	 identification	 and	
characterisation	of	drug	targets	and	development	of	effective	chemotherapies.	
	









that	allow	 for	selectivity,	 can	be	exploited	 for	drug	development.	For	obvious	reasons,	













that	predicting	which	 targets	are	essential	 for	 the	parasite	while	 in	 the	human	host	 is	
often	 difficult.	 Additionally,	 well‐validated	molecular	 targets	 do	 not	 always	 yield	 new	





screening.	 This	 has	 resulted	 in	 the	 identification	 of	 several	 thousands	 of	 potent	






antimalarial	 compounds	 [103,	 105‐108],	most	 of	which	 are	 particularly	 active	 against	
the	 clinically	 important	 asexual	 intraerythrocytic‐stage	 of	 the	 parasite	 life‐cycle,	
although	some	are	also	active	against	the	liver‐stage	and	sexual	forms.	
	
Although	 whole‐cell	 phenotypic	 drug	 screening	 has	 so	 far	 been	 very	 successful	 in	
identifying	new	antiplasmodial	compounds,	the	challenge	remains	to	elucidate	the	mode	
of	action	(MoA)	of	these	compounds	in	order	to	facilitate,	through	medicinal	chemistry,	
the	 improvements	 required	 for	 better	 antimalarial	 activity	 as	 well	 as	 better	
pharmacokinetics	profiles.	
	





Pantothenate	 (23,	 Scheme	 1.1),	 the	 ionized	 form	 of	 pantothenic	 acid,	 also	 known	 as	
vitamin	 B5,	 is	 a	 water‐soluble	 compound	 with	 a	 name	 derived	 from	 the	 Greek	 word	
pantothen	 meaning	 "from	 everywhere".	 It	 gets	 this	 name	 as	 a	 result	 of	 its	 ubiquitous	
presence	 in	small	quantities	 in	virtually	all	natural	 food	sources	 [109]	–	consequently,	
vitamin	 B5	 deficiency	 is	 very	 rare,	 although	 it	 has	 been	 reported	 in	 cases	 of	 severe	
malnutrition	in	World	War	II	prisoners	[109].	When	occurring,	B5	avitaminosis	results	in	
symptoms	that	include	fatigue,	allergies,	nausea,	numbness,	painful	burning	and	tingling	
in	 the	 feet,	 and	 abdominal	 pain;	 all	 of	 which	 are	 reversed	 by	 pantothenic	 acid	
supplementation	[109].	
	






Certain	 bacteria,	 fungi	 and	 plants	 have	 the	 ability	 to	 synthesise	 pantothenate	de	novo	
while	animals	and	eukaryotes	(and	some	prokaryotes)	must	acquire	this	nutrient	from	
external	 sources.	 Following	 uptake	 or	 de	 novo	 synthesis,	 pantothenate	 is	 used	 to	














arrows	 represent	 movement	 into	 the	 apicoplast	 (grey	 square,	 a	 vestigial	 plastid	 organelle	
derived	 from	a	 secondary	 endosymbiosis,	which	 is	 part	 of	 an	 apical	 structure	designed	 to	 aid	
entry	of	the	parasite	into	a	host	cell	and	also	hosts	several	metabolic	processes	including	lipid,	
isoprenoid,	 haem,	 amino‐acids,	 ion‐sulphur	 cluster	 synthesis	 among	 other	 functions)	 –	 in	 the	














by	 phosphopantothenoylcysteine	 synthetase	 (PPCS)	 to	 form	 4'‐
phosphopantothenoylcysteine	 (25).	 Following	 this,	 the	 cysteine	 portion	 of	 4'‐
phosphopantothenoylcysteine	 is	 decarboxylated	 in	 a	 reaction	 catalysed	 by	
phosphopantothenoylcysteine	 decarboxylase	 (PPCDC)	 resulting	 in	 4’‐
phosphopantetheine	 (26).	 In	 the	 fourth	 step,	 phosphopantetheine	 adenylyltransferase	
(PPAT)	 catalyses	 the	 attachment	 of	 an	 adenylyl	 group	 to	 4’‐phosphopantetheine	
resulting	 in	 the	 formation	 of	 dephospho‐CoA	 (27).	 In	 the	 final	 step,	 dephospho‐CoA	
kinase	(DPCK)	catalyses	the	phosphorylation	of	dephospho‐CoA	at	the	3’‐position	of	the	
ribose	 moiety	 culminating	 in	 the	 production	 of	 CoA	 (28)	 [111].	 The	 4’‐
phosphopantetheine	prosthetic	group	is	then	covalently	attached	to	a	conserved	serine	
residue	 in	 a	 pre‐formed	 inactive	 acyl	 carrier	 protein	 (apo‐ACP)	 converting	 it	 into	 an	
active	 holo‐ACP	 form	 in	 a	 reaction	 catalysed	 by	 ACP	 synthase	 (AcpS).	 ACP	 hydrolase	
(AcpH)	 is	 then	 responsible	 for	 4’‐phosphopantetheine	 prosthetic	 group	 recycle	 [112,	
113].	
	
It	 has	 been	 shown	 that	 only	 the	 dextrorotatory	 (D)‐(‐)	 isomer	 of	 pantothenate	 has	




CoA	 is	 essential	 in	many,	 if	 not	 all,	 living	 organisms.	 All	 genome	 sequences	 known	 to	
date	 encode	 enzymes	 that	 utilize	 CoA	 or	 its	 thioesters	 as	 substrates.	 Among	 other	
activities,	 CoA	 functions	 as	 the	 universal	 acyl	 group	 carrier	 and	 carbonyl‐activating	
group	 in	 several	 critical	 reactions	 in	 cellular	 metabolism.	 It	 is	 the	 source	 of	 the	 4’‐
phosphopantetheine	prosthetic	group	as	already	discussed.	ACP	and	CoA	play	a	critical	



















of	 intraerythrocytic‐stage	 malaria	 parasites	 in	 human	 RBCs.	 Since	 then,	 their	
groundbreaking	 discovery	 has	 aided	 the	 completion	 of	 other	 remarkable	 studies	 and	
proved	 to	 be	 an	 essential	 tool	 for	 antimalarial	 drug	 research.	 For	 instance,	 while	
investigating	the	nutritional	requirements	for	P.	falciparum	grown	in	in	vitro	continuous	
cultures,	Divo	and	co‐workers	[123]	demonstrated	that	the	parasite	exhibits	an	absolute	
requirement	 for	 pantothenate.	 In	 their	 studies	 the	 authors	 showed	 that	 parasite	
proliferation	was	inhibited	by	82%	when	all	water‐soluble	vitamins	were	omitted	from	
the	culture	medium.	On	the	other	hand,	parasite	proliferation	was	normal	when	each	of	










Under	 physiological	 conditions	 the	 membrane	 of	 normal,	 uninfected	 human	
erythrocytes	 can	be	 considered	 to	be	 impermeable	 to	pantothenate,	 since	 the	 vitamin	
crosses	the	membrane	at	a	very	slow	rate	[124].	However,	it	has	been	demonstrated	that	
pantothenate	 avidly	 traverses	 the	 membrane	 of	 P.	 falciparum‐infected	 RBCs,	 and	 the	
rapid	 pantothenate	 uptake	 results	 from	 the	 fact	 that	 the	maturing	 parasite	 inside	 the	
host	RBC	induces	the	formation	of	so	called	“new	permeation	pathways”	(NPPs)	on	the	
membrane	 of	 the	 erythrocyte	 to	 serve	 as	 gateways	 through	 which	 it	 imports	 the	




An	 in	 depth	 analysis	 of	 the	 mechanism	 of	 transport	 of	 pantothenate	 across	 the	
membrane	of	the	parasite	and	the	membrane	of	the	RBC	has	revealed	several	important	
differences.	 First,	 P.	 falciparum	 parasites	 take	 up	 pantothenate	 through	 a	
H+:pantothenate	 symporter	 system,	 which	 means	 that	 the	 transport	 of	 pantothenate	
throughout	 the	 membrane	 is	 dependent	 on	 H+	 as	 opposed	 to	 the	 Na+‐dependent	
pantothenate	 transporter	 system	 in	 mammalian	 cells.	 Once	 pantothenate	 is	 taken	 up	
and	 reaches	 the	 cytosol	 of	 the	 erythrocyte	 it	 enters	 the	 parasitophorous	 vacuole	 (a	
vacuole	that	 is	 formed	during	erythrocyte	 invasion	and	where	the	parasite	resides)	by	
diffusion	or	through	channels	present	on	the	membrane	of	the	vacuole.	Afterwards	it	is	
transported	across	the	parasite	plasma	membrane	by	the	H+‐coupled	transporter	which	
has	 a	 1	 to	 1	 stoichiometry,	 meaning	 that	 the	 transport	 of	 one	 H+	 ion	 down	 the	
electrochemical	 gradient	 is	 associated	 with	 the	 transport	 of	 a	 single	 pantothenate	
molecule	 into	 the	 parasite	 cytosol	 [128].	 Second,	 the	 mammalian	 pantothenate	
transporter	 system	 is	 characterised	 by	 high	 substrate	 affinity,	 exhibiting	 a	Michaelis‐









Although	 some	molecular	 details	 of	 the	 pantothenate	 transport	 systems	 remain	 to	 be	
elucidated,	 it	 is	 accepted	 that	 since	 the	 pantothenate	 requirements	 of	 infected	
erythrocytes	 differ	 compared	 to	 their	 normal	 healthy	 counterparts,	 such	 disparities	




Once	pantothenate	 reaches	 the	 cytosol,	 the	P.	 falciparum	 PanK	 (PfPanK)	—	which	has	
been	 shown	 to	 have	 an	 exceptionally	 high	 affinity	 (Km	 of	 ~	 0.3	 μM)	 for	 the	 vitamin,	
rapidly	 phosphorylates	 it	 resulting	 in	 its	 trapping	 inside	 the	 parasite.	 The	 enzyme	







It	 has	 been	 reported	 that	 the	 pantothenate	 phosphorylation	 product,	 4’‐
phosphopantothenate,	accumulates	in	infected	RBCs	as	well	as	in	isolated	parasites,	but	
not	 in	 healthy	 uninfected	 erythrocytes.	 This	 is	 an	 indication	 that	 CoA	 biosynthesis	 is	
regulated	differently	 in	 the	parasite	versus	 in	 the	host	RBCs.	Similar	 to	what	occurs	 in	
the	 parasite	 cytosol,	PfPanK	 activity	 in	 parasite	 lysates	 is	 inhibited	by,	 CoA	 indicating	














Contrary	 to	 what	 is	 known	 about	 PfPanK,	 with	 biochemical	 activity	 that	 has	 been	
demonstrated	in	P.	falciparum,	no	biochemical	evidence	of	the	activity	of	the	other	CoA	
biosynthesis	 pathway	 enzymes	 has	 been	 demonstrated	 in	 the	 parasite.	 Nevertheless,	
taking	 into	 consideration	 the	 presence	 of	 candidate	 genes,	 and	 the	 demonstrated	
capacity	of	the	parasite	to	synthesise	CoA	[125],	 it	 is	postulated	that	PPCS,	PPCDC	and	




DPCK	 has	 been	 shown	 to	 possess	 an	 apicoplast	 amino‐terminal	 bipartite	 leader	





















consider	 targeting	 this	 enzyme	 in	 endeavours	 for	 antimalarial	 drug	 development.	
Although	both	the	human	and	PfPanK	belong	to	the	same	type	II	pantothenate	kinases	
and	 share	 some	 common	 aspects	 as	 already	 discussed,	 they	 also	 exhibit	 major	





CoA	utilization	 in	 fatty	acid	biosynthesis	 [134,	135,	138].	Fatty	acids	are	precursors	of	
essential	structural	and	metabolic	components	including,	among	others,	phospholipids,	
which	 are	 necessary	 for	 the	 formation	 and	 function	 of	 cell	membranes	 as	well	 as	 for	
plasma	lipoproteins.	Fatty	acids	are	synthesized	from	malonyl‐CoA,	which	is	formed	by	
the	 carboxylation	 of	 acetyl‐CoA.	 Malonyl‐CoA	 serves	 as	 a	 universal	 precursor	 for	
elongation	of	acyl	chains	under	the	action	of	a	complex	of	associated	enzymes	known	as	










acid	 biosynthesis	 and	 that	 it	 relied	 on	 scavenging	 lipids	 from	 the	 host	RBC.	However,	







each	 reaction	 in	 the	 fatty	 acids	 biosynthesis	 is	 catalysed	 by	 a	 discrete	 enzyme	 [140],	
humans	 harbour	 a	 type	 I	 FAS	 system	 in	 which	 a	 large	 multifunctional	 polypeptide	
contains	 all	 the	 enzymes	 required	 for	 all	 the	 reactions	 of	 the	 de	 novo	 fatty	 acid	
biosynthesis	[134,	139,	141].	Considering	the	differences	in	fatty	acids	biosynthesis	in	P.	
falciparum	 versus	 human	 cells,	 and	 the	 large	 amounts	 of	 fatty	 acids	 required	 by	 the	
parasite,	 either	 from	 de	 novo	 synthesis	 (which	 is	 said	 not	 to	 be	 essential	 during	 the	





A	 consequence	 of	 the	 attractiveness	 of	 the	 CoA	 metabolic	 pathway	 as	 a	 target	 for	
antiplasmodial	drug	development	as	discussed	above	 is	 that	over	 the	years,	numerous	






compounds	 with	 chemical	 structures	 resembling	 that	 of	 pantothenate	 have	 been	
synthesised	 and	 tested	 against	 different	 malaria	 parasites.	 Some	 of	 the	 compounds	
prepared	were	observed	to	have	parasite	proliferation	promoting	activity	while	others	
seemed	 not	 to	 affect	 the	 parasite	 multiplication.	 Encouragingly,	 some	 compounds	
exhibited	potent	 inhibitory	properties	against	clinically	 important	malaria	parasites	 in	
both	in	vitro	and	in	vivo	systems.	
	







The	 observation	 that	 calcium	 pantothenate	 promoted	 the	 development	 of	
intraerythrocytic	 stage	 P.	 lophurae	 in	 cultures,	 grasped	 the	 interest	 of	 scientists	 who	





previously	 synthesized	 and	 tested	 against	 some	 pathogenic	 bacteria,	were	 among	 the	
first	 pantothenic	 acid	 related	 compounds	 examined	 for	 their	 activity	 against	 malaria	
parasites	 [144].	 The	 activity	 of	 these	 compounds	was	 tested	 in	 vivo	 against	 the	 avian	






malaria	 parasites	 P.	 lophurae,	 P.	 gallinaceum	 and	 P.	 relictum	 in	 ducks,	 chickens	 and	
canaries,	respectively.	
	
When	 incorporated	 in	 the	 ration	 used	 to	 feed	 the	 birds,	 both	 compounds	 were	
essentially	inactive	against	the	parasites.	Nevertheless,	D‐pantoyltauramide	at	doses	of	2	
g/kg	 body	 weight	 (b.w.)	 per	 day	 or	 400	mg/kg	 b.w./day	 administered	 intravenously	











P.	 falciparum	 in	monkey	 and	 human	 erythrocytes	 respectively	 in	 in	 vitro	 experiments	
[147].	 Some	 compounds,	 including	 compounds	 31a‐e,	 (figure	 1.9),	 were	 even	 more	
active	 than	 quinine,	 the	 gold	 standard	 antimalarial	 drug	 at	 the	 time.	 The	most	 active,	
compound	(31d)	was	four	times	more	potent	than	quinine	when	tested	against	a	blood‐
induced	infection	of	P.	gallinaceum	in	which	peak	parasitaemia	was	reached	4	days	post‐
infection	 [144]	 and,	 sixteen	 times	more	potent	 against	 a	 blood‐induced	 infection	with	
the	same	parasite,	 in	which	peak	parasitaemia	was	reached	7	days	post‐infection.	 It	 is	
relevant	 to	 point	 out	 here	 that	 the	 latter	 test	 is	 a	 more	 sensitive	 test	 for	 the	







pharmacokinetic	 and	 antiplasmodial	 activity,	 the	 N‐substituted	 analogues	 of	
pantoytauramide	 proved	 to	 be	 better	 tolerated	 (less	 toxic)	 than	 quinine	 after	









After	 having	 shown	 some	 antimicrobial	 activity	 against	 several	 pathogenic	 bacteria	 in	
vitro,	 the	 pantothenate	 analogue	 phenylpantothenone	 (32,	 figure	 1.10)	 was	 tested	
against	 various	 malaria	 parasites.	 It	 is	 interesting	 to	 note	 that	 when	 tested	 in	 vivo	
against	P.	lophurae	in	ducks,	phenylpantothenone	failed	to	impair	parasite	proliferation.	
However,	when	 screened	against	 the	 same	parasite	 and	 also	 against	P.	gallinaceum	 in	
chickens,	the	compound	exhibited	an	antiplasmodial	activity	equivalent	or	greater	than	
that	of	quinine	[144].	As	had	been	observed	with	the	previous	compounds,	the	activity	of	






D‐phenylpantothenone	 was	 decreased	 by	 the	 concomitant	 administration	 of	
pantothenate.	
	
As	 D‐phenylpantothenone	 had	 demonstrated	 some	 antiplasmodial	 activity	 against	
various	 malaria	 parasites	 with	 varying	 potency	 in	 different	 hosts,	 structural	
modifications	were	sketched	and	a	number	of	analogues	prepared.	The	new	compounds	
demonstrated	 improved	activity	against	 the	parasites	and	among	 these,	 compound	33	
(figure	1.10)	exhibited	greater	antiplasmodial	activity	 compared	 to	 the	parent	drug	D‐
phenylpantothenone.	This	particular	compound	was	threefold	more	effective	against	P.	
gallinaceum	 than	quinine,	 and	 its	 activity	was	 suppressed	when	 co‐administered	with	
pantothenate	[144].	
	
After	 development	 of	 methods	 for	 in	 vitro	 cultivation	 of	 various	 species	 of	 malaria	
parasites	—	 including	 the	 avian	parasites	P.	 lophurae	 and	P.	gallinaceum,	 the	monkey	
parasite	P.	coatneyi	and	the	clinically	 important	human	parasite	P.	falciparum	—	for	at	
least	one	life	cycle,	the	antiplasmodial	activity	of	the	compounds	was	screened	again	in	
vitro.	 All	 the	 previous	 in	 vivo	 results	were	 confirmed	 in	 the	 in	 vitro	 experiments	with	
some	of	the	compounds	demonstrating	even	higher	antiplasmodial	potency	[147,	149].	
	
Interestingly,	 although	 some	 D‐phenylpantothenone	 analogues	 and	 N‐substituted	
pantoyltauramides	 were	 active	 against	 several	 malaria	 parasites	 in	 different	 in	 vivo	
models	 and	 were	 less	 toxic	 than	 quinine,	 none	 of	 them	 have	 been	 tested	 for	 their	
antimalarial	activity	in	humans	or	other	primates.	












been	 investigated	 in	 vitro	 for	 its	 antiplasmodial	 activity	 against	 P.	 falciparum.	 The	
compound	 exhibited	 an	 IC50	 (the	 concentration	 that	 inhibits	 parasite	 proliferation	 by	
50%)	 of	 60	 µM	 against	 the	 CQ‐resistant	 parasites	 of	 the	 FAF6	 strain	 [121].	 When	
administered	 orally	 at	 1.4	 g/kg	 b.w./day	 for	 4	 days	 to	 mice	 infected	 with	 P.	 vinckei	
vinckei,	 pantothenol	 was	 active,	 significantly	 reducing	 parasitaemia	 in	 the	 treated	
animals,	 although	 not	 resulting	 in	 cure.	 Not	 surprisingly,	 the	 in	 vitro	 antiplasmodial	




dehydrogenase,	 resulting	 in	 the	 production	 of	 pantothenate	 [150].	 Considering	 the	
metabolic	 pathway	 targeted	 by	 these	 compounds,	 it	 can	 be	 deduced	 that	 the	 in	 vivo	
conversion	 of	 pantothenol	 to	 pantothenate	 not	 only	 will	 reduce	 the	 concentration	 of	










Despite	 the	 poor	 in	vivo	 growth	 inhibition	 results	 obtained,	 it	 is	 relevant	 to	 point	 out	
that	in	vitro	experiments	demonstrated	that	pantothenol	at	the	concentrations	required	
for	 inhibition	 of	 parasite	 proliferation	was	 selective	 towards	 the	 parasite	 and	 did	 not	
affect	the	proliferation	of	mammalian	T‐lymphocyte	cells	(Jurkat	cell	line).	Saliba	and	co‐
workers	 [121]	 also	 demonstrated	 that	 pantothenol	 inhibited	 parasite	 proliferation	







Other	 pantothenate	 analogues	 known	 as	 N‐pantoyl‐substituted	 amines	 —	 including	
compounds	 35‐39	 (figure	 1.11)	 with	 chemical	 structures	 related	 to	 pantothenol	 —	
which	 had	 demonstrated	 antibacterial	 activity,	 have	 also	 been	 tested	 against	 malaria	
parasites,	 revealing	 in	vitro	 growth	 inhibitory	 activity	 at	 concentrations	of	 10‐200	μM	
[126,	151].	
	
Other	 compounds	 which	 like	 pantothenol,	 result	 from	 simple	 modifications	 of	 the	 ‐
alanine	 moiety	 of	 pantothenate	 have	 been	 prepared	 and	 tested	 against	 different	
pathogenic	 microorganisms.	 Some	 of	 these,	 including	 CJ‐15,801	 (40,	 figure	 1.9),	 a	






metabolic	 product	 of	 the	 fungus	 Seimatosporium	 sp.,	 have	 also	 been	 tested	 in	 vitro	
against	 the	 human	 malaria	 parasite	 P.	 falciparum	 [152].	 The	 compound	 inhibited	
parasite	 proliferation	 with	 an	 IC50	 of	 39	 ±	 3	 µM	 in	 the	 presence	 of	 standard	
concentrations	 (~1	µM)	of	 pantothenate	 in	 the	 culture	medium.	At	 a	 concentration	of	
~250	 µM	 under	 standard	 parasite	 growth	 conditions,	 CJ‐15,801	 completely	 inhibited	
parasite	proliferation.	However,	when	the	concentration	of	pantothenate	in	the	culture	
medium	 was	 increased	 to	 100	 µM	 or	 500	 µM,	 the	 antiplasmodial	 activity	 was	
terminated,	again	 indicating	 that	CJ‐15,801	 interfered	with	pantothenate	utilization	by	
the	parasite.	
	
CJ‐15,801	 was	 also	 found	 to	 be	 selective	 towards	 the	 parasite	 as	 it	 did	 not	 inhibit	























microorganisms,	 the	 most	 studied	 and	 class	 representative	 PanAm,	 n‐










acids	 biosynthesis	 [161,	 162].	 Crypto‐ACP	 is	 recycled	 back	 to	 apo‐ACP	 through	 a	
hydrolytic	 reaction	 catalysed	 by	 AcpH	 (scheme	 1.2).	 However,	 it	 has	 not	 been	
determined	whether	the	induction	of	stasis	in	bacterial	replication	caused	by	this	class	
of	compounds	results	from	the	inhibition	of	CoA	biosynthesis,	the	inhibition	of	fatty	acid	










Scheme	 1.2	 ‐	 In	 bacteria	 N‐substituted	 pantothenamides	 (such	 as	 N5‐Pan)	 act	 as	




analogues	 against	 P.	 falciparum,	 previous	 researchers	 in	 our	 laboratory	 developed	 a	
method	for	simultaneous	synthesis	and	purification	of	PanAm	[157].	Using	this	method,	
a	 mini‐series	 of	 147	 PanAms	 was	 prepared	 and	 tested	 in	 vitro	 against	 different	
pathogenic	 bacteria	 as	 well	 as	 against	 P.	 falciparum	 parasites.	 Until	 the	 recent	
publication	of	a	study	[163]	done	in	collaboration	with	our	co‐workers	at	the	Australian	
National	University	(ANU)	–	part	of	which	is	described	in	this	dissertation,	no	research	
specifically	 investigating	 the	 activity	 of	 PanAms	 against	 malaria	 parasites	 had	 been	
published	in	the	literature.	
	









that	 our	 laboratory	 has	 recently	 generated	 a	 mini‐library	 of	 PanAms	 that	 were	
demonstrated	 in	 previous	 studies	 to	 be	 active	 against	 various	 pathogenic	 bacteria	 as	
well	as	against	malaria	parasites,	this	project	was	initiated	with	two	major	aims:	
	




P.	 falciparum	 parasites.	 Specifically,	 it	 was	 aimed	 to	 determine	 whether	 the	
antiplasmodial	activity	of	this	class	of	compounds	results	from:	
(i)		 Inhibition	 of	 CoA	 biosynthesis	 by	 virtue	 of	 interference	 with	 the	
phosphorylation	of	pantothenate	by	PfPanK,	or;	
















Chapter	 2	 consists	 of	 a	 detailed	 description	 of	 the	 materials	 and	 methods	 used	 to	
generate	and	analyse	all	the	results	presented	in	this	dissertation.	
	
In	 Chapter	 3	 the	 results	 obtained	 with	 the	 in	 vitro	 antimalarial	 growth	 assays	
performed	with	PanAms	that	were	chemically	modified	to	improve	their	antiplasmodial	
activity	 are	 reported,	 and	 includes	 a	 structure	 activity	 analysis	 to	 tease	 out	 how	 best	
potency/stability	can	be	achieved.	
	
In	 Chapter	 4	 the	 work	 done	 towards	 elucidating	 the	 MoA	 of	 PanAms	 is	 discussed,	
specifically,	 the	 experiments	 and	 their	 results,	 performed	 to	 determine	 whether	 the	
antiplasmodial	activity	of	N‐substituted	pantothenamides	resulted	from	inhibition	of	the	
parasite	CoA	metabolism	 through	 interference	with	 the	pantothenate	phosphorylation	















1.	 Kakkilaya,	 D.B.S.	Malaria	 Site	 ‐	 All	 About	Malaria.	 2004	 [cited	 2013	 23	 June];	
Available	from:	http://www.malariasite.com/malaria/History.htm.	
2.	 Carter,	 R.	 and	 K.N.	Mendis,	Evolutionary	 and	 historical	 aspects	 of	 the	 burden	 of	
malaria.	Clin	Microbiol	Rev,	2002.	15(4):	p.	564‐94.	















11.	 Woube,	 M.,	 Geographical	 distribution	 and	 dramatic	 increases	 in	 incidences	 of	
malaria:	consequences	of	the	resettlement	scheme	in	Gambela,	SW	Ethiopia.	Indian	
J	Malariol,	1997.	34(3):	p.	140‐63.	
12.	 Cui,	 L.,	 et	 al.,	 Malaria	 in	 the	 Greater	 Mekong	 Subregion:	 Heterogeneity	 and	
complexity.	Acta	Tropica,	2012.	121(3):	p.	227‐39.	













and	 Clinical	 Aspects,	 M.W.P.	 Pelmann,	 Editor.	 1999,	 Harwood	 Academic:	
Amsterdam.	p.	19‐55.	






20.	 Biamonte,	 M.A.,	 J.	 Wanner,	 and	 K.G.	 Le	 Roch,	 Recent	 advances	 in	malaria	 drug	
discovery.	Bioorg	Med	Chem	Lett,	2013.	23(10):	p.	2829‐43.	
21.	 CDC,	 C.f.D.C.a.P.	 Malaria.	 2010;	 Available	 from:	
http://www.cdc.gov/malaria/about/disease.html.	
22.	 Abdalla,	 S.,	 et	 al.,	 The	 anaemia	 of	 P.	 falciparum	malaria.	 Br	 J	 Haematol,	 1980.	
46(2):	p.	171‐83.	
23.	 Chang,	 K.H.,	M.	 Tam,	 and	M.M.	 Stevenson,	 Inappropriately	 low	 reticulocytosis	 in	
severe	 malarial	 anemia	 correlates	 with	 suppression	 in	 the	 development	 of	 late	
erythroid	precursors.	Blood,	2004.	103(10):	p.	3727‐35.	






24.	 Anuar,	 M.	 and	 P.K.	 Yap,	 Severe	 malaria	 with	 disseminated	 intravascular	
coagulation.	Med	J	Malaysia,	1979.	33(3):	p.	264‐5.	
25.	 Lercari,	 G.,	 et	 al.,	Apheresis	 for	 severe	malaria	 complicated	 by	 cerebral	malaria,	
acute	 respiratory	 distress	 syndrome,	 acute	 renal	 failure,	 and	 disseminated	
intravascular	coagulation.	J	Clin	Apher,	1992.	7(2):	p.	93‐6.	
26.	 Thanachartwet,	V.,	 et	al.,	Acute	Renal	Failure	 in	Patients	with	Severe	Falciparum	
Malaria:	Using	 the	WHO	2006	and	RIFLE	Criteria.	 Int	 J	Nephrol,	 2013.	2013:	 p.	
841518.	
27.	 WHO,	 W.H.O.	 Malaria	 Vaccine	 Rainbow	 Tables.	 2013;	 Available	 from:	
http://www.who.int/vaccine_research/links/Rainbow/en/.	
28.	 Birkett,	 A.J.,	 et	 al.,	 Malaria	 vaccine	 R&amp;D	 in	 the	 Decade	 of	 Vaccines:	
Breakthroughs,	 challenges	 and	 opportunities.	 Vaccine,	 2013.	 31,	 Supplement	
2(0):	p.	B233‐B243.	










34.	 Le	Bras,	 J.	and	R.	Durand,	The	mechanisms	of	resistance	 to	antimalarial	drugs	 in	
Plasmodium	falciparum.	Fundam	Clin	Pharmacol,	2003.	17(2):	p.	147‐53.	






35.	 Tracy,	 J.W.	 and	 L.T.J.	 Webster,	 Drugs	 Used	 in	 the	 Chemotherapy	 of	 Protozoal	
Infections.	 Malaria,	 in	 Goodman	 &	 Gilman's	 The	 Pharmacological	 Basis	 of	
Therapeutics,	J.G.	Hardman,	et	al.,	Editors.	1996,	McGraw‐Hill.	p.	965‐85.	
36.	 Wellems,	 T.E.	 and	 C.V.	 Plowe,	 Chloroquine‐resistant	malaria.	 J	 Infect	 Dis,	 2001.	
184(6):	p.	770‐6.	
37.	 Garcia‐Bustos,	 J.F.	 and	 F.J.	 Gamo,	 Antimalarial	 drug	 resistance	 and	 early	 drug	
discovery.	Curr	Pharm	Des,	2013.	19(2):	p.	270‐81.	
38.	 Wongsrichanalai,	 C.,	 et	 al.,	Epidemiology	of	drug‐resistant	malaria.	 Lancet	 Infect	
Dis,	2002.	2(4):	p.	209‐18.	
39.	 Sanchez,	 C.P.,	 et	 al.,	 Genetic	 linkage	 analyses	 redefine	 the	 roles	 of	 PfCRT	 and	
PfMDR1	 in	 drug	 accumulation	 and	 susceptibility	 in	Plasmodium	 falciparum.	 Mol	
Microbiol,	2011.	82(4):	p.	865‐78.	
40.	 Gharbi,	 M.,	 et	 al.,	 Longitudinal	 study	 assessing	 the	 return	 of	 chloroquine	
susceptibility	of	Plasmodium	 falciparum	 in	 isolates	 from	travellers	returning	 from	
West	and	Central	Africa,	2000‐2011.	Malar	J,	2013.	12(1):	p.	35.	
41.	 Naing,	C.,	 et	 al.,	Efficacy	and	 safety	of	chloroquine	 for	 treatment	 in	patients	with	
uncomplicated	Plasmodium	vivax	infections	in	endemic	countries.	Trans	R	Soc	Trop	
Med	Hyg,	2010.	104(11):	p.	695‐705.	
42.	 Zhang,	G.Q.,	 et	 al.,	Multiplex	PCR	and	oligonucleotide	microarray	 for	detection	of	
single‐nucleotide	 polymorphisms	 associated	 with	 Plasmodium	 falciparum	 drug	
resistance.	J	Clin	Microbiol,	2008.	46(7):	p.	2167‐74.	











are	 associated	with	mutant	 Pfmdr‐1,	 not	 Pfcrt	 in	Madagascar.	 PLoS	 One,	 2010.	
5(10):	p.	e13281.	
46.	 Hill,	 D.R.,	 et	 al.,	 Primaquine:	 report	 from	 CDC	 expert	 meeting	 on	 malaria	
chemoprophylaxis	I.	Am	J	Trop	Med	Hyg,	2006.	75(3):	p.	402‐15.	
47.	 Vale,	 N.,	 R.	 Moreira,	 and	 P.	 Gomes,	 Primaquine	 revisited	 six	 decades	 after	 its	
discovery.	Eur	J	Med	Chem,	2009.	44(3):	p.	937‐53.	
48.	 White,	 N.J.,	 Primaquine	 to	 prevent	 transmission	 of	 falciparum	 malaria.	 Lancet	
Infect	Dis,	2013.	13(2):	p.	175‐81.	
49.	 Sutanto,	 I.,	 et	 al.,	 The	 effect	 of	 primaquine	 on	 gametocyte	 development	 and	
clearance	 in	 the	 treatment	 of	 uncomplicated	 falciparum	 malaria	 with	
dihydroartemisinin‐piperaquine	 in	 South	 sumatra,	Western	 indonesia:	 an	 open‐
label,	randomized,	controlled	trial.	Clin	Infect	Dis,	2013.	56(5):	p.	685‐93.	
50.	 Beutler,	 E.	 and	 S.	 Duparc,	 Glucose‐6‐phosphate	 dehydrogenase	 deficiency	 and	
antimalarial	drug	development.	Am	J	Trop	Med	Hyg,	2007.	77(4):	p.	779‐89.	







in	 Plasmodium	 falciparum:	 a	 zoomed	 image	 at	 the	 molecular	 level	 within	 a	
geographic	context.	Acta	Trop,	2013.	125(2):	p.	163‐90.	






54.	 Duah,	 N.O.,	 et	 al.,	 Surveillance	 of	molecular	markers	 of	 Plasmodium	 falciparum	




using	 2	 vs	 3	 or	more	 doses	 of	 sulfadoxine‐pyrimethamine	 and	 risk	 of	 low	 birth	
weight	in	Africa:	systematic	review	and	meta‐analysis.	Jama,	2013.	309(6):	p.	594‐
604.	
57.	 Luzzatto,	 L.,	 The	 rise	 and	 fall	 of	 the	 antimalarial	 Lapdap:	 a	 lesson	 in	
pharmacogenetics.	Lancet,	2010.	376(9742):	p.	739‐41.	
58.	 Lang,	 T.	 and	 B.	 Greenwood,	 The	 development	 of	 Lapdap,	 an	 affordable	 new	
treatment	for	malaria.	Lancet	Infect	Dis,	2003.	3(3):	p.	162‐8.	
59.	 Miller,	 A.K.,	 et	 al.,	 Pharmacokinetic	 Interactions	 and	 Safety	 Evaluations	 of	
Coadministered	 Tafenoquine	 and	 Chloroquine	 in	 Healthy	 Subjects.	 Br	 J	 Clin	
Pharmacol,	2013.	
60.	 Yuthavong,	 Y.,	 et	 al.,	 Malarial	 dihydrofolate	 reductase	 as	 a	 paradigm	 for	 drug	
development	against	a	 resistance‐compromised	 target.	 Proc	Natl	Acad	 Sci	U	 S	A,	
2012.	109(42):	p.	16823‐8.	
61.	 Gregson,	 A.	 and	 C.V.	 Plowe,	 Mechanisms	 of	 resistance	 of	 malaria	 parasites	 to	
antifolates.	Pharmacol	Rev,	2005.	57(1):	p.	117‐45.	
62.	 Fidock,	 D.A.,	 Microbiology.	 Eliminating	 malaria.	 Science,	 2013.	 340(6140):	 p.	
1531‐3.	
63.	 Price,	 R.N.,	 et	 al.,	 Effects	 of	 artemisinin	 derivatives	 on	malaria	 transmissibility.	
Lancet,	1996.	347(9016):	p.	1654‐8.	






64.	 Awad,	 M.I.,	 et	 al.,	 Descriptive	 study	 on	 the	 efficacy	 and	 safety	 of	 artesunate	
suppository	 in	 combination	with	 other	 antimalarials	 in	 the	 treatment	 of	 severe	
malaria	in	Sudan.	Am	J	Trop	Med	Hyg,	2003.	68(2):	p.	153‐8.	
65.	 Dondorp,	 A.M.,	 et	 al.,	 Artemisinin	 resistance:	 current	 status	 and	 scenarios	 for	
containment.	Nat	Rev	Microbiol,	2010.	8(4):	p.	272‐80.	
66.	 Bradley,	 S.G.	 and	 F.	 Marciano‐Cabral,	 Antiparasitic	 Drugs,	 in	 Principles	 of	
Pharmacology,	Basic	Concepts	&	Clinical	Applications,	 P.L.	Munson,	R.A.	Mueller,	
and	G.R.	Breese,	Editors.	1995,	Chapman	&	Hall:	New	York.	p.	1437‐73.	
67.	 Cui,	 L.,	 et	 al.,	 Mechanisms	 of	 in	 vitro	 resistance	 to	 dihydroartemisinin	 in	
Plasmodium	falciparum.	Mol	Microbiol,	2012.	86(1):	p.	111‐28.	
68.	 Haynes,	 R.K.,	 et	 al.,	 A	 partial	 convergence	 in	 action	 of	 methylene	 blue	 and	
artemisinins:	 antagonism	 with	 chloroquine,	 a	 reversal	 with	 verapamil,	 and	 an	
insight	into	the	antimalarial	activity	of	chloroquine.	ChemMedChem,	2011.	6(9):	p.	
1603‐15.	
69.	 Klonis,	 N.,	 et	 al.,	 Artemisinin	 activity	 against	 Plasmodium	 falciparum	 requires	







72.	 Wang,	 J.,	 et	 al.,	 Artemisinin	 directly	 targets	 malarial	 mitochondria	 through	 its	
specific	mitochondrial	activation.	PLoS	One,	2010.	5(3):	p.	e9582.	






73.	 Eckstein‐Ludwig,	 U.,	 et	 al.,	 Artemisinins	 target	 the	 SERCA	 of	 Plasmodium	
falciparum.	Nature,	2003.	424(6951):	p.	957‐61.	
74.	 Bhisutthibhan,	 J.,	 et	 al.,	 The	 Plasmodium	 falciparum	 translationally	 controlled	
tumor	protein	homolog	and	 its	reaction	with	 the	antimalarial	drug	artemisinin.	 J	
Biol	Chem,	1998.	273(26):	p.	16192‐8.	









SERCA	 (PfATP6)	with	 resistance	 to	 artemisinins.	 Antimicrob	 Agents	 Chemother,	
2012.	56(5):	p.	2546‐52.	
79.	 Bustamante,	C.,	et	al.,	In	vitro‐reduced	susceptibility	to	artemether	in	P.	falciparum	
and	 its	association	with	polymorphisms	 on	 transporter	genes.	 J	 Infect	 Dis,	 2012.	
206(3):	p.	324‐32.	


















85.	 Hyde,	 J.E.,	 Exploring	 the	 folate	 pathway	 in	 Plasmodium	 falciparum.	 Acta	 Trop,	
2005.	94(3):	p.	191‐206.	
86.	 Wermuth,	 C.G.,	 et	 al.,	 Glossary	 of	 Terms	 Used	 in	 Medicinal	 Chemistry.	 Pure	 &	
Applied	Chemistry,	1998.	70(5):	p.	1129‐43.	
87.	 Staedke,	 S.G.,	 et	 al.,	 Amodiaquine,	 sulfadoxine/pyrimethamine,	 and	 combination	
therapy	for	treatment	of	uncomplicated	falciparum	malaria	in	Kampala,	Uganda:	a	
randomised	trial.	Lancet,	2001.	358(9279):	p.	368‐74.	
88.	 Adjuik,	M.,	 et	 al.,	Amodiaquine‐artesunate	versus	amodiaquine	 for	uncomplicated	
Plasmodium	 falciparum	 malaria	 in	 African	 children:	 a	 randomised,	 multicentre	
trial.	Lancet,	2002.	359(9315):	p.	1365‐72.	
89.	 Mutabingwa,	 T.,	 et	 al.,	 Chlorproguanil‐dapsone	 for	 treatment	 of	 drug‐resistant	
falciparum	malaria	in	Tanzania.	Lancet,	2001.	358(9289):	p.	1218‐23.	
90.	 Venture,	 M.M.	 Coatem	Dispersible	 (Artemether‐Lumefantrine).	 2009	 [cited	 2013	












93.	 Valdés,	A.F.,	 et	 al.,	 In	vitro	antimalarial	activity	and	cytotoxicity	of	 some	 selected	
cuban	medicinal	plants.	Rev	Inst	Med	Trop	Sao	Paulo,	2010.	52:	p.	197.	
94.	 Clough,	 B.	 and	R.J.M.	Wikon,	Antibiotics	and	 the	plasmodial	plastid	organelle,	 in	
Antimalarial	 Chemotherapy:	 Mechanisms	 of	 Action,	 Resistance,	 and	 New	 Drug	
Discovery,	P.J.	Rosenthal,	Editor.	2001,	Humana	Press:	Totawa,	NJ.	
95.	 Canfield,	 C.J.,	 M.	 Pudney,	 and	 W.E.	 Gutteridge,	 Interactions	 of	 atovaquone	with	
other	 antimalarial	 drugs	 against	Plasmodium	 falciparum	 in	 vitro.	 Exp	 Parasitol,	
1995.	80(3):	p.	373‐81.	
96.	 Martiney,	 J.A.,	 A.	 Cerami,	 and	 A.F.	 Slater,	 Verapamil	 reversal	 of	 chloroquine	





98.	 Bitonti,	 A.J.,	 et	 al.,	 Reversal	 of	 chloroquine	 resistance	 in	 malaria	 parasite	
Plasmodium	falciparum	by	desipramine.	Science,	1988.	242(4883):	p.	1301‐3.	
99.	 van	Schalkwyk,	D.A.,	J.C.	Walden,	and	P.J.	Smith,	Reversal	of	chloroquine	resistance	
in	 Plasmodium	 falciparum	 using	 combinations	 of	 chemosensitizers.	 Antimicrob	
Agents	Chemother,	2001.	45(11):	p.	3171‐4.	
100.	 Adovelande,	 J.,	 J.	 Deleze,	 and	 J.	 Schrevel,	 Synergy	 between	 two	 calcium	 channel	
blockers,	verapamil	and	fantofarone	(SR33557),	in	reversing	chloroquine	resistance	
in	Plasmodium	falciparum.	Biochem	Pharmacol,	1998.	55(4):	p.	433‐40.	
101.	 Guantai,	 E.	 and	 K.	 Chibale,	 Chloroquine	 resistance:	 proposed	 mechanisms	 and	
countermeasures.	Curr	Drug	Deliv,	2010.	7(4):	p.	312‐23.	
















107.	 Dharia,	 N.V.,	 A.	 Chatterjee,	 and	 E.A.	 Winzeler,	 Genomics	 and	 systems	 biology	 in	
malaria	drug	discovery.	Curr	Opin	Investig	Drugs,	2010.	11(2):	p.	131‐8.	
108.	 Gamo,	 F.J.,	 et	 al.,	 Thousands	 of	 chemical	 starting	 points	 for	 antimalarial	 lead	
identification.	Nature,	2010.	465(7296):	p.	305‐10.	
109.	 Higdon,	 J.,	 V.J.	 Drake,	 and	 N.	 Plesofsky.	 Pantothenic	 Acid.	 2008	 [cited	 2013	
07/07/2013];	 Available	 from:	
http://lpi.oregonstate.edu/infocenter/vitamins/pa/.	
110.	 Strauss,	 E.,	Coenzyme	A	Biosynthesis	and	Enzymology,	 in	Comprehensive	Natural	
Products	 II:	 Chemistry	 and	 Biology,	 L.	 Mander	 and	 H.‐W.	 Liu,	 Editors.	 2010,	
Newnes.	p.	351‐10.	
111.	 Genschel,	U.,	Coenzyme	A	biosynthesis:	 reconstruction	of	 the	pathway	 in	archaea	
and	an	evolutionary	scenario	based	on	comparative	genomics.	Mol	Biol	Evol,	2004.	
21(7):	p.	1242‐51.	
112.	 Jackowski,	 S.	 and	 C.O.	 Rock,	 Turnover	 of	 the	 4'‐phosphopantetheine	 prosthetic	
group	of	acyl	carrier	protein.	J	Biol	Chem,	1984.	259(3):	p.	1891‐5.	











115.	 Kimura,	 S.,	 et	 al.,	 Antagonism	 of	 L(‐)pantothenic	 acid	 on	 lipid	 metabolism	 in	
animals.	J	Nutr	Sci	Vitaminol	(Tokyo),	1980.	26(2):	p.	113‐7.	
116.	 Daugherty,	 M.,	 et	 al.,	 Complete	 reconstitution	 of	 the	 human	 coenzyme	 A	
biosynthetic	pathway	 via	 comparative	genomics.	 J	 Biol	 Chem,	 2002.	277(24):	 p.	
21431‐9.	
117.	 Halavaty,	 A.S.,	 et	 al.,	 Structural	 characterization	 and	 comparison	 of	 three	 acyl‐
carrier‐protein	 synthases	 from	 pathogenic	 bacteria.	 Acta	 Crystallogr	 D	 Biol	
Crystallogr,	2012.	68(Pt	10):	p.	1359‐70.	
118.	 Lambalot,	 R.H.	 and	 C.T.	Walsh,	 Cloning,	 overproduction,	 and	 characterization	 of	
the	Escherichia	coli	holo‐acyl	carrier	protein	synthase.	J	Biol	Chem,	1995.	270(42):	
p.	24658‐61.	
119.	 Upadhyay,	 S.K.,	 et	 al.,	 Structural	 insights	 into	 the	 acyl	 intermediates	 of	 the	
Plasmodium	falciparum	fatty	acid	synthesis	pathway:	the	mechanism	of	expansion	
of	the	acyl	carrier	protein	core.	J	Biol	Chem,	2009.	284(33):	p.	22390‐400.	














123.	 Divo,	A.A.,	et	al.,	Nutritional	requirements	of	Plasmodium	 falciparum	 in	culture.	I.	
Exogenously	 supplied	 dialyzable	 components	 necessary	 for	 continuous	 growth.	 J	
Protozool,	1985.	32(1):	p.	59‐64.	







pantothenate	 kinase	 and	 represses	 the	 proliferation	 of	 malaria	 parasites.	
Antimicrob	Agents	Chemother,	2005.	49(11):	p.	4649‐57.	
127.	 Ginsburg,	H.,	et	al.,	Characterization	of	permeation	pathways	appearing	in	the	host	
membrane	 of	 Plasmodium	 falciparum	 infected	 red	 blood	 cells.	 Mol	 Biochem	
Parasitol,	1985.	14(3):	p.	313‐22.	
128.	 Saliba,	 K.J.	 and	 K.	 Kirk,	 H+‐coupled	 pantothenate	 transport	 in	 the	 intracellular	
malaria	parasite.	J	Biol	Chem,	2001.	276(21):	p.	18115‐21.	
129.	 Prasad,	 P.D.,	 et	 al.,	 Cloning	 and	 functional	 expression	 of	 a	 cDNA	 encoding	 a	











131.	 Wang,	 H.,	 et	 al.,	 Human	 placental	 Na+‐dependent	 multivitamin	 transporter.	
Cloning,	functional	expression,	gene	structure,	and	chromosomal	localization.	J	Biol	
Chem,	1999.	274(21):	p.	14875‐83.	
132.	 EuPathDB,	 P.	 PlasmoDB	 ‐	 Plasmodium	 Genomics	 Resource.	 [Website]	 2013	 25	




134.	 Spry,	 C.,	K.	Kirk,	 and	K.J.	 Saliba,	Coenzyme	A	biosynthesis:	an	antimicrobial	drug	
target.	FEMS	Microbiol	Rev,	2008.	32(1):	p.	56‐106.	
135.	 van	Dooren,	G.G.,	et	al.,	Processing	of	an	apicoplast	leader	sequence	in	Plasmodium	
falciparum	 and	 the	 identification	 of	 a	 putative	 leader	 cleavage	 enzyme.	 J	 Biol	
Chem,	2002.	277(26):	p.	23612‐9.	
136.	 Hong,	B.S.,	 et	al.,	Prokaryotic	 type	 II	and	 type	 III	pantothenate	kinases:	The	same	






139.	 Roberts,	 C.W.,	 et	 al.,	 Fatty	 acid	 and	 sterol	 metabolism:	 potential	 antimicrobial	
targets	 in	 apicomplexan	 and	 trypanosomatid	 parasitic	 protozoa.	 Mol	 Biochem	
Parasitol,	2003.	126(2):	p.	129‐42.	
140.	 Wilson,	R.J.,	Progress	with	parasite	plastids.	J	Mol	Biol,	2002.	319(2):	p.	257‐74.	






141.	 Waller,	 R.F.,	 et	 al.,	 A	 type	 II	 pathway	 for	 fatty	 acid	 biosynthesis	 presents	 drug	
targets	in	Plasmodium	falciparum.	Antimicrob	Agents	Chemother,	2003.	47(1):	p.	
297‐301.	
142.	 Yu,	 M.,	 et	 al.,	 The	 fatty	 acid	 biosynthesis	 enzyme	 FabI	 plays	 a	 key	 role	 in	 the	
development	 of	 liver‐stage	malarial	 parasites.	 Cell	 Host	 Microbe,	 2008.	 4(6):	 p.	
567‐78.	





145.	 Blanchard,	K.C.	 and	L.H.	 Schid,	Chemical	 series	of	potential	 interest.	 A	 Survey	 of	
Antimalarial	Drugs,	1946.	1:	p.	1941‐5.	







149.	 Trager,	W.,	Coenzyme	A	and	 the	antimalarial	action	 in	vitro	of	antipantothenate	
against	Plasmodium	 lophurae,	P.	coatneyi	and	P.	 falciparum.	Trans	N	Y	Acad	Sci,	
1966.	28(8):	p.	1094‐108.	
150.	 Abiko,	 Y.,	 M.	 Tomikawa,	 and	 M.	 Shimizu,	 Enzymatic	 conversion	 of	
pantothenylalcohol	to	pantothenic	acid.	J	Vitaminol	(Kyoto),	1969.	15(1):	p.	59‐69.	






151.	 Lehane,	 A.M.,	 et	 al.,	 Feedback	 inhibition	 of	 pantothenate	 kinase	 regulates	
pantothenol	uptake	by	the	malaria	parasite.	J	Biol	Chem,	2007.	282(35):	p.	25395‐
405.	
152.	 Saliba,	 K.J.	 and	 K.	 Kirk,	 CJ‐15,801,	 a	 fungal	 natural	 product,	 inhibits	 the	
intraerythrocytic	 stage	 of	 Plasmodium	 falciparum	 in	 vitro	 via	 an	 effect	 on	
pantothenic	acid	utilisation.	Mol	Biochem	Parasitol,	2005.	141(1):	p.	129‐31.	
153.	 Akinnusi,	T.O.,	K.	Vong,	and	K.	Auclair,	Geminal	dialkyl	derivatives	of	N‐substituted	
pantothenamides:	 synthesis	 and	 antibacterial	 activity.	 Bioorg	 Med	 Chem,	 2011.	
19(8):	p.	2696‐706.	
154.	 Choudhry,	 A.E.,	 et	 al.,	 Inhibitors	 of	 pantothenate	 kinase:	 novel	 antibiotics	 for	
staphylococcal	infections.	Antimicrob	Agents	Chemother,	2003.	47(6):	p.	2051‐5.	







purification	 of	 N‐substituted	 pantothenamides,	 known	 inhibitors	 of	 coenzyme	 A	
biosynthesis	and	utilization.	Org	Biomol	Chem,	2008.	6(23):	p.	4348‐55.	
158.	 Ivey,	 R.A.,	 et	 al.,	 The	 structure	 of	 the	 pantothenate	 kinase	 ADP	 pantothenate	
ternary	 complex	 reveals	 the	 relationship	between	 the	binding	 sites	 for	 substrate,	
allosteric	regulator,	and	antimetabolites.	J	Biol	Chem,	2004.	279(34):	p.	35622‐9.	






159.	 Virga,	 K.G.,	 et	 al.,	 Structure‐activity	 relationships	 and	 enzyme	 inhibition	 of	
pantothenamide‐type	 pantothenate	 kinase	 inhibitors.	 Bioorg	 Med	 Chem,	 2006.	
14(4):	p.	1007‐20.	





162.	 Zhang,	 Y.M.,	 et	 al.,	 Acyl	 carrier	 protein	 is	 a	 cellular	 target	 for	 the	 antibacterial	
action	of	 the	pantothenamide	class	of	pantothenate	antimetabolites.	 J	Biol	Chem,	
2004.	279(49):	p.	50969‐75.	






































All	 general	 chemicals,	 reagents,	 culture	media	 and	 chloroquine	 diphosphate	 salt	 used	
during	 this	 study	were	 purchased	 from	 Sigma‐Aldrich.	 Antibiotics	 and	Albumax	 II	 for	
cell	culturing	and	SYBR	Safe	DNA	gel	stain	(10	000	×	concentrate	in	Dimethyl	Sulphoxide	
(DMSO))	 for	 fluorescence	 assays	 were	 purchased	 from	 Invitrogen.	 Scintillation	 fluids	
(Microscint	 O	 and	 Microscint	 40)	 were	 obtained	 from	 Perkin‐Elmer	 Inc.	 All	 the	






pantothenic	acid	or	one	of	 two	structural	analogues	 in	which	 its	β‐alanine	moiety	was	
replaced	with	either	glycine	(to	give	α‐pantothenic	acid)	or	γ‐aminobutyric	acid	(to	give	




of	 PanAms	 were	 prepared,	 referred	 to	 as	 α‐pantothenamides	 (α‐PanAms),	 normal‐










Table	 2.1	 Chemical	 structures	 of	N‐substituted	 pantothenamides	 tested	 in	 vitro	
against	intraerythrocytic‐stage	P.	falciparum	parasites	
 
Entry	#	 R	group	 Entry	#	 R	group		 Entry	#	 R	group	
41	 	 46	 	
51	
42	 	 47	 52	
	













Pantoyltauramides	 (Table	 2.2)1	 as	 well	 as	‐methyl	 pantothenamides	 (‐MePanAms)	
and	 β‐methyl	 pantothenamides	 (β‐MePanAms)	 (Table	 2.3)1	 were	 also	 dissolved	 in	
DMSO	as	200	mM	stocks	and	stored	at	‐20°C	until	used	[2].	
	
Table	 2.2	 Structures	 of	 N‐substituted	 pantoyltauramides	 tested	 in	 vitro	 against	
intraerythrocytic‐stage	P.	falciparum	parasites	
 
Entry	#	 R	group	 Entry	#	 R	group		 Entry	#	 R	group	














Table	 2.3	 Structures	 of	 N‐substituted	 α‐methyl	 and	 β‐methyl	 pantothenamides	
tested	in	vitro	against	intraerythrocytic‐stage	P.	falciparum	parasites	
	
Entry	#	 R	group	 Entry	#	 R	group		
41	 	 52	
42	 	 53	 	





























v/v	Acetonitrile	 (ACN):	H2O	as	50	–	300	mM	stock	 solutions	 and	 stored	at	 ‐20°C	until	
required.	
	










Sodium	 D‐[1‐14C]pantothenate	 with	 specific	 activity	 of	 50	 mCi/mmol	 was	 purchased	
from	American	Radiolabeled	Chemicals,	 Inc.	St.	Louis,	MO,	USA	and	was	used	 in	 initial	
experiments.	Subsequently,	sodium	D‐[2,3‐14C]pantothenate	was	prepared	by	Dr.	David	
Choveaux	 from	 β‐[2,3‐14C]alanine	 with	 specific	 activity	 of	 110	 mCi/mmol	 (also	
purchased	 from	 American	 Radiolabeled	 Chemicals,	 Inc.	 St.	 Louis,	 MO,	 USA)	 using	 a	
previously	 described	method	 [3].	 Radiolabelled	 versions	 of	 selected	 PanAms,	 namely	
[14C]N‐hexyl	 ‐PanAm	 (43a*1),	 [14C]N‐hexyl	 n‐PanAm	 (43b*),	 [14C]N‐hexyl	 HoPanAm	
(43c*)	 and	 [14C]N‐benzyl	 n‐PanAm	 (48b*),	 were	 synthesised	 by	 Prof.	 Erick	 Strauss	
using	 [1‐14C]n‐hexylamine	 hydrochloride	 and	 [7‐14C]benzylamine	 hydrochloride	 (both	








(for	 experiments	 conducted	 at	 ANU),	 and	was	 obtained	 from	Prof.	 Jacky	 Snoep	 at	 the	
                                                            
1 An asterisk combined with a number identifying a structure denotes a radioactive compound. 




































Plasmids	 used	 for	 the	 expression	 of	 Bacillus	 subtilis	 phosphopantetheinyl	 transferase	
(Sfp)	 (pET29‐Sfp),	 E.	 coli	 PanK	 (pET28a‐EcCoaA),	 PPAT	 (pET28‐EcCoaD)	 and	 DPCK	
(pET28‐EcCoaE),	 all	 carrying	a	kanamycin	 resistance	gene	 (KanR)	and	encoding	 for	N‐
terminal	hexahistidine	tag	(6×His‐tag)	fusion	proteins	were	available	in	our	laboratory.	
Plasmids	used	for	the	expression	of	a	 truncated	version	of	PfACP	(residues	S57‐Q137)	
with	 an	 N‐terminal	 6×His‐tag	 (pSPr22,	 described	 in	 Du	 et	 al.	 [4]),	 and	 a	 non‐tagged	
PfACP	 (pJGa7,	 described	 in	 Gallagher	 and	 Prigge	 [5]),	 both	 based	 on	 the	 pMAL‐cHT	
expression	 vector	 described	 in	Muench	 et	 al.	 [6]	 and	 therefore	 carrying	 an	 ampicilin	
resistance	gene	(AmpR),	as	well	as	the	constitutively	tobacco	etch	virus	(TEV)	protease	




The	 plastic	 and	 glassware	 used	 were	 typically	 purchased	 from	 Sigma‐Aldrich,	 from	
Lasec	 SA	 or	 from	 Merck	 &	 Co.,	 Inc.	 Falcon	 15‐ml	 tubes,	 50‐ml	 tubes	 and	 250‐ml	
ventilated	 and	 sealed	 tissue	 culture	 flasks	 were	 used	 for	 all	 cell	 culture	 and	 in	 vitro	
assays.	 Nunc	 cell	 culture	 clear	 96‐well	 plates	 (flat‐bottomed)	 were	 used	 for	 parasite	
growth	 assays	 as	 well	 as	 SYBR	 green‐based	 fluorescence	 measurements.	 Nunc	 flat‐
bottomed	black	96‐well	plates	were	used	for	fluorescamine‐based	fluorescence	assays.	
















1‐yl]	 ethanesulfonic	 acid	 (HEPES),	 11	 mM	 glucose,	 200	 µM	 hypoxanthine,	 24	 µg/ml	
gentamycin	 and	 0.6%	 w/v	 Albumax	 II,	 pH	 7.4	 (Albumax‐complete	 RPMI)	 to	 a	 final	
hematocrit	of	~5%.	Cultures	were	grown	at	37°C	in	sealed	tissue	culture	flasks	gassed	
with	 a	 low	O2	 gas	mixture	 (1%	O2,	 3%	CO2,	 in	N2)	 and	 constant	 rotary	 shaking	 (~50	
rpm)	to	promote	synchronized	growth	of	the	parasites	[7].	
	
One	 to	 five	days	before	using	 cultures	 for	experiments	 the	 cultures	were	 treated	with	
5%	 (w/v)	 D‐sorbitol	 solution	 for	 10	 min	 at	 37°C	 to	 ensure	 that	 cultures	 were	






In	preparation	 for	use	of	RBCs	 for	 cultivation	of	P.	 falciparum	 parasites,	 fresh	blood	–	
collected	in	heparinised	plastic	blood	bags	and	maintained	at	4°C	for	a	maximum	of	two	
weeks	 after	 collection	 from	 healthy	 donors	 –	 was	 washed	 to	 ensure	 minimal	
contamination	with	leukocytes	and	coagulated	proteins.	For	this	purpose,	the	blood	was	
centrifuged	 in	 50‐ml	 sterile	 Falcon	 tubes	 at	 1500×g	 for	 8	 min	 after	 which	 the	






supernatant,	 the	 cells	 at	 the	 interface	 between	 the	 supernatant	 and	 the	 RBCs,	 and	
occasional	 blood	 clots	 were	 removed.	 Next,	 the	 RBCs	 were	 washed	 three	 times	 by	
adding	one	equivalent	volume	of	RPMI	1640	 incomplete	medium	–	which	differs	 from	
complete	medium	by	lacking	Albumax	II	–	followed	by	centrifugation	and	removal	of	the	




For	 experiments	 performed	 with	 parasites	 isolated	 from	 their	 host	 RBCs,	 mature	
trophozoite‐stage	P.	 falciparum	were	 isolated	from	the	erythrocytes	by	treatment	with	
saponin	 (0.05%	 w/v),	 a	 plant‐derived	 glycoside	 detergent	 that	 interacts	 with	 the	
cholesterol	contained	in	the	membranes	of	erythrocytes	resulting	in	lytic	pores.	Saponin	
also	 interacts	 with	 the	 cholesterol	 in	 the	 membrane	 of	 the	 parasitophorous	 vacuole	
rendering	it	permeable	to	large	solutes	including	proteins,	however	it	does	not	damage	
the	 parasite	 plasma	membrane	which	 lacks	 cholesterol	 [9].	 Immediately	 after	 adding	
saponin	to	P.	falciparum	parasite	culture	suspension,	the	mixture	was	briefly	mixed	then	
centrifuged	 for	 8	 min	 at	 2000×g	 at	 room	 temperature.	 The	 supernatant	 (containing	
haemoglobin,	 other	 components	 of	 RBCs	 cytosol	 and	 RBCs	 plasma	 membranes)	 was	
discarded.	 The	 resultant	 pellet	 of	 parasites	 was	 washed	 by	 re‐suspension	 in	 malaria	
saline	buffer	(25	mM	HEPES,	125	mM	NaCl,	5	mM	KCl,	20	mM	glucose	and	1	mM	MgCl2,	
pH	 7.1)	 followed	 by	 centrifugation	 at	 14000×g	 for	 30	 s	 and	 discarding	 of	 the	
supernatant.	 The	 washing	 steps	 were	 repeated	 (typically	 3‐4	 times)	 until	 the	
supernatant	was	clear.	
	











parasites	 were	 triturated	 by	 repeated	 (10	 times)	 aspiration	 and	 vigorous	 flushing	
through	a	25‐gauge	injection	needle.	The	lysate	was	then	centrifuged	at	2000×g	for	30	





The	 number	 of	 trophozoites	 in	 parasite	 lysates	 was	 determined	 by	 counting	 in	 an	
improved	Neubauer	haemocytometer	under	light	microscopy	at	a	magnification	of	100×.	
Parasitaemia	in	P.	falciparum	cultures	was	determined	by	counting	infected	versus	non	




The	 antiplasmodial	 activity	 of	 test	 compounds	 was	 assessed	 in	 two	 complete	 culture	
media	 that	 had	 been	 subjected	 to	 different	 treatment	 conditions	 prior	 to	 use.	 “Fresh”	











Parasite	proliferation	was	assessed	using	 the	Smilkstein	et	al.	 [10]	 fluorescence‐based	
SYBR	 green	 assay	with	minor	modifications.	 Experiments	were	 carried	 out	 in	 96‐well	
plates	starting	with	parasites	in	the	ring	stage,	a	haematocrit	of	1%	and	a	parasitaemia	
at	 1%.	 	 Parasites	 were	 cultured	 in	 standard	 RPMI‐1640	 complete	 medium	 (which	
contains	 1	 µM	 pantothenate)	 or	 RPMI‐1640	 complete	 medium	 supplemented	 with	
pantothenate	 to	 a	 final	 concentration	 of	 100	 µM.	 Two‐fold	 serial	 dilutions	 of	 PanAms	
(from	 200	 µM	 to	 0.0195	 µM)	were	made	 in	 triplicate	 in	 final	 volumes	 of	 200	 µl.	 CQ‐





in	 a	 desiccator,	 flushed	 with	 low	 oxygen	 gas	 mixtures	 (1%	 O2,	 3%	 CO2,	 in	 N2)	 and	
incubated	at	37°C	for	96	h	to	allow	the	parasites	to	complete	two	intraerythrocytic‐stage	
cycles.	Following	the	96	h	incubation	time,	the	plates	were	immediately	frozen	at	‐80°C	
until	 processed	 for	 determining	 parasite	 proliferation.	 To	 quantify	 parasite	
multiplication,	100	µl	of	SYBR	Safe	solution	consisting	of	2	µl	of	SYBR	Safe	DNA	gel	stain	
(10	 000	 ×	 concentrate	 in	 DMSO)	 in	 10	 ml	 lysis	 solution	 (20	 mM	 Tris,	 5	 mM	 EDTA,	
0.008%	w/v	saponin,	0.08%	v/v	Triton	X‐100,	pH	7.5)	were	added	per	well	on	new	96‐
well	plates	–	final	DMSO	concentration	of	0.001%.	Next,	the	frozen	plates	containing	the	
cultures	 were	 thawed	 at	 room	 temperature	 and	 their	 contents	 were	 resuspended	
thoroughly	by	up‐and‐down	pipetting	followed	by	transfer	of	100	µL	of	the	suspension	
into	 the	 wells	 of	 the	 plate	 containing	 the	 SYBR	 Safe	 solution.	 Fluorescence	 was	 then	
measured	 immediately	with	Excitation	 and	Emission	wavelengths	 of	 490	nm	and	520	







Labtech	GmbH;	 for	 experiments	 conducted	 at	 ANU)	 or	 a	 Varioskan	multimode	 reader	
(Thermo	 Fisher	 Scientific	 Inc.;	 for	 experiments	 done	 at	 SUN).	 The	 background	




2.2.8.1	 Time‐course	 phosphorylation	 of	 [14C]Pantothenate	 and	
[14C]Pantothenamides	by	P.	falciparum	pantothenate	kinase	from	parasite	lysates	
To	 assess	 the	 ability	 of	 PfPanK	 in	 parasite	 lysates	 prepared	 from	 saponin‐isolated	
trophozoites	 to	 phosphorylate	 [14C]Pan	 (23*),	 [14C]N‐hexyl	 ‐PanAm	 (43a*),	 [14C]N‐





Phosphorylation	 reactions	 were	 performed	 at	 37°C	 using	 parasite	 lysates	 at	 a	 final	
concentration	 of	 2.0–2.5×107	 parasite	 cells/ml.	 The	 lysates	 had	 been	 previously	





reactions	were	 retrieved	 in	 duplicate	 and	 added	 to	 designated	wells	 of	Whatman	 96‐
well	UNIFILTERTM	350	plates	(with	0.45	μm	PP	filter	bottom	and	short	drip	directors)	






that	 had	 been	 pre‐loaded	 with	 50	 μl	 of	 150	mM	 Ba(OH)2.	 The	 samples	 were	 quickly	
mixed	 with	 the	 Ba(OH)2	 in	 the	 wells	 by	 up‐and‐down	 pipetting	 to	 terminate	 the	
phosphorylation	 reaction	 as	 a	 result	 of	 protein	precipitation.	After	 completing	 sample	
retrieval,	 50	 μl	 of	 150	 mM	 ZnSO4	 was	 added	 to	 each	 well	 and	 the	 plates	 were	 left	
standing	for	10	min	at	room	temperature	to	allow	further	precipitation	out	of	solution,	
of	 any	 phosphorylated	 compounds	 by	 the	 Somogyi	 reagent.	 Subsequently,	 non‐
phosphorylated	compounds	in	solution	were	removed	by	means	of	applying	vacuum	to	
the	 bottom	 of	 the	 plates,	 leaving	 only	 the	 radiolabelled	 phosphorylated	 compounds	
(solid)	 trapped	on	 the	 filter	 in	 each	well.	The	plates	were	 subsequently	washed	 twice	
with	water	(200	μl	in	each	well)	and	once	with	200	μl	95%	(v/v)	ethanol	and	kept	under	







minute	 (rcpm)	 values	 into	 molar	 concentrations,	 two	 50	 μl	 aliquots	 of	 the	
phosphorylation	reaction	mixtures	were	added	to	two	wells	of	a	96‐well	OptiPlateTM	96	
plate.	Next,	150	μl	of	Microscint‐40	was	added	into	each	well	and	the	plate	was	sealed	at	
the	 top	 side	 with	 TopSeal‐A	 Press‐on	 Adhesive	 Sealing	 Film	 before	 the	 amount	 of	
radioactivity	 in	 each	 well	 was	 counted	 in	 the	 same	 Scintillation	 and	 Luminescence	
Counter	as	described	above.	
 






2.2.8.2	 Determining	 P.	 falciparum	 pantothenate	 kinase	 kinetic	 parameters	 for	
pantothenate	and	for	pantothenamides	
To	determine	whether	 PanAms	 are	 inhibitors	 or	 alternative	 substrates	 of	PfPanK,	 the	
phosphorylation	of	radioactively‐labelled	[14C]Pan	(23*)	and	[14C]PanAms	(43a‐c*	and	
48b*)	were	performed	as	described	above	(section	2.2.8.1)	with	the	test	compounds	at	






PanAms	were	 determined	 from	 reactions	 containing	 0.2	 μM	 [14C]Pan	 (23*)	 in	 kinase	
buffer	and	the	specific	PanAm	in	concentrations	ranging	between	0.1	and	100	μM.	After	
equilibration	 at	 37°C	 for	 10	min,	 the	 reaction	was	 initiated	 by	 adding	 an	 appropriate	
volume	(typically	10	µl)	of	parasite	lysate	that	had	been	thawed	on	ice.	Phosphorylation	






parasite	 lysate	 served	 as	 blanks	 (0%	 phosphorylation),	 while	 reactions	 in	 which	 no	
PanAms	were	added	served	as	100%	phosphorylation	controls.	Concentration‐response	
curves	 were	 then	 generated	 as	 percentages	 in	 relation	 to	 the	 100%	 phosphorylation	
control.	








Escherichia	 coli	 BL21*(DE3)	 cells	 (only	 referred	 to	 as	BL21	 cells	 for	 the	 remainder	 of	
this	dissertation)	were	made	chemically	competent	for	uptake	of	DNA	by	streaking	the	
cells	 on	 LB	 agar	 plate	without	 any	 antibiotic	 and	 grown	 overnight	 at	 37°C.	 Next,	 one	
colony	 was	 picked	 from	 the	 agar	 plate	 and	 inoculated	 in	 5	 ml	 of	 LB	 broth	 medium	
without	 any	 antibiotics	 and	 incubated	 overnight	 with	 shaking	 at	 200	 revolutions	 per	
minute	 (rpm)	at	37°C.	The	culture	was	 then	diluted	1:100	(5	ml	culture	suspension	 in	
500	 ml	 culture	 medium)	 and	 incubated	 at	 37°C	 with	 shaking	 at	 200	 rpm	 until	 the	















cooled	on	 ice	 for	5	min.	Nine	hundred	µl	 of	 LB	broth	medium	without	 any	antibiotics	









resuspended	 in	 the	 remaining	 ~150	 µl	 of	 supernatant	 and	 plated	 in	 an	 agar	 plate	
containing	50	µg/ml	 kanamycin	 (for	 the	pET‐based	plasmids)	 or	100	µg/ml	 ampicilin	
(for	the	plasmids	encoding	PfACP).	Sterilized	glass	beads	were	placed	onto	the	agar	and	
rotated	 to	 spread	 the	 cell	 suspension	 before	 incubation	 with	 the	 lid	 down	 at	 37°C	
overnight.	
	
To	 introduce	 the	 TEV	 protease‐encoding	 plasmid	 into	 BL21	 cells	 that	 were	 already	





competent	 and	 transformed	 with	 the	 second	 plasmid,	 pRK586	 (KanR)	 as	 described	
above	 (section	 2.2.9.1),	 except	 that	 the	 LB	 broth	 culture	medium	 used	 contained	 100	
µg/ml	ampicilin	instead	of	an	antibiotic‐free	culture	medium.	An	LB	agar	plate	with	both	


















and	 quantities	 as	 specified	 above	 (section	 2.2.9.2).	 These	 starter	 cultures	 were	
incubated	 at	 37°C	 with	 shaking	 at	 200	 rpm	 until	 they	 became	 slightly	 cloudy.	 The	








protein	 purification	 or	 were	 stored	 at	 ‐20°C	 until	 required.	 Different	 incubation	






per	 gram	 of	 wet	 cell	 pellet	 and	 maintained	 at	 temperatures	 below	 10°C	 to	 minimise	












The	 supernatant	was	 retrieved	 and	 filtered	 using	Acrodisc®	 Premium	25	mm	 syringe	
filter	with	GxF/0.4	µm	pore	size	GHP	Membrane	(Pall	Life	Sciences)	before	injection	into	
an	ÄKTAprime‐system.	The	crude	cell	extract	was	loaded	into	1.0	ml	GE	Healthcare	Life	
Sciences	 HiTrapTM	 HP	 column	 preloaded	 with	 Ni2+.	 After	 washing	 steps	 and	 column	
equilibration	at	a	flow	rate	of	0.5	ml/min,	the	entire	filtered	protein	extract	was	injected	
slowly	 into	the	system	allowing	the	binding	of	the	6×His‐tagged	protein	to	the	column	
preloaded	with	Ni2+.	Before	 retrieving	 the	protein	 trapped	 in	 the	Ni2+	 column,	 a	wash	
step	with	15%	elution	buffer	(20	mM	Tris,	0.05%	w/v	sodium	azide,	500	mM	imidazole,	
500	 mM	 NaCl,	 pH	 7.9)	 and	 85%	 binding	 buffer	 was	 initiated	 to	 remove	 any	 non‐
specifically	 bound	 proteins.	 Elution	 of	 the	 target	 protein	was	 achieved	with	 stepwise	
increase	of	the	concentration	of	imidazole	by	increasing	the	proportion	of	elution	buffer	
while	 monitoring	 with	 UV	 absorption	 at	 280	 nm.	 The	 elution	 buffer	 –	 with	 high	
concentrations	 of	 imidazole	 and	 salts	 –	 containing	 the	 purified	 protein	 was	 then	
exchanged	 with	 a	 no‐imidazole	 and	 low	 salts	 containing	 gel	 filtration	 buffer	 (25	mM	
Tris,	 5	 mM	 MgCl2,	 pH	 8.0)	 using	 the	 same	 ÄKTAprime‐system,	 now	 with	 a	 HiTrap	
Desalting	5	ml	 column,	pre‐packed	with	 Sephadex	G‐25	 Superfine	 (GE	Healthcare	Life	
Sciences).	
	













polyacrylamide	gel	 electrophoresis	 (PAGE).	Appropriate	volumes	of	 the	proteins	were	
mixed	 with	 equal	 volumes	 of	 2×SDS‐PAGE	 sample	 loading	 buffer	 (0.125	 M	 Tris‐HCl,	










The	 gels	 were	 then	 stained	with	 Coomassie	 Brilliant‐Blue	 stain	 (45%	methanol,	 40%	
H2O,	 10%	 acetic	 acid	 and	 5%	 w/v	 Coomassie	 Brilliant‐Blue)	 and	 destained	 with	
destaining	 solution	 (45%	 methanol,	 45%	 H2O,	 10%	 acetic	 acid)	 to	 visualise	 protein	
bands	migrated	 in	 the	 gel.	 Protein	 identification	was	made	 through	 estimation	 of	 the	
molecular	weight	of	protein	bands	migrated	on	the	gel	 in	comparison	with	proteins	of	










Commercial	 CoA	 trilithium	 salt	 (Sigma‐Aldrich)	 and	 CoA	 from	 P.	 falciparum	 parasite	
lysates,	as	well	as	PfACP	overexpressed	in	BL21	and	from	P.	falciparum	parasite	lysates,	
were	 labelled	 with	 7‐diethylamino‐3‐(4‐maleimidylphenyl)‐4‐methylcoumarin	 (CPM).	
This	 compound	 is	 a	 profluorescent	 coumarin	 maleimide	 derivative	 that	 becomes	
fluorescent	 upon	 reaction	 with	 thiols	 [12].	 Commercial	 CoA	 or	 BL21	 overexpressed	
PfACP	were	 reacted	with	CPM	dissolved	 to	 2	mM	 in	DMSO,	 in	 argon‐purged	buffer	 at	










parasites	 to	 mature	 to	 the	 1st	 and	 2nd	 generation	 of	 trophozoites	 post	 treatment	
respectively,	 the	 parasitized	 RBCs	 were	 retrieved	 by	 centrifugation	 and	 parasites	
isolated	from	the	RBCs	as	described	under	section	2.2.3.	
	






Following	 parasite	 isolation,	 thophozoites	 were	 counted	 as	 described	 previously	
(section	2.2.5)	and	lysates	were	prepared	from	parasite	suspensions	containing	varying	
numbers	of	parasites	(~1.0	×	105	to	~2.5	×	1012	parasites/ml).	Next,	volumes	of	10‐25	µl	






























The	 fluorescence	 was	 monitored	 with	 the	 FLD	 detector	 at	 excitation	 and	 emission	
wavelengths	of	387	and	465	nm,	respectively,	with	chromatographic	peaks	at	retention	

























being	 equilibrated	 with	 80%	 v/v	 solvent	 A	 (0.1%	 v/v	 trifluoroacetic	 acid	 (TFA)	 in	
distilled	and	deionised	H2O)/20%	v/v	solvent	B	(0.1%	TFA	in	ACN)	at	a	flow	rate	of	1	










of	 a	 fluorescence‐based	 assay	 described	 previously	 for	 measurement	 of	N‐acetyl‐1‐D‐
myoinosityl‐2‐amino‐2‐deoxy‐a‐D‐glucopyranoside	 deacetylase	 activity	 [14].	
Recombinant	human	pantetheinase	(Novoprotein	Scientific,	Inc.)	at	a	final	concentration	
of	 100	 ng/ml	 or	 an	 equivalent	 volume	 of	 phosphate‐buffered	 saline	 (PBS;	 10	 mM	
phosphate	 buffer,	 2.7	 mM	 KCl,	 137	 mM	 NaCl,	 pH	 7.4)	 or	 Albumax	 II	 (at	 a	 final	
concentration	 0.6%,	 w/v)	 was	 added	 to	 solutions	 (at	 37	 ˚C)	 of	 100	 mM	 potassium	
phosphate,	 pH	7.5,	 0.5	mM	dithiothreitol	 (DTT),	 0.01%	 (w/v)	BSA,	 0.1%	 (v/v)	DMSO,	
with	 or	 without	 pantothenamides	 at	 a	 final	 concentration	 of	 200	 µM.	 At	 appropriate	
time	points,	aliquots	of	30	µL	of	the	reaction	mixtures	were	retrieved	in	duplicate	and	
mixed	with	 10	 µl	 20%	 (v/v)	 TCA	 to	 terminate	 the	 reaction.	 Following	 removal	 of	 the	
precipitated	protein	by	centrifugation	(14	000×g,	15	min),	25	µl	of	each	supernatant	was	
transferred	to	the	wells	of	a	black	96‐well	plate	and	75	µl	1	M	borate	(pH	9.0)	followed	






by	 30	 µl	 10	 mM	 fluorescamine	 in	 ACN	 was	 added	 to	 each	 well.	 The	 plate	 was	 then	
incubated	 at	 37˚C	 for	 10	 min	 before	 fluorescence	 was	 measured	 using	 a	 Varioskan	
spectral	 scanning	multimode	 reader	 (Thermo	 Scientific)	with	 excitation	 and	 emission	
wavelengths	of	390	nm	and	485	nm,	respectively	for	experiments	performed	at	SUN	or	
using	a	FLUOROstar	OPTIMA	multidetection	microplate	reader	(BMG	Labtech	GmbH)	for	





To	 test	 for	 statistically	 significant	 differences	 between	 the	means	 of	 two	 groups,	 two‐
tailed	 student	 t	 tests	were	 performed,	 paired	 or	 unpaired	 as	 appropriate.	 To	 test	 for	
significant	differences	between	the	means	of	more	than	two	groups,	one‐way	analysis	of	
variance	 (ANOVA)	 was	 performed.	 Pairwise	 comparisons	 were	 made	 post‐hoc	 with	
Tukey’s	 multiple	 comparisons	 test.	 ANOVA	 was	 performed	 using	 Instat	 3	 (GraphPad	
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to	 all	 chemotherapeutic	 agents	 currently	 in	 use,	 and	 also	 in	 response	 to	 the	 current	
malaria	eradication	research	agenda	[1‐3].	
	
The	 pipeline	 for	 antimalarial	 compounds	 is	 currently	 robust,	 particularly	 for	 the	




investigation	may	soon	become	 ineffective	as	 they	are	affected	by	 the	phenomenon	of	







carrier,	 CoA	 [4]	 and,	 as	 discussed	 before,	 P.	 falciparum	 parasites	 have	 absolute	
requirement	 for	 an	 exogenous	 supply	 of	 this	 nutrient	 –	 at	 least	 during	 its	
intraerythrocytic	 stage	 [5]	 –	 and	 a	 sensitivity	 to	 compounds	 that	 interfere	 with	 the	
parasite’s	 ability	 to	 utilize	 the	 nutrient.	 Structural	 analogues	 of	 pantothenic	 acid	 have	
















SUN	 indicated	 that	 PanAms	 had	 only	 modest	 in	 vitro	 antiplasmodial	 activity	 against	
intraerythrocytic‐stage	 P.	 falciparum	 parasites	 with	 the	 most	 potent	 compound	 (54c,	
table	 2.1)	 showing	 IC50	 of	 1.1	 ±	 0.2	 µM	 [16].	 It	 was	 then	 suspected	 that	 the	 poor	
antiplasmodial	 potency	was	 due	 to	 some	 degree	 of	 inactivation	 or	 degradation	 of	 the	
compounds	 during	 growth	 inhibition	 experiments.	 Later	 on,	 while	 examining	 the	
antiplasmodial	 activity	 of	 a	 series	 of	 PanAms	 against	 intraerythrocytic‐stage	 P.	
falciparum	 parasites,	 our	 collaborators	 at	 ANU	 serendipitously	 discovered	 that	 the	
antiplasmodial	potency	of	the	compounds	was	enhanced	considerably	when	the	parasite	
culture	 medium	 being	 used	 –	 which	 contains	 the	 commonly	 used	 serum	 substitute	
Albumax	 II	 [17]	or	human	 serum	–	was	pre‐incubated	at	37°C	 for	 a	prolonged	period	
(aged	 medium).	 Growth	 experiments	 performed	 with	 the	 aged	 medium	 allowed	
observation	 of	 the	 sub‐micromolar	 (IC50	 =	 20	 ±	 2	 nM)	 potency	 of	 PanAms	 that	 had	
shown	 no	 antiplasmodial	 effect	 when	 tested	 under	 standard	 culturing	 conditions	 in	
freshly	prepared	culture	medium	(fresh	medium).	
	






The	 final	 piece	 of	 the	 puzzle	 fell	 into	 place	 with	 the	 realisation	 of	 the	 presence	 of	
temperature‐sensitive	enzymes	with	pantetheinase	activity	in	parasite	culture	medium	
and	 that	 this	might	 explain	 the	 altered	 PanAms	 antiplasmodial	 activity	 in	 aged	 versus	
fresh	medium.	Pantetheinase	 activity	 is	 associated	with	 the	Vanin	proteins,	which	 are	
members	 of	 the	nitrilase	 superfamily	 that	 occur	 ubiquitously	 in	 soluble	 or	membrane	
bound	 forms	 in	 various	 tissues.	 The	 proteins	 play	 the	 physiological	 role	 of	 recycling	
pantothenic	acid	and	the	antioxidant	cysteamine	using	an	invariant	Glu‐Lys‐Cys	catalytic	
triad	 to	 hydrolyze	 the	 CoA	 metabolite	 pantetheine	 [18,	 19].	 Being	 promiscuous,	 the	





pantothenamides.	 The	 natural	 function	 of	 the	 pantetheinase	 enzymes	 is	 to	 hydrolyze	 the	 CoA	




Their	 susceptibility	 to	 degradation	 by	 the	 naturally	 occurring	 Vanin	 pantetheinases,	
present	 particularly	 in	 the	 serum	 of	 mammals	 [19],	 severely	 hampered	 the	 further	
development	 of	 PanAms	 as	 antiplasmodial	 agents.	 One	 approach	 through	 which	 this	
limitation	 could	 be	 addressed	would	 be	 to	 co‐administer	 PanAms	with	 pantetheinase	






inhibitors,	 as	 promoted	 by	 Ruan	 et	 al.	 [22]	 and	 by	 Jasen	 et	 al.	 [23].	 However,	 such	 a	
strategy	 would	 eventually	 require	 a	 separate	 optimization	 of	 the	 properties	 of	 two	
compound	sets,	and	possibly	result	 in	adverse	effects	associated	with	 inhibition	of	 the	
physiological	 function	 of	 pantetheinases	 [19].	 Therefore,	 an	 alternative	 approach	was	
investigated	in	which	the	molecular	structures	of	the	PanAms	were	modified	to	render	
them	 less	 susceptible	 to	 pantetheinase	 degradation	 while	 maintaining	 or	 improving	
their	antiplasmodial	potency.	To	achieve	this,	a	previously‐described	series	of	PanAms	
[24]	was	 investigated	 to	better	understand	 the	antiplasmodial	activity	of	 the	modified	
compounds.	 The	 series	was	 prepared	 from	 pantothenic	 acid	 or	 one	 of	 two	 structural	
analogues	 in	which	 the	β‐alanine	moiety	was	 replaced	with	 either	 glycine	 (to	 form	α‐
pantothenic	acid)	or	γ‐aminobutyric	acid	(to	result	in	homopantothenic	acid),	followed	
by	 introduction	 of	 the	 amide	 moiety	 via	 condensation	 with	 a	 range	 of	 amines	
representing	 four	 chemical	motifs	 into	each	of	 the	 three	acids	 in	parallel.	With	 such	a	
strategy,	 three	 sets	 of	 PanAms	 were	 prepared	 as	 detailed	 in	 the	 previous	 chapter	
(chapter	2,	section	2.1.2).	
	
It	 is	 important	 to	 note	 that	 the	 structural	 modification	 of	 the	 β‐alanine	 moiety	 of	
pantothenic	 acid	 (either	 by	 removal	 or	 addition	 of	 a	methylene	 group	 to	 form	α‐	 and	
HoPanAms	 respectively)	 results	 in	 alterations	 of	 the	 pantothenoyl	 moiey	 and,	 since	
previous	 studies	 showed	 that	 pantetheinase	 relies	 on	 the	 pantothenoyl	 moiety	 of	 its	
substrate	for	recognition	[20,	21]	 it	was	expected	that	the	modifications	would	reduce	
the	 scissile	 amide	 bond’s	 susceptibility	 to	 attack	 by	 the	 Cys	 residue	 of	 the	 enzyme’s	
catalytic	 triad	 and	 thereby	 prevent	 or	 reduce	 the	 rate	 of	 the	 pantetheinase‐mediated	
degradation	 of	 the	 α‐PanAms	 and	 HoPanAms	 series	 relative	 to	 that	 of	 the	 n‐PanAms	
counterparts.	 Consequently,	 α‐PanAms	 and	 HoPanAms	 should	 act	 as	 pantetheinase‐









In	 this	 chapter,	 the	 experiments	 that	 were	 performed	 to	 explore	 the	 merits	 of	 this	
strategy,	as	well	as	the	potential	of	the	α‐PanAms,	HoPanAms	and	other	pantothenic	acid	
analogues,	 namely	 the	 α‐MePanAms,	 β‐MePanAms	 as	 well	 as	 pantoyltauramides	 for	





Whether	 α‐PanAms	 and	 HoPanAms	 were	 more	 resistant	 to	 pantetheinase‐mediated	
degradation	 compared	 to	 their	 normal	 counterparts	 under	 in	 vitro	 conditions	 was	
investigated	 first.	 This	 was	 tested	 directly	 by	 incubating	 five	 sets	 of	 α‐,	 n‐	 and	
HoPanAms,	 each	 with	 a	 different	 type	 of	 amide	 substituent,	 in	 the	 presence	 of	






signal	 to	 that	 obtained	 from	 a	 standard	 curve	 prepared	 using	 the	 pure	 amine	 that	 is	
expected	to	be	released	upon	hydrolysis.	On	the	other	hand,	under	the	same	conditions,	
the	hydrolysis	of	members	of	 the	α‐PanAm	and	HoPanAm	series	was	only	between	5‐
15%	 complete,	 except	 in	 the	 case	 of	 the	 compounds	 44a	 and	 44c	 where	 it	 was	







of	 the	n‐PanAm	series	confers	 resistance	 to	degradation	by	pantetheinases,	or	at	 least	
reduces	 the	 rate	 of	 its	 degradation	 (figure	 3.2)	 due	 to	 reduced	 or	 lack	 of	 substrate	
recognition	by	the	enzyme.	
Time (h)



















Figure	 3.1	 ‐	 Hydrolysis	 of	 pantothenamide	 44b	 in	 the	 presence	 of	 recombinant	 human	
pantetheinase	and	Albumax	II.	The	time	courses	show	the	concentration	of	isobutylamine	–	the	
amine	 product	 of	 degradation	 of	 pantothenamide	 44b	 –	 detected	 during	 its	 incubation	 with	
recombinant	 human	 pantetheinase	 (100	 ng/ml;	 black	 circles),	 Albumax	 II	 (0.6%,	 w/v;	 grey	
circles),	or	an	equivalent	volume	of	water	(white	circles),	and	during	 incubation	of	Albumax	II	
(0.6%,	w/v)	 in	 the	 absence	 of	 PanAm	44b	 (grey	 squares).	 At	 each	 time‐point,	 the	 amount	 of	
primary	 amine	 was	 measured	 using	 a	 fluorescamine‐based	 fluorescence	 assay.	 Fluorescence	
measurements	 were	 converted	 to	 isobutylamine	 concentrations	 using	 a	 standard	 curve	
generated	using	isobutylamine	samples	of	known	concentration	that	had	been	processed	in	the	
same	 manner	 as	 the	 test	 samples.	 The	 data	 are	 from	 four	 independent	 experiments,	 each	
performed	 in	 duplicate,	 and	 error	 bars	 represent	 SEM.	Where	 not	 visible,	 the	 error	 bars	 are	
smaller	than	the	symbols.	










































































Figure	 3.2	 ‐	 Recombinant	 human	 pantetheinase‐mediated	 hydrolysis	 of	 N‐substituted	
pantothenamides.	Five	sets	of	α‐PanAms	(black	bars),	n‐PanAms	(light	grey	bars)	and	HoPanAms	







n‐PanAm	 in	 a	 given	 set	 (	 P	 <	 0.005;	 	 P	 <	 0.001,	 one	 way	 ANOVA).	 Note	 that	 since	 the	


















this	 feature	would	 translate	 into	 increased	 antiplasmodial	 potency	 in	 the	 presence	 of	
pantetheinase.	 The	 inhibitory	 activity	 of	 15	 sets	 of	 α‐PanAm,	n‐PanAm	 and	HoPanAm	
compounds	 was	 determined	 in	 vitro	 against	 intraerythrocytic	 P.	 falciparum	 parasites	
(strain	 3D7)	 in	 96	h	 growth	 assays	 initiated	with	parasites	 predominantly	 in	 the	 ring	
stage	 as	described	 in	 chapter	2	 section	2.2.7.	 For	 these	 experiments,	 freshly	prepared	
complete	 culture	medium	was	 used	 to	 ensure	 the	 presence	 of	 pantetheinase	 activity.	
From	the	IC50	values	obtained	in	this	manner	(Table	3.1),	it	is	evident	that	modification	
of	 the	 β‐alanine	 moiety	 in	 an	 n‐PanAm	 significantly	 improves	 their	 antiplasmodial	
activity	 (P	 <	 0.05	 and	 P	 <	 0.01	 for	 α‐PanAm	 and	 HoPanAm	 members	 respectively	
compared	to	their	n‐PanAm	counterparts,	unpaired	t‐test).	
	

























18	±	3	 >	200	 2.8	±	1.4	 14.	±	2	 7.5	±	6.2	 2.2	±	0.1	
42	
	
5.3	±	3.2	 >	200	 10	±	3	 ND	 ND	 ND	
43	 7.5	±	0.3	 >	200	 10	±	6	 7.9	±	1.8	 0.6	±	0.01	 14	±	7	
44	
	
18	±	2	 100	±	2.8	 11	±	5	 17	±	1	 0.8	±	0.7†	 2.2	±	0.2	
45	
	
161	±	40	 >	200	 7.5	±	0.7	 140		40	 >200	 3.3		0.5	
46	
	
12	±	1	 >	200	 1.7	±	0.3	 11	±	1	 0.3	±	0.02	 1.9	±	0.1	
47	
	
3.4	±	0.8	 53	±	11	 2.1	±	0.1	 4.2	±	0.2	 0.020±0.003†	 2.7	±	0.3	
48	 110	±	13	 >	200	 3.1	±	1.6	 127	±	16	 >	200	 4.7	±	0.5	
49	 >	200	 >	200	 23	±	1	 71	±	8	 >	200	 10	±	1	
50	 >200	 >	200	 24	±	1	 >	200	 >	200	 22	±	1	
51	 81	±	12	 >	200	 5.7	±	0.2	 64	±	16	 136	±	34	 4.9	±	1.3	
52	 47	±	1	 116	±	12	 2.8	±	1.4	 45	±	6	 117	±	12	 2.0	±	0.1	
53	 145	±	44	 >	200	 2.1	±	0.9	 116	±	21	 156	±	22	 1.9	±	1.0	
54	 155	±	27	 >	200	 1.1	±	0.5	 6.7	±	0.5	 38	±	6	 ND	
55	
	












When	 analyzing	 the	 results	 of	 the	 growth	 assays	 performed	 in	 fresh	 medium,	 it	 is	











compared	 to	 the	potency	 of	 the	 compounds	 tested	 in	 fresh	medium	and,	 the	 fact	 that	
further	incubation	of	the	medium	for	a	total	of	80	h	improved	the	antiparasitic	activity	of	
compound	 44b	 (N‐isobutyl‐n‐PanAm)	 even	 further	 in	 previous	 studies	 [25],	 other	
methods	for	ageing	the	culture	medium	to	eliminate	as	much	pantetheinase	activity	as	
possible	 were	 investigated.	 This	 aged	 medium	 would	 then	 be	 used	 to	 examine	 the	
intrinsic	antiplasmodial	activity	of	PanAms,	without	the	impairment	caused	by	residual	
pantetheinase‐mediated	 degradation.	 Freshly	 prepared	 culture	medium	was	 split	 into	
five	different	50	ml‐centrifuge	 tubes	 followed	by	different	 treatments.	Tube	Nr.	1	was	
incubated	 at	 room	 temperature	 (~25°C)	 under	 UV	 irradiation	 for	 2	 hours	 then	 kept	
refrigerated	(4°C)	for	~20	h,	tube	Nr.	2	was	incubated	at	56°C	for	4	hours,	tube	Nr.	3	was	
incubated	at	37°C	 for	40	h,	 tube	Nr.	4	was	 incubated	at	56°C	overnight	 (12‐16	h)	and	
tube	Nr.	5	was	kept	refrigerated	at	4°C	for	a	maximum	of	22	h	before	use.	The	culture	














































effect	 of	 pre‐incubating	 complete	 culture	 medium	 at	 room	 temperature	 (~25°C)	 for	 2	 hours	










56°C	 for	 4	 hours	 (IC50	 =	 3.7	 ±	 2.6	 µM)	 which	 practically	 revealed	 similar	 growth	
inhibitory	activities.	Although	the	incubation	of	culture	medium	at	25°C	under	UV	light	
(IC50	=	27.2	±	2.2	µM)	did	exhibit	some	effect,	the	improvement	was	smaller	compared	to	







in	 that	medium	was	 enhanced	 by	~4‐fold	 compared	 to	 the	 activity	 observed	 in	 fresh	
medium	maintained	at	4°C	(IC50	=	99.9	±	2.8	µM).	These	results	influenced	the	decision	





resistance	 to	 pantetheinase	 degradation,	 the	 antiplasmodial	 activity	 of	 the	 15	 sets	 of	
pantothenamides	 was	 tested	 in	 culture	 medium	 that	 had	 most	 of	 the	 pantetheinase	
activity	 inactivated	through	prolonged	incubation	at	56°C	(aged	medium)	as	described	
in	chapter	2,	section	2.2.6	and	compared	to	the	antiplasmodial	activity	in	fresh	medium	
with	pantetheinase	activity.	The	 results	 show	 that	while	 the	potency	of	 the	n‐PanAms	







fresh	 culture	 medium	 were	 found	 to	 be	 more	 potent	 in	 “aged”	 medium.	 Under	 such	












and	 in	 fresh	medium	 (figure	 3.4).	While	 the	 activity	 of	 the	n‐PanAm	was	 significantly	


























































































































Figure	 3.4	 ‐	 Antiplasmodial	 activity	 of	 PanAms	 in	 fresh	 (closed	 circles)	 and	 in	 aged	 (open	
circles)	 medium.	 The	 concentration	 response	 curves	 show	 the	 effect	 of	 increasing	
concentrations	of	α‐PanAm	43a	(Panel	A),	n‐PanAm	43b	(Panel	B)	and	HoPanAm	43c	(Panel	C)	















confer	 resistance	 to	 pantetheinase	 degradation	 while	 at	 the	 same	 time	 preserving	
antiplasmodial	activity.	
	
3.2.2.4	 Structure‐activity	 relationship	 analysis	 of	 pantothenamides	
antiplasmodial	activity	





n‐PanAm	47b	with	 an	 IC50	 of	 20	 ±	 3	 nM	was	 the	most	 potent,	 followed	 by	 the	 linear	
thioether‐substituted	n‐PanAm	46b	with	an	IC50	of	300	±	20	nM.	In	contrast,	 the	most	
potent	modified	pantothenamide	was	HoPanAm	54c	 that	 had	 an	 IC50	 of	 1.1	±	0.5	µM.	
This	indicates	that	although	structural	modification	imparts	pantetheinase‐resistance,	it	
does	 so	 at	 the	 cost	 of	 losing	 antiplasmodial	 potency	 –	 most	 probably	 because	 of	 the	




activity	 relationship	 between	 the	 α‐,	 n‐	 and	HoPanAm	 counterparts	 in	 relation	 to	 the	
amide	 substitution.	 This	 is	 not	 surprising	 if	 it	 is	 assumed	 that	 all	 three	 series	 of	
compounds	 interact	with	 the	same	 target,	 since	 the	shortening	or	elongation	of	 the	β‐
alanine	moiety	by	one	methylene	group	would	displace	the	amide	substituent	relative	to	
the	pantoyl	moiety	that	all	three	hold	in	common.	Conversely,	 it	can	then	be	predicted	













to	 the	 same	 relative	 position	 as	 in	n‐PanAm	47b	 has	 an	 IC50	 of	 4.7	 ±	 0.5	 μM.	 Similar	
trends	 can	 be	 observed	 for	 the	 n‐PanAm	 43b	 and	 HoPanAm	 41c	 suggesting	 that	 all	
three	series	of	compounds	exert	 their	antiplasmodial	activity	 through	 interaction	with	
the	same	target(s).	
	
PanAms	with	a	 linear	 thioether	 substituent	were	among	 the	most	 potent	 structurally‐
modified	compounds	tested	in	aged	medium,	with	HoPanAm	46c	exhibiting	the	lowest	
IC50	 value	 of	 these	 at	 1.9	 ±	 0.1	 µM.	 This	 compound	 and	 its	 alpha‐	 and	 normal‐	













3.2.3	 Antiplasmodial	 activity	 of	 N‐substituted	 α‐methyl	 and	 β‐methyl	
pantothenamides	
The	 results	 detailed	 above	 confirmed	 that	 structural	 modification	 of	 the	 β‐alanine	
moiety	 of	 the	 pantothenamide	 core	 structure	 conferred	 resistance	 to	 pantetheinase‐
mediated	degradation,	but	that	divergence	from	the	β‐alanine	core	structure	also	caused	
a	 loss	 in	potency.	Therefore	a	new	series	of	 compounds	was	synthesised	 in	which	 the	








Scheme	 3.2	 ‐	 Schematic	 representation	 of	 the	 parallel	 synthesis	 of	 α‐	 and	 β‐methylated	 N‐
substituted	pantothenamides.	
	
To	 test	 this	 proposal,	 α‐	 and	 β‐methylated	 analogues	 of	 the	 n‐PanAms	 that	 had	
demonstrated	the	most	potent	growth	inhibition	of	P.	 falciparum	parasites	 in	previous	
experiments	were	synthesized.	For	preparation	of	these	methylated	pantothenamides,	a	
method	 previously	 developed	 in	 our	 laboratory	 and	 described	 elsewhere	 [24]	 for	 the	







this	 method,	 α‐	 and	 β‐methylated	 pantothenic	 acid	molecules	 are	 prepared	 and	 then	
converted	to	their	corresponding	activated	thioesters.	Following	the	preparation	of	the	
thioesters,	aminolysis	reactions	were	performed	with	the	appropriate	amines	to	result	
in	 the	 desired	 α‐methyl	 and	 β‐methyl	 PanAms	 (α‐MePanAms	 and	 β‐MePanAms	






the	 n‐PanAms	 under	 the	 same	 conditions.	 Eight	 of	 the	 eleven	 β‐MePanAms	 tested	
exhibited	 IC50	 values	 significantly	 lower	 than	 their	 normal	 counterparts	 (P	 <	 0.01,	
unpaired	t‐test,	n	=3),	with	two	of	these	compounds	exhibiting	IC50	values	below	20	µM.	
Similarly,	nine	of	the	eleven	α‐MePanAms	tested	exhibited	IC50	values	lower	than	their	
equivalent	 normal‐counterparts	 (P	 <	 0.01,	 unpaired	 t‐test,	 n=3),	 with	 four	 of	 them	
demonstrating	 antiplasmodial	 activity	 at	 IC50	 values	 below	 20	 µM.	 In	 general,	 the	 α‐
MePanAm	 compounds	 showed	 increased	 potency	 compared	 to	 their	 β‐methylated	
counterparts,	 suggesting	 that	 placement	 of	 the	 methyl	 group	 is	 an	 important	
consideration	for	the	retention	of	activity.	Of	all	the	compounds	tested,	the	improvement	
on	 the	 antiplasmodial	 activity	 of	 the	 phenethyl‐substituted	 pantothenamide	was	most	
striking,	 with	 the	 α‐MePanAm	 47d	 having	 an	 IC50	 that	 is	 more	 than	 880‐fold	 lower	
compared	 to	 its	n‐PanAm	equivalent,	decreasing	 from	an	 IC50	of	53	±	11	µM	to	0.06	±	
0.02	µM	(mean	±	SEM,	n=3).	
	










human	 pantetheinase	 as	 detailed	 before	 (chapter	 2,	 section	 2.2.13).	 The	 amount	 of	
amine	 released	 under	 these	 conditions	 was	 then	 determined	 using	 the	 described	
fluorescamine‐based	fluorescence	assay.	The	hydrolysis	of	the	compounds	was	assessed	
after	24	h.	As	predicted,	 the	n‐PanAms	were	completely	hydrolyzed	 in	the	presence	of	
vanin,	 their	 α‐	 and	 β‐methylated	 counterparts	were	 only	marginally	 degraded	 (figure	
3.5).	

































































Figure	 3.5	 ‐	 Hydrolysis	 of	 α‐	 and	 β‐methylated	 pantothenamides	 by	 recombinant	 human	
pantetheinase.	Four	sets	of	selected	α‐MePanAms	(black	bars),	n‐PanAms	(light	grey	bars)	and	
β‐MePanAms	(dark	grey	bars)	–	structure	identifiers	indicated	below	the	bars,	and	structure	of	
amide	 substituent	 shown	above	–	were	 treated	with	 recombinant	human	pantetheinase.	After	
24	 h,	 the	 amount	 of	 amine	 released	 was	 determined	 by	 means	 of	 a	 fluorescamine‐based	
fluorescence	 assay.	 Values	 represent	 the	 mean	 from	 three	 independent	 experiments,	 each	
performed	in	duplicate;	the	error	bars	represent	SEM.	Where	not	visible,	the	error	bars	are	right	
on	the	edge	of	the	column.	The	asterisks	above	the	error	bars	represent	the	significance	of	the	
difference	 between	 the	 values	 determined	 for	 the	 respective	 α‐MePanAm	 and	 β‐MePanAm	
series	 members	 versus	 the	 n‐PanAms	 in	 a	 given	 set	 (	 P	 <	 0.005;	 	 P	 <	 0.001,	 one	 way	
ANOVA).	Note	 that	 since	 the	 fluorescence	 intensity	 of	 the	 fluorescamine‐amine	 conjugates	 for	
different	complexes	is	dependent	on	the	structure	of	the	amine,	the	fluorescence	measurements	
are	not	necessarily	comparable	between	the	different	sets.	





















42	 	 >	200	 >	200	 66	±	4	
43	 	 134	±	6	 23	±	1	 32	±	1	













60	 	 >	200	 76	±	2	 108	±	6	
61	 >	200	 20		2	 33		2	
63	 >	200	 >	200	 41		2	
	
These	results	clearly	demonstrate	that	the	introduction	of	the	methyl	group	on	the	α‐	or	
β‐carbons	of	 the	β‐alanine	moiety	of	n‐PanAms,	which	 increases	 the	 steric	bulk	 in	 the	
vicinity	 of	 the	 amide	 carbonyl	 group,	 does	 indeed	 decrease	 the	 susceptibility	 to	
pantetheinase‐mediated	degradation	of	these	compounds.	










that	 have	 been	 synthesized	 and	 tested	 against	 avian	 malaria	 parasites	 in	 the	 1940s,	
namely	the	pantoyltauramides	[26,	27].	To	achieve	this	objective,	a	set	of	N‐substituted	
pantoyltauramides	was	prepared	in	our	laboratory.1	Three	of	these	(compounds	56,	57	
and	58)	were	assessed	 for	 their	antiplasmodial	activity	against	 intraerythrocytic‐stage	































56	 5.7	±	0.2	 4.8	±	0.1	 113	±	2	 125	±	7	 	 20	 26	
57	
	
8.2	±	0.2	 11	±	0.2	 278	±	14	 257	±	7	 	 34	 25	






inhibitors	 of	 intraerythrocytic‐stage	 P.	 falciparum	 parasites	 as	 demonstrated	 if	
comparing	compounds	with	the	same	amine	substituent.	For	example,	compounds	47a‐
e	exhibited	IC50	values	ranging	between	0.06	±	0.02	µM	and	53	±	11	µM	in	fresh	medium,	
compared	 to	 the	 IC50	 value	of	 35	±	2	 for	 the	pantoyltauramide	58.	 In	 fact,	 among	 the	
pantothenamides,	 only	 n‐PanAm	 47b	 with	 a	 poor	 IC50	 of	 53	 ±	 11	 in	 fresh	 medium	
exhibited	 poorer	 antiplasmodial	 activity	 when	 compared	 to	 the	 pantoytauramide	
bearing	the	same	amine	substituent.	
	
To	 assess	 the	 antiplasmodial	 activity	 of	 pantoyltauramides	 in	 a	 culture	medium	with	












affect	 the	 antiplasmodial	 activity	 of	 the	 pantoyltauramides,	 suggesting	 that	 these	




While	 the	pantoyltauramides	are	structurally	very	similar	 to	the	pantothenamides,	 the	
exchange	of	an	amide	for	a	sulphonamide	group	could	have	important	effects	on	target	
selectivity,	which	could	explain	their	comparatively	lower	potency.	Subsequently,	it	was	
set	out	 to	 investigate	whether	pantoyltauramides	exerted	 their	antiplasmodial	activity	
“on‐target”,	i.e.	like	the	pantothenamides,	affect	processes	in	P.	falciparum	parasites	that	
are	dependent	on	pantothenic	acid	 [25].	This	was	done	by	 investigating	 the	activity	of	










Although	a	detailed	explanation	of	 the	mechanisms	 through	which	 the	observed	shifts	
occur	 remain	 to	 be	 elucidated,	 the	 results	 confirm	 that	 pantoyltauramides	 exert	 their	






antiplasmodial	 inhibitory	 effects	 by	 affecting	 processes	 that	 depend	 on	 pantothenate.	







In	 these	 studies	 it	 was	 shown	 that	 pantothenate	 analogues	 –	 including	N‐substituted	
pantothenamides	 and	 N‐substituted	 pantoyltauramides	 –	 inhibit	 growth	 of	
intraerythrocytic‐stage	P.	 falciparum	 parasites,	with	 the	 former	 analogues	 doing	 so	 at	
sub‐micromolar	 and	 the	 latter	 at	 low	micromolar	 concentrations.	 In	 both	 cases,	 these	
compounds	 act	 through	 inhibition	 of	 pantothenate‐dependent	 processes,	 most	 likely	
CoA	 biosynthesis	 and	 utilization.	 It	 was	 also	 demonstrated	 that	 the	 antiplasmodial	




While	 additional	 studies	 on	 the	 potential	 rescue	 effect	 that	 addition	 of	 pantothenate	
could	 have	 in	 cultures	 that	 had	 been	 treated	with	 PanAms	 or	 pantoyltauramides	 are	
warranted,	 the	 observation	 that	 the	 antiplasmodial	 activity	 of	 PanAms	 and	
pantoyltauramides	could	be	negated	(as	shown	by	the	increase	in	the	IC50	values)	in	the	
experiments	 where	 culture	 medium	 was	 supplemented	 with	 pantothenate	 clearly	
indicates	 that	 the	 pantothenate	 analogues	 interfere	 with	 pantothenate‐dependent	
processe(s)	in	the	intraerythrocytic‐stage	P.	falciparum.	parasites.	






Overall,	 this	 work	 has	 provided	 significant	 insight	 towards	 understanding	 the	
pantothenamide	 class	 of	 antimicrobials,	 and	 affords	 new	 avenues	 that	 can	 be	
investigated	for	improvement	of	the	antiplasmodial	activity	of	this	class	of	compounds.	
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N‐substituted	 pantothenamides	 have	 been	 shown	 to	 possess	 antibacterial	 activity	 in	
vitro	 against	 E.	 coli	 and	 S.	 aureus	 among	 other	 susceptible	 bacteria	 [1‐5].	 In	 those	
microorganisms,	the	compounds	bind	to	and	serve	as	substrates	for	bacterial	PanK,	the	
first	 enzyme	 in	 the	 CoA	 biosynthesis	 pathway,	 and	 as	 a	 consequence	 competitively	
inhibit	 PanK‐catalysed	 pantothenate	 phosphorylation	 [4,	 6‐9].	 Upon	 phosphorylation,	
the	 resulting	4'‐phosphopantothenamides	are	 further	 transformed	by	PPAT	and	DPCK	




cause	bacteriostasis	 in	 susceptible	bacteria,	 it	 is	 still	not	known	whether	 their	activity	




The	 results	 reported	 in	 the	 previous	 chapter	 of	 this	 dissertation	 (chapter	 3),	
demonstrated	that	some	PanAms	are	potent	antiplasmodial	compounds	with	IC50	values	
comparable	 to	 that	of	chloroquine,	 the	benchmark	 for	sensitive	parasites.	Moreover,	 it	
was	shown	that	chemical	modifications	that	render	PanAms	resistant	to	pantetheinase	
degradation	 while	 maintaining	 their	 antiplasmodial	 activity	 can	 be	 exploited	 for	
development	of	this	class	of	compounds	as	potential	antimalarial	medications.	The	“on‐
target”	activity,	revealed	by	demonstrating	that	the	IC50	of	PanAms	was	increased	when	
concentration	 response	 assays	 were	 performed	 in	 growth	 media	 with	 excess	
pantothenate	 concentration	 impelled	 further	 investigation	 to	 elucidate	 the	 exact	










The	 first	 experiments	 were	 directed	 at	 determining	 the	 manner	 in	 which	 PanAms	





same	 amide	 substitution	 when	 tested	 in	 culture	 medium	 that	 was	 devoid	 of	
pantetheinase	activity.		The	second	set	of	experiments	where	designed	to	investigate	the	
potential	 targets	 of	 the	 PanAms	 in	 the	 event	 that	 they	 acted	 as	 antimetabolites,	 i.e.	
exerting	an	effect	downstream	of	PfPanK‐catalysed	phosphorylation.	This	was	done	by	




4.2.1	 Interaction	 of	 N‐substituted	 pantothenamides	 with	 PfPanK:	 pantothenate	
phosphorylation	inhibition	
A	 simple,	 yet	 effective	 test	 to	 establish	whether	 the	 relative	 potency	 observed	 for	 the	
various	 PanAms	 series	 correlates	 with	 their	 interaction	 with	 PfPanK	 is	 to	 test	 these	
compounds	 for	 their	 ability	 to	 inhibit	 pantothenate	 phosphorylation.	 Compounds	 that	
have	a	high	affinity	 for	PfPanK	–	be	 it	as	actual	 inhibitors,	or	as	alternative	substrates	
that	effectively	compete	with	pantothenate	for	the	enzyme	–	will	show	potent	inhibition,	






while	 those	 that	 have	 a	 low	 affinity	 or	 poor	 interaction	 will	 not.	 To	 assess	 this,	 22	
selected	 PanAms	 of	 the	 α‐,	 n‐	 and	 HoPanAm	 series	 that	 represent	 some	 chemical	
diversity	 in	 their	 amide	 moieties	 were	 selected	 based	 on	 the	 in	 vitro	 antiplasmodial	
activity	in	standard	(fresh)	as	well	as	in	aged	culture	medium	(chapter	3,	section	3.2.2).		
	
The	PanAms	were	 tested	at	 concentrations	 ranging	between	0.1	and	100	μM	 for	 their	
ability	 to	 interfere	 with	 the	 phosphorylation	 of	 0.2	 μM	 [14C]pantothenate	 by	 parasite	
lysates	which	 contain	PfPanK.	 Parasite	 lysates	where	 used	 since	PfPanK	has	 not	 been	




precipitation	 assay	 detailed	 in	 chapter	 2,	 section	 2.2.8.	 From	 the	 data	 generated,	 a	
concentration‐response	profile	was	then	established	for	each	compound.	Representative	























































































































































































































Figure	4.1	Effect	 of	 PanAms	on	 the	 in	vitro	phosphorylation	 of	 [14C]pantothenate	 by	PfPanK	
containing	 trophozoite‐stage	 P.	 falciparum	 parasite	 lysates.	 Concentration‐response	
experiments	were	performed	for	all	the	compounds	shown	in	Table	4.1.	The	plots	are	examples	
of	 the	profiles	generated	for	the	set	of	N‐phenethyl	PanAms	(47a‐c),	panels	A,	B	and	C	and	N‐











In	 figure	 4.1	 it	 can	 be	 observed	 that	 an	 increase	 in	 the	 concentration	 of	 the	 PanAms	
directly	correlates	with	a	decrease	 in	 the	amount	of	 the	pantothenate	phosphorylated.	
The	 concentration‐response	 profiles	 were	 subsequently	 used	 to	 calculate	 the	
concentration	 of	 each	 PanAm	 that	 results	 in	 50%	 inhibition	 (IC50)	 of	 pantothenate	
phosphorylation.	 This	 was	 done	 by	 fitting	 a	 Sigmoidal,	 Logistic,	 3	 Parameter	 dose‐
response/variable	 slope	 to	 the	 data,	 using	 nonlinear	 least	 squares	 regression	 and	
averaging	the	IC50	estimates	from	at	least	two	independent	experiments.	Most	of	the	n‐




Table	 4.1	 –	 Comparison	 of	 the	 N‐substituted	 PanAm‐mediated	 inhibition	 of	



































1.2		1.6	 0.2		0.1	 <	0.1	 18	±	3	 >	200	 2.8	±	1.4 14.	±	2	 7.5	±	6.2	 2.2	±	0.1
43	
	
31		6	 <	0.1	 0.3		0.1	 7.5	±	0.3 >	200	 10	±	6	 7.9	±	1.8	 0.6	±	0.01	 14	±	7	
46	
	
1.3		0.2	 <	0.1	 0.2		0.02	 12	±	1	 >	200	 1.7	±	0.3 11	±	1	 0.3	±	0.02	 1.9	±	0.1
47	
	
2.9		0.8	 <	0.1	 0.2		0.1	 3.4	±	0.8 53	±	11 2.1	±	0.1 4.2	±	0.2	0.020±0.003†	 2.7	±	0.3
48	
	












ND ND ND ND	 ND	 ND
ND	‐	Not	determined	due	to	limited	stock	of	compounds	
	







can	 be	 deduced	 from	 the	 results	 is	 that	 the	 n‐PanAms	 are	 significantly	 more	 potent	
inhibitors	of	parasite	 lysate‐mediated	pantothenate	phosphorylation	 than	 their	α‐	 and	
HoPanAm	 counterparts.	 This	 suggests	 that	 possibly	 the	 n‐PanAms	 have	 the	 strongest	
interaction	with	the	PfPanK	in	the	parasite	lysates,	either	as	inhibitors	or	as	substrates.	
This	 is	 not	 surprising	 considering	 that	 pantothenate	 (the	 natural	 substrate	 for	 PanK)	
and	the	n‐PanAms	have	the	intact	β‐alanine	moiety	in	common.	The	n‐PanAms	therefore	
have	 a	 molecular	 structure	 more	 suitable	 for	 interaction	 with	 the	 active	 site	 of	 the	
enzyme	than	their	two	structurally	modified	counterparts.	Moreover,	the	results	of	the	
in	 vitro	 antiplasmodial	 activity	 tests	 against	 intraerythrocytic‐stage	 P.	 falciparum	
parasites	 in	 aged	 medium	 (i.e.	 with	 inactivated	 pantetheinase),	 as	 reported	 in	 the	
section	 3.2.2	 of	 the	 previous	 chapter	 (and	 shown	 again	 in	 table	 4.1	 for	 selected	
compounds),	showed	that	the	n‐PanAms	also	exhibited	the	most	potent	antiplasmodial	
activity	 compared	 to	 their	 shortened	 and	 lengthened	 counterparts.	 Taken	 together,	
these	 results	 indicate	 that	 the	 interaction	 of	 PanAms	 with	 PfPanK	 contained	 in	
trophozoite‐stage	parasite	 lysates	 is	 a	key	element	 in	 the	MoA	of	 these	 compounds	 in	
intraerythrocytic‐stage	P.	falciparum	parasites.	
	
A	 SAR	 analysis	 of	 the	 amide	 substituents	 suggests	 that	 some	 groups	 do	 show	 greater	
potency	 across	 the	 three	 sets	 of	 PanAms	 tested	 than	 others.	 For	 example,	 the	 α‐	 and	
HoPanAm	with	amide	substituents	prepared	from	secondary	amines	(such	as	80a,	c	and	
81a,	 c)	 are	 poor	 inhibitors	 of	 PfPanK‐mediated	 pantothenate	 phosphorylation	 in	
comparison	to	compounds	with	amide	substituents	prepared	from	primary	unbranched	
aliphatic	 (41a,	 c)	 and	 heteroatom‐containing	 aliphatic	 amines	 (46a,	 c),	 and	 primary	
amines	with	substituents	containing	aromatic	groups	(47a,	c	and	48a,	c)	and	aliphatic	












the	 most	 potent	 inhibitors	 of	 parasite	 lysates	 PfPanK’s‐mediated	 pantothenate	
phosphorylation	 activity,	 it	 cannot	 distinguish	 whether	 this	 is	 due	 to	 the	 compounds	
acting	as	inhibitors	of	the	enzyme’s	activity,	or	if	the	n‐PanAms	in	fact	act	as	preferred	
alternative	substrates	and	therefore	can	effectively	compete	with	pantothenate	for	 the	
enzyme’s	 active	 site.	To	 investigate	 if	 any	 of	 the	 PanAms	 served	 as	 substrate	 for	 the	
enzyme	contained	in	parasite	lysates,	phosphorylation	reactions	with	PfPanK	containing	
parasite	lysates	were	performed	with	a	range	of	concentrations	of	each	of	four	selected	
[14C]‐labelled	 PanAms,	 namely	 N‐hexyl	 ‐PanAm,	 N‐hexyl	 n‐PanAm	 and	 N‐hexyl	




fresh	and	aged	medium	as	 reported	previously	 (chapter	3,	 section	3.2.2.1)	and	also	 to	
include	compounds	representing	all	three	PanAm	types	(with	the	same	aliphatic	amide	
substitution)	and	at	least	one	PanAm	with	an	aromatic	amide	substitution.	A	limited	but	
representative	number	of	 compounds	were	used	 for	 these	 tests	due	 to	 restrictions	on	
the	availability	of	their	radiolabelled	versions.	
	






Phosphorylation	 reactions	were	 also	 performed	with	 pantothenate	 under	 the	 same	 in	
vitro	conditions	for	comparison.	The	reactions	were	assayed	using	the	Somogyi	reagent‐
based	 precipitation	method	detailed	 in	 chapter	 2,	 section	 2.2.8.	 From	 the	 time‐course	
data	 at	 each	 concentration	 ranging	 from	0.005	 to	 0.31	µM	 for	 [14C]N‐benzyl	n‐PanAm	
(48b*),	 0.04	 to	 2.5	 µM	 for	 [14C]Pan	 (23*),	 [14C]N‐hexyl	 n‐PanAm	 (43b*)	 and	 [14C]N‐
hexyl	HoPanAm	(43c*),	and	from	0.08	to	5	µM	for	[14C]N‐hexyl	α‐PanAm	(43a*),	initial	
rates	were	determined	–	an	example	of	time‐course	phosphorylation	reaction	of	Pan	and	
PanAms	by	PfPank	 containing	 parasite	 lysates	 is	 shown	 in	 figure	 4.2.	 From	 the	 initial	
rates,	the	activity	profiles	shown	in	figure	4.3	were	then	obtained.	



































and	 [14C]N‐benzyl	n‐PanAm	 (48b*,	white	 squares)	 by	PfPank	 from	parasite	 lysates	 at	 37°C	 in	
kinase	 buffer	 (50	 mM	 Tris,	 5	 mM	 ATP,	 5	 mM	 MgCl2,	 pH	 7.4)	 increased	 linearly.	 At	 pre‐
determined	time	intervals,	up	to	120	minutes,	samples	of	the	phosphorylation	reaction	mixtures	
were	retrieved	and	treated	as	described	in	chapter	2,	section	2.2.8.1.	Panel	A	(inset)	shows	the	
time‐course	 phosphorylation	 of	 the	 tested	 compounds	 during	 the	whole	 period	 assayed	 (120	
min).	 Panel	 B	 is	 a	 magnification	 of	 the	 initial	 30	 min,	 a	 time	 period	 during	 which	 the	



























































Figure	 4.3	 ‐	 Phosphorylation	 of	 pantothenate	 and	 selected	 pantothenamides	 by	 PfPanK	 in	
parasite	 lysates.	 Activity	 profiles	 of	 selected	 PanAms	 at	 increasing	 substrate	 concentrations.	
Panel	 A	 indicates	 the	 phosphorylation	 of	 pantothenate	 and	 Panels	 B,	 C,	 D	 and	 E	 show	 the	
phosphorylation	of	N‐hexyl	α‐PanAm	(43a),	N‐hexyl	n‐PanAm	(43b),	N‐hexyl	HoPanAm	(43c)	
and	N‐benzyl	n‐PanAm	(48b)	 respectively.	The	phosphorylation	 reactions	were	 carried	out	 in	
kinase	buffer	(50	mM	Tris,	5	mM	ATP,	5	mM	MgCl2,	pH	7.4)	using	a	modified	and	miniaturised	
Somogyi	 reagent‐based	 assay	 as	 described	 in	 chapter	 2,	 section	 2.2.8.2.	 Initial	 rates	 were	
determined	from	the	time	course	data	at	each	concentration.	Symbols	represent	the	mean	of	two	
independent	experiments	and	the	error	bars	show	range/2.	The	solid	curves	show	the	best	fit	of	
the	Michaelis‐Menten	 equation	 to	 the	 data,	 from	which	 the	 kinetic	 parameters	 (Vmax	 and	Km)	
were	determined.	
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As	 can	 be	 seen	 from	 the	 activity	 profiles,	 all	 of	 the	 PanAms	 tested	were	 taken	 by	 the	
PfPanK	 enzyme	 contained	 in	 parasite	 lysates	 as	 substrates,	 showing	 phosphorylation	
activity	 (Vmax	 of	 0.01	 ±	 0.01	 to	 0.06	 ±	 0.01	 µmol.s‐1/107	 cells)	 in	 a	 range	 similar	 to	 that	
exhibited	 for	 the	natural	 substrate,	 pantothenate	 (Vmax	 of	 0.07	±	0.02	 µmol.s‐1/107	 cells).	
These	 results	 are	 consistent	 with	 previous	 studies	 in	 which	 the	 pantothenic	 acid	
analogue	pantothenol	was	demonstrated	to	serve	as	a	substrate	for	PfPanK	in	parasite	



















Comparing	 the	 kinetic	 parameters,	 it	 appears	 that,	 in	 general,	 the	 maximal	 rates	 of	
phosphorylation	(Vmax)	of	the	PanAms	(regardless	of	structure)	are	generally	lower	than	
that	 of	 pantothenate	 (PfPanK’s	 natural	 substrate)	 except	 for	N‐hexyl	 α‐PanAm	 (43a)	
with	a	Vmax	of	0.06	±	0.01	µmol.s‐1/107	cells.	The	normal	PanAms	N‐hexyl	n‐PanAm	(43b)	
and	N‐benzyl	n‐PanAm	(48b)	showing	maximal	rates	of	phosphorylation	~6‐fold	lower	






than	 the	 phosphorylation	 of	 pantothenate	 where,	 among	 the	 compounds	 tested,	 the	
ones	that	exhibited	the	lowest	phosphorylation	rates.	A	comparison	of	the	Km	values	of	
the	 compounds	 tested	 reveals	 that	 both	 the	 n‐PanAms	 tested	 (Compounds	 43b	 and	
48b)	 exhibit	 values	 at	 least	 an	 order	 of	 magnitude	 lower	 than	 the	 Km	 obtained	 for	
pantothenate.	The	Km	for	the	HoPanAm	43c	is	~2.5‐fold	lower,	while	the	‐PanAm	43a	
is	 the	 only	 compound	 with	 a	 Km	 higher	 than	 that	 for	 pantothenate	 (~5‐fold	 higher).	
These	 findings	 suggest	 that	 the	 n‐PanAms	 act	 as	 preferred	 substrates	 of	 the	 PfPanK	
contained	in	the	complex	matrix	that	parasite	lysates	are	and,	that	the	potent	inhibition	
of	 pantothenate	 phosphorylation	 observed	 may	 be	 a	 result	 of	 these	 compounds	
effectively	 competing	with	pantothenate	 for	 the	 enzyme’s	 active	 site.	Moreover,	 based	
on	 the	 available	 data,	 there	 is	 indication	 that	 PanAms	 are	 not	 inhibitors	 of	 parasite	
lysate	 contained	 PfPanK’s	 phosphorylation	 activity,	 providing	 evidence	 against	 the	





To	 further	confirm	 that	 the	PanAms	(and	particularly	 the	n‐PanAms)	mainly	 inhibit	P.	
falciparum	by	acting	as	antimetabolites,	i.e.	that	they	act	as	substrates,	and	not	inhibitors	
of	 PfPanK,	 the	 PanAm	 analogue	 deoxy‐N5‐Pan	 (compound	 79)	 was	 prepared	 (figure	
4.3).	This	compound	has	 the	same	amide	substitution	as	N5‐Pan	(compound	41b)	but	
lacks	 its	 4'‐hydroxyl	 group	 and	 as	 such	 cannot	 be	 phosphorylated	 by	 PfPanK	 but	 it	
should	 retain	 all	 the	other	 important	binding	 interactions	with	 the	 enzyme.	 Since	N5‐
Pan	acts	as	an	excellent	substrate	of	PfPanK,	 it	was	 therefore	expected	that	deoxy‐N5‐
Pan	should	act	as	a	competitive	inhibitor	of	the	enzyme	with	potency	similar	to	that	seen	






for	 N5‐Pan	 in	 the	 inhibition	 tests	 described	 previously	 (section	 4.2.1).	 However,	
inhibition	 tests	done	under	similar	conditions	as	all	 the	other	PanAms	(50	mM	Tris,	5	
mM	ATP,	5	mM	MgCl2,	 pH	7.4)	 revealed	 that	deoxy‐N5‐Pan	 (79)	has	 an	 IC50	 value	 for	













Figure	 4.4	 ‐	 Inhibition	 of	 pantothenate	 phosphorylation	 by	 N5‐Pan	 (41b,	 black	 circles)	 and	
deoxy‐N5‐Pan	 (79,	 white	 circles).	 The	 concentration	 response	 curves	 show	 the	 effect	 of	
increasing	concentrations	of	N5‐Pan	and	deoxy‐N5‐Pan	on	inhibition	of	phosphorylation	of	0.2	
µM	pantothenate	by	PfPanK	 from	 lysates	prepared	 from	trophozoite‐stage	parasites.	The	data	
were	 obtained	 from	 two	 independent	 experiments	 each	 carried	 out	 in	 duplicate	 (error	 bars	
represent	range/2).	Where	not	shown,	error	bars	are	smaller	than	the	symbol.	
	
Deoxy‐N5‐Pan’s	poor	 inhibition	of	pantothenate	phosphorylation	 indicates	 that	 the	4'‐
OH	 that	 accepts	 the	 phosphoryl	 group	 forms	 crucial	 binding	 interactions	 with	 the	
PfPanK	enzyme.	This	suggests	that	the	enzyme	is	predisposed	to	the	binding	of	PanAms	
that	can	act	as	alternate	substrates,	and	consequently	that	serves	as	a	gateway	to	their	
metabolic	 activation	 as	 CoA	 antimetabolite	 inhibitors.	 This	 conclusion	 was	 further	
confirmed	 by	 the	 results	 of	 tests	 in	 which	 deoxy‐N5‐Pan	 (79)	 and	 also	 deoxy‐N‐
phenethyl	n‐PanAm	(83)	–	the	4'‐deoxy	analogue	of	N‐phenethyl	n‐PanAm	(47b),	which	
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showed	 the	most	potent	 antiplasmodial	 activity	 in	 the	 tests	described	 in	 the	previous	
chapter	 –	were	 evaluated	 for	 their	 ability	 to	 inhibit	 parasite	 proliferation	 (figure	4.5).	
These	results	showed	that	neither	compound	is	sufficiently	potent	to	cause	P.	falciparum	
parasite	growth	inhibition	below	50%	of	the	control,	even	at	the	highest	concentration	




These	 findings	 clearly	 show	 that	 the	 in	 vitro	 antiplasmodial	 potency	 of	 the	 PanAms	
correlates	with	their	PfPanK‐mediated	phosphorylation	activity,	and	they	do	not	rule	out	
the	 possibility	 that,	 in	 addition	 to	 initially	 interfering	 with	 pantothenate	







of	 PfPanK	 in	 intraerythrocytic‐stage	 P.	 falciparum	 parasites	 was	 investigated.	
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Figure	 4.5	 ‐	 Antiplasmodial	 activity	 of	 selected	 normal	 pantothenamides	 (black	 circles)	 and	
deoxy‐pantothenamides	 (white	 circles)	 in	 culture	medium	 treated	 at	 56°C	 for	 18h	 to	 remove	
pantetheinase	 activity.	 Panel	 A	 and	 panel	 B	 show	 the	 concentration	 response	 curves	 as	
measured	using	the	SYBR	Green	I‐based	growth	assay,	for	increasing	concentrations	of	N5‐Pan	
(41b)	and	deoxy‐N5‐Pan	(79),	and	 for	N‐phenethyl	n‐PanAm	(47b)	and	deoxy‐N‐phenethyl	n‐
PanAm	 (83)	 respectively.	 Symbols	 represent	 the	mean	of	 two	 independent	 experiments,	 each	





























4.2.4.1	 Effect	 of	 PanAm	 treatment	 on	 the	 CoA	 levels	 in	 P.	 falciparum	 parasite	
cultures	
To	determine	the	effect	of	PanAm	treatment	on	the	CoA	levels	of	P.	falciparum	parasites,	
cultures	 in	aged	medium	with	 the	parasites	 synchronised	at	 ring	 stage	were	 split	 into	
three	 equal	 parts.	 Two	 of	 the	 cultures	 splits	were	 treated	with	N5‐Pan	 (41b)	 to	 final	
concentrations	of	50	µM	and	100	µM	respectively,	while	an	equivalent	volume	of	DMSO	
–	 the	solvent	used	to	dissolve	 the	PanAm	–	was	added	to	 the	 third	culture	 to	serve	as	
control	(DMSO	final	concentration	never	exceeded	0.05%	v/v	in	parasite	cultures).	
	
The	 parasites	 cultures	were	 then	 incubated	 following	 standard	 protocols	 for	 24	 h	 (to	
allow	the	parasites	to	mature	from	ring	stage	to	the	first	generation	of	trophozoites	post	
treatment)	 and	 72	 h	 (to	 allow	 the	 parasites	 to	 grow	 to	 the	 second	 generation	 of	
trophozoites	post	 treatment	with	 the	PanAm).	Cultures	were	 then	retrieved	and,	 after	
isolating	the	parasites	at	trophozoite	stage	from	infected	RBCs	as	described	in	chapter	2,	
section	 2.2.3,	 parasites	 were	 counted	 as	 detailed	 in	 chapter	 2,	 section	 2.2.5	 before	
lysates	were	prepared	in	parasite	suspensions	containing	~2.5	×	1010	cells/ml,	following	
the	 procedures	 described	 in	 chapter	 2,	 section	 2.2.4.	 Next,	 the	 CoA	 present	 in	 the	
parasite	lysates	was	labelled	with	excess	(0.5	mM	final	concentration)	7‐diethylamino‐3‐
(4‐maleimidylphenyl)‐4‐methylcoumarin	 (CPM)	 under	 argon	 atmosphere	 to	 allow	
complete	 fluorescence	 labelling	of	all	 free	 thiol	groups	 in	 the	parasite	 lysate.	This	was	
followed	by	analysis	of	the	derivatized	lysate	using	a	reverse‐phase	HPLC	C18	columns	
as	detailed	 in	chapter	2,	section	2.2.12	(figure	4.6).	The	area	under	 the	curve	(AuC)	of	
the	 peaks	 corresponding	 to	 fluorescently‐labelled	 CoA	 (identified	 by	 comparison	 to	 a	
known	standard)	was	subsequently	used	to	generate	quantitative	data	 for	comparison	
between	the	samples	(figure	4.7).	
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possibly	 represent	TCEP	adducts	 of	 CPM.	 	The	CoA	peak	 is	 skewed	by	 approximately	1.5	min	
possibly	as	a	result	of	CPM	 labelling.	Panel	B	 shows	 the	chromatograms	of	 the	control	culture	
(black	line),	cultures	treated	with	50	µM	N5‐Pan	(red	line)	and	cultures	treated	with	100	µM	N5‐
Pan	 (green	 line)	 for	 24	 h	 post‐treatment	 analysed	 in	 a	 similar	 manner.	 Lysates	 were	
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Figure	4.7	–	Testing	the	effect	of	different	concentrations	of	N5‐Pan	(41b)	on	the	levels	of	CoA	
in	P.	 falciparum	 parasite	 cultures	 incubated	 for	 24	h	 and	72	 h	 post‐treatment.	 The	 bars	were	
generated	 from	HPLC	 data	 similar	 to	 that	 shown	 in	 figure	 4.6	 by	 determining	 the	 AuC	 of	 the	








in	 the	 control	 culture.	 For	 a	 more	 precise	 evaluation	 of	 the	 effect	 of	 PanAms,	 future	














lysates	prepared	 from	control	 cultures	 and	 cultures	 treated	with	N5‐Pan	as	described	
for	the	CoA	level	analyses,	were	examined	by	conformation‐sensitive	PAGE	and	by	HPLC	
as	detailed	in	chapter	2,	sections	2.2.9.5	and	2.2.12.	The	identity	of	the	ACP	forms	from	
cultured	 parasites	 was	 confirmed	 by	 comparison	 with	 heterologously‐expressed	 and	
purified	PfACP	standards;	the	identity	of	which	were	confirmed	by	LC‐ESI‐MS	analysis,	








The	 immature	 carrier	 protein,	 apo‐ACP	 as	 well	 as	 the	 crypto‐ACP	 (reporter‐modified	
ACP)	forms	which	lack	a	thiol	group	on	their	structures	could	not	be	labelled	with	CPM.	
The	 competitive	 production	 and	 accumulation	 of	 immature	 apo‐ACP	 and	 crypto‐ACP	
forms	 results	 in	 decreased	 levels	 of	 the	 mature	 and	 functional	 holo‐ACP	 that	 can	 be	
labelled	with	CPM.	The	 levels	of	 the	holo‐ACP	forms	in	N5‐Pan‐treated	cultures	should	
therefore	decrease	as	a	 function	of	 increasing	 the	dose	of	N5‐Pan	administered	 to	 the	
cultures.	
	






















































































Panel	D:	 The	 same	 gel	 as	 shown	 in	 panel	C,	 but	 after	Coomassie	blue	 staining.	 Lanes	2	 and	3	
were	loaded	with	heterologously	expressed	and	purified	6×His‐PfACP	as	described	in	chapter	2,	
section	 2.2.9.4.	 Lanes	 4	 and	 5	were	 loaded	with	 crude	 extracts	 of	 E.	 coli	 cells	 heterologously	
expressing	PfACP	without	any	added	 tag,	and	not	purified	by	any	means.	The	upper	bands	on	
this	panel,	visualised	only	after	Coomassie	Brilliant	Blue	staining	correspond	to	dimeric	forms	of	
holo‐ACP.	 These	 forms	 cannot	 be	 fluorescently‐labelled	with	CPM	 since	 the	 probe	 reacts	 only	
with	free	thiols.	
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parasite	 cultures	 were	 treated	 with	 N5‐Pan	 and	 incubated	 for	 24	 hours	 followed	 by	 lysate	
preparation	 and	 analysis	 by	 conformation‐sensitive	 polyacrylamide	 gel	 electrophoresis	 and	
HPLC.	Panel	A	shows	a	gel	of	samples	prepared	from	control	cultures	(lane	1),	cultures	treated	










1           2           3 
A






Analysis	 by	 conformation‐sensitive	 PAGE	 of	 cultures	 treated	with	 50	 µM	 and	 100	 µM	
N5‐Pan	 did	 not	 show	 clear	 differences	 in	 the	 levels	 of	 the	 CPM‐labelled	 holo‐ACP	
compared	to	control	cultures	(figure	4.9,	Panel	A),	possibly	due	to	poor	dynamic	range	
offered	 by	 this	 means	 of	 analysis	 (i.e.	 camera	 sensor	 is	 already	 saturated	 at	 low	
fluorescence	levels).	
	
However,	 when	 the	 samples	 were	 analysed	 by	 HPLC,	 the	 quantity	 of	 holo‐ACP	 –	 as	
indicated	 by	 the	 AuC	 of	 the	 corresponding	 peaks	 on	 HPLC	 chromatograms	 –	 in	 the	
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Figure	4.10	‐	Effect	of	increasing	concentrations	of	N5‐Pan	on	holo‐ACP	levels	in	P.	falciparum	
parasites	 incubated	 for	 24	 h	 (Panel	A)	 and	 72	 h	 (Panel	B)	 post‐treatment	 in	 culture	medium	
treated	at	56°C	for	18	h	to	remove	pantetheinase	activity1.	The	bars	were	generated	from	data	
representing	 the	AuC	of	CPM	fluorescently‐labelled	peaks	corresponding	 to	holo‐ACP	on	HPLC	
chromatograms	 from	 two	 independent	 experiments.	 The	 difference	 between	 the	 treated	
cultures	(50	µM	and	100	µM)	and	the	control	cultures	at	24	hours	post‐treatment	(Panel	A)	and	
between	the	cultures	treated	at	100	µM	and	the	control	cultures	after	 incubation	for	72	hours	
















observed	 low	 levels	 of	 holo‐ACP	 is	 most	 likely	 the	 result	 of	 the	 higher	 levels	 of	 the	
antimetabolite	 ethyldethia‐CoA	 (the	 product	 of	N5‐Pan	being	 transformed	by	 the	 CoA	
biosynthetic	enzymes)	compared	to	CoA;	under	such	circumstances	the	prosthetic	group	
derived	 from	 the	 PanAm	 is	 preferentially	 transferred	 to	 apo‐ACP	 which	 results	 in	
decreased	levels	of	free	holo‐ACP.	Note	that	after	72	h,	there	is	practically	no	difference	
between	 the	 levels	 of	 CPM‐labelled	holo‐ACP	 in	 the	 cultures	 treated	 at	 50	µM	N5‐Pan	
compared	to	the	control	culture.	This	is	possibly	a	result	of	N5‐Pan	being	consumed	or	
degraded	over	time	resulting	in	the	levels	of	CoA	rising	again	and,	as	a	consequence,	the	




stage	 Plasmodium	 spp	 parasites	 survival	 and	 replication	 in	 vitro	 [14].	 However,	 the	
findings	described	here	suggest	that	PfACP	is	actively	being	produced	during	this	stage	
of	 the	 parasite’s	 life	 cycle.	 Whether	 ACP	 plays	 an	 important	 role	 in	 fatty	 acids	
biosynthesis	 or	 any	 other	 functions	 during	 intraerythrocytic‐stage	 P.	 falciparum	
parasites	has	not	been	established	[13‐15].	Nevertheless,	the	fact	that	intraerythrocytic‐
stage	 parasites	 from	 which	 the	 apicoplast	 had	 been	 removed	 could	 be	 cultivated	
indefinitely	 in	 vitro	 –	 provided	 that	 the	 culture	 medium	 was	 supplemented	 with	
isopentenyl	 pyrophosphate,	 a	 product	 of	 the	 non‐mevalonate	 isoprenoid	 precursor	
biosynthesis	 pathway	 –	 suggests	 that	 fatty	 acids	 metabolism	 is	 not	 essential	 [16].	
Although	the	results	reported	in	the	present	section	of	this	dissertation	suggest	that	CoA	
and	 ACP	 are	 targeted	 by	 PanAms	 and	 play	 an	 important	 role	 in	 the	MoA	 of	 PanAms,	










In	 this	 part	 of	 the	 study,	 the	 target(s)	 of	 the	 antiplasmodial	 action	 of	 PanAms	 was	
investigated,	specifically	focusing	on	the	basis	of	the	apparent	selectivity	between	the	α‐,	
n‐,	and	HoPanAm	series.	Compounds	belonging	to	all	three	series	were	found	to	serve	as	
alternative	 substrates	 for	 PfPanK	 based	 on	 their	 inhibition	 of	 pantothenate	
phosphorylation	by	the	enzyme	present	 in	parasite	 lysates	and	on	the	results	of	 the	 in	
vitro	phosphorylation	assay	studies.	This	was	found	to	be	especially	the	case	for	the	n‐
PanAms,	which	 revealed	 to	 interact	more	 actively	with	 the	enzyme	and	as	 such	 could	
effectively	 compete	 with	 pantothenate	 for	 the	 enzyme’s	 activity.	 This	 indicates	 that	
while	 the	n‐PanAms	are	present	at	high	concentrations,	 they	can	competitively	 inhibit	
pantothenate	 phosphorylation	 resulting	 in	 decreased	 quantities	 of	 4’‐
phosphopantothenic	 acid	 and	 therefore	 reduced	 CoA	 biosynthesis.	 Subsequent	
experiments	 confirmed	 that	 indeed	both	CoA	 and	holo‐ACP	 levels	were	 reduced	upon	
PanAm	treatment.	
	
Taking	 the	 factors	 discussed	 above	 into	 consideration,	 it	 seems	 reasonable	 to	 assume	
that	the	PanAms	act	through	a	combination	of	factors	which	may	include	pantothenate	
phosphorylation	inhibition	(in	the	period	immediately	after	PanAm	administration),	the	
reduction	 of	 CoA	 and	holo‐ACP	 levels,	 and	 the	 formation	 of	 CoA	 antimetabolites	 (and	
ACPs	 loaded	 with	 inactive	 prosthetic	 groups).	 However,	 only	 the	 first	 two	 of	 these	
factors	were	 studied	 here,	 and	 further	 studies	 are	 required	 to	 confirm	 that	 the	 third	
takes	place,	and	to	allow	definite	conclusions	to	be	drawn.	Nonetheless,	the	experiments	
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of	 these	 compounds	 to	 interfere	 with	 the	 utilization	 of	 pantothenate	 which	 is	 an	
essential	 nutrient	 required	 for	 the	 biosynthesis	 of	 coenzyme	 A	 in	 basically	 all	 living	





The	utilization	of	metabolic	pathways	as	 targets	 for	antimicrobial	 chemotherapy	 is	 an	




by	 bacteria,	 were	 the	 first	 antimicrobial	 agents	 used	 systemically	 for	 the	 prophylaxis	
and	 therapy	 of	 human	 bacterial	 infections	 [5].	 Sulphonamides	 are,	 until	 now,	 still	
successfully	 used	 as	 antibacterial	 chemotherapies,	 particularly	 in	 combination	 with	
other	drugs	as	discussed	in	the	introductory	chapter	of	this	dissertation.	Sulphonamides	








of	 folic	 acid.	 The	 Sulphadoxine/Pyrimethamine	 combination,	 commonly	 known	 as	
Fansidar®,	has	been	for	 long	time	as	an	antimalarial	combination	and	for	some	time	it	
was	 second	only	 to	 chloroquine	 as	 the	most	 commonly	 administered	 antimalarial	 [6].	
The	 importance	 of	 PABA	 analogues	 and	 of	 the	 sulphonamides	 in	 particular	 in	 the	
treatment	of	microbial	infections	during	around	70	years	from	their	institution	validates	
the	 approach	 of	 exploiting	 the	 mechanisms	 involved	 in	 the	 utilization	 of	 essential	
nutrients	 as	 targets	 for	 antimicrobial	 agents.	 Thus,	 the	 uptake	 mechanisms	 and	 the	
enzymes	 involved	 in	 the	 metabolism	 of	 nutrients	 identified	 as	 essential	 for	 the	
development	 of	 pathogenic	 microorganisms	 constitute	 important	 targets	 for	
development	of	future	effective	antimicrobial	chemotherapies.	
	
5.1.1	 Pantothenamides	 are	 potent	 antiplasmodial	 agents	 susceptible	 to	
degradation	under	physiological	conditions	
While	 investigating	 the	 antiplasmodial	 activity	 of	 PanAms,	 researchers	 in	 a	
collaborator’s	 laboratory	 at	 the	 Australian	 National	 University	 noticed	 that	 the	
antiplasmodial	 activity	 of	 PanAms	 when	 measured	 using	 freshly	 prepared	 culture	
medium	 was	 lower	 compared	 to	 when	 it	 was	 measured	 in	 medium	 that	 had	 been	
repeatedly	 incubated	 at	 37°C	 for	 prolonged	 periods.	 This	 phenomenon	 was	
subsequently	 traced	 to	 the	 presence	 of	 a	 thermo‐labile	 enzyme	 with	 pantetheinase	
activity	 present	 in	 the	 serum	 substitute	 (Albumax	 II)	 used	 to	 prepare	 the	 culture	
medium.	
	







antiplasmodial	 activity	 of	 the	 compounds	 tested	 in	 freshly‐prepared	medium	 resulted	
from	their	degradation	by	these	enzymes	with	pantetheinase	activity.	The	enzymes	are	
members	 of	 the	 nitrilase	 superfamily	 and	 play	 an	 important	 physiological	 role	 by	
recycling	 pantothenic	 acid	 from	 the	 CoA	 metabolite	 pantetheine,	 and	 producing	 the	
antioxidant	 cysteamine	 as	 a	 secondary	product	 [7,	 8].	 In	 this	 study	 it	was	 shown	 that	
these	 enzymes	 are	 promiscuous	 and	 degrade	 PanAms	 (regardless	 of	 the	 structure	 of	
their	 amide	 substituents)	 to	pantothenic	 acid	 and	 the	 respective	 amine,	 rendering	 the	
compounds	inactive	against	P.	falciparum	parasites	[9].	
	







resulted	 in	 expected	 improvement	 in	 the	 antiplasmodial	 activity	of	 the	n‐PanAms,	 the	
series	 of	 	 compounds	 that	 contain	 the	 same	 number	 of	 methylene	 groups	 in	 the	 β‐
alanine	moiety	as	pantothenic	acid	[9].	
	
5.1.2	 Structural	 modification	 of	 pantothenamides	 confers	 resistance	 to	
pantetheinase‐mediated	degradation	
To	 try	and	 identify	PanAms	 that	are	 resistant	 to	pantetheinase‐mediated	hydrolysis,	 a	
set	of	modified	PanAms	previously	prepared	by	other	researchers	in	our	laboratory	[10]	






were	 tested	 for	 their	 resistance	 to	 pantetheinase	 degradation	 and	 also	 for	 their	
antiplasmodial	 activity.	 It	 was	 found	 that	 compounds	 that	 had	 a	 modified	 β‐alanine	
moiety	(i.e.	α‐	and	HoPanAms,	in	which	the	scissile	amide	bond	was	displaced	relative	to	
their	normal	counterparts)	proved	to	be	resistant	to	degradation	by	pure	pantetheinase	




To	overcome	 this	problem,	 selected	n‐PanAms	were	modified	by	 addition	of	 a	methyl	
group	to	either	the	α‐	or	β‐	position	of	the	β‐alanine	moiety	to	prevent	or	retard	their	
degradation.	These	new	PanAms	exhibited	resistance	to	pantetheinase	degradation	and	
therefore	 showed	 improved	 antiplasmodial	 activity	 compared	 to	 their	 n‐PanAms	
counterparts	 when	 tested	 in	 culture	 media	 in	 which	 the	 enzyme	 was	 present.	 This	
demonstrated	that	PanAm	modification,	particularly	when	maintaining	the	length	of	the	
β‐alanine	 moiety,	 is	 a	 promising	 path	 for	 exploration	 and	 development	 of	 novel	
antimalarial	drugs	active	against	intraerythrocytic‐stage	parasites.	
	
Another	 class	 of	 potentially	 pantetheinase‐resistant	 pantothenate	 analogues	 that	 was	
investigated	 for	 their	 antiplasmodial	 activity	 is	 the	 class	 of	 N‐substituted	
pantoyltauramides.	These	compounds	also	inhibited	P.	falciparum	parasite	proliferation	
through	 the	 inhibition	 of	 pantothenate‐dependent	 processes	 –	 as	 confirmed	 by	 the	
increase	 in	 the	 IC50	when	 the	 compounds	were	 tested	 in	 culture	medium	with	 excess	
pantothenate.	
	







In	 addition	 to	 investigating	 the	 antiplasmodial	 activity,	 the	 MoA	 of	 PanAms	 was	
investigated	in	this	study.	In	this	respect,	the	effect	of	selected	PanAms	on	the	activity	of	
PfPanK	 containing	 parasite	 lysates	 was	 investigated	 under	 in	 vitro	 standardised	
conditions.	All	compounds	tested,	which	included	members	of	the	α‐,	n‐	and	HoPanAms,	
were	found	to	serve	as	substrates	of	the	enzyme.	Among	the	different	sets	of	α‐,	n‐	and	






Further	 investigation	 of	 the	MoA	 of	 PanAms	 revealed	 that	 treatment	 of	P.	 falciparum	
parasite	 culrures	with	 these	 compounds	 results	 in	 lower	 CoA	 levels	 (probably	 due	 to	
their	conversion	to	non‐functional	CoA	antimetabolites)	and	lower	functional	holo‐ACP	
levels.	 Thus,	 as	 discussed	 in	 chapter	 4,	 the	 results	 indicate	 that	 the	 antiplasmodial	



















The	 results	described	 in	 this	dissertation	 indicate	 that	one	of	 the	major	hindrances	 to	
development	of	PanAms	as	antimalarial	drugs	is	the	susceptibility	of	the	compounds	to	
pantetheinase‐mediated	 degradation.	 Having	 been	 demonstrated	 in	 this	 dissertation	
and	 by	 de	 Villiers	 et	 al.	 [11]	 that	 structural	modifications	 can	 render	 the	 compounds	
resistant	to	the	deleterious	effect	of	the	pantetheinase	enzymes,	one	of	the	crucial	steps	
towards	 improving	 the	 antiplasmodial	 activity	 of	 PanAms	 will	 be	 to	 modify	 these	
compounds	to,	not	only	(i)	confer	resistance	to	pantetheinase‐mediated	degradation,	but	




possibly	 an	 improved	 pharmacokinetic	 profile,	 could	 potentially	 be	 achieved	 by	
replacement	of	 the	PanAms’	key	hydrolysable	amide	bond	with	bioisosteric	groups.	 In	
such	 an	 approach,	 n‐PanAms	 with	 amide	 substituents	 related	 to	 the	 most	 potent	
antiplasmodial	 activity	 should	 be	 considered	 for	 modification	 and	 evaluation	 of	 the	
compounds’	 antiplasmodial	 activity.	 Such	 a	 strategy	 is	 important	 for	 circumventing	










Some	 authors	 have	 suggested	 the	 combination	 of	 PanAms	with	 known	 pantetheinase	
inhibitors	[12,	13].	However,	such	a	strategy	would	eventually	require	the	optimization	
of	the	properties	of	two	compound	sets,	and	possibly	result	in	complications	related	to	




The	 studies	 described	 in	 this	 dissertation	 showed	 that	 PanAms	 are	 potent	
antiplasmodial	 agents	 when	 their	 in	 vitro	 degradation	 by	 serum	 pantetheinase	 is	
negated.	 It	 was	 also	 demonstrated	 that	 the	 mode	 of	 action	 of	 these	 compounds	 is	
through	interference	with	the	parasite’s	utilization	of	pantothenate	by	hijacking	its	PanK	
enzyme	 to	 initiate	 their	 (PanAms)	 transformation	 into	 inhibitory	 CoA	 antimetabolites	
and	 also	 the	 so‐called	 crypto‐ACPs	 that	 are	modified	with	 non‐functional	 4’‐phospho‐
PanAm	moieties	instead	of	the	normal	4’‐phosphopantetheine.	However,	to	establish	the	
exact	 basis	 for	 its	 inhibition,	 it	will	 be	 important	 to	 determine	 the	major	 form	 of	 the	
antimetabolite	in	the	intraerythrocytic‐stage	parasite	–	i.e.	whether	it	is	the	4’‐phospho‐
PanAm	 form,	 the	 dephospho‐CoA	 or	 CoA	 antimetabolite	 forms,	 or	 whether	 it	 is	 all	
mainly	 trapped	 on	 the	 ACP	 –	 as	 this	 is	most	 likely	 to	 be	 the	 form	 that	 interacts	with	
target	(or	targets)	that	cause	the	observed	inhibition	of	parasite	proliferation.	This	could	




Furthermore,	 the	 investigation	 of	 the	 mode	 of	 action	 of	 PanAms	 against	
intraerythrocytic‐stage	 malaria	 parasites	 should	 also	 examine	 the	 effect	 of	 non‐






pantothenate	 analogue	 compounds	 on	 the	 levels	 of	 CoA	 and	 ACP	 on	 treated	 cultures.	





5.2.3	 Investigation	 of	 the	 antiplasmodial	 activity	 of	 pantothenamides	 in	 in	 vivo	
systems	and	against	liver‐stage	parasites	
A	number	of	pantothenate	analogues	have	been	shown	 to	possess	 in	vivo	 antimalarial	
activity	 in	 mice,	 monkeys,	 or	 birds	 [1,	 14,	 15].	 In	 light	 of	 the	 identified	 methods	 to	
overcome	the	pantetheinase‐mediated	degradation	of	PanAms	during	the	course	of	this	
study,	such	approaches	should	be	used	and,	 the	PanAms	evaluated	 in	vivo	 to	ascertain	
their	efficacy	against	malaria	parasites	in	animal	(mouse)	models	of	the	disease.	The	in	











IC50	values	for	the	 inhibition	of	P.	 falciparum	growth)	of	 tested	HoPanAm	ranged	from	







significantly	 lower	 than	 to	parasite	 cells	 [11].	This	 justifies	 the	prospect	 that	 the	most	















as	presented	 in	 this	dissertation,	PanAms	clearly	affect	CoA	and	ACP	 levels;	 therefore,	
these	compounds	would	be	predicted	to	be	active	against	that	stage	of	the	parasites’	life	
cycle	since	de	novo	fatty	acid	synthesis	–	which	depend	on	both	CoA	and	ACP	–	is	more	
important	 for	 the	development	of	 the	 liver‐stage	 [16]	 than	 the	 intraerythrocytic‐stage	
parasites.	
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Abstract
Growth of the virulent human malaria parasite Plasmodium falciparum is dependent on an extracellular supply of
pantothenate (vitamin B5) and is susceptible to inhibition by pantothenate analogues that hinder pantothenate utilization.
In this study, on the hunt for pantothenate analogues with increased potency relative to those reported previously, we
screened a series of pantothenamides (amide analogues of pantothenate) against P. falciparum and show for the first time
that analogues of this type possess antiplasmodial activity. Although the active pantothenamides in this series exhibit only
modest potency under standard in vitro culture conditions, we show that the potency of pantothenamides is selectively
enhanced when the parasite culture medium is pre-incubated at 37uC for a prolonged period. We present evidence that this
finding is linked to the presence in Albumax II (a serum-substitute routinely used for in vitro cultivation of P. falciparum) of
pantetheinase activity: the activity of an enzyme that hydrolyzes the pantothenate metabolite pantetheine, for which
pantothenamides also serve as substrates. Pantetheinase activity, and thereby pantothenamide degradation, is reduced
following incubation of Albumax II-containing culture medium for a prolonged period at 37uC, revealing the true, sub-
micromolar potency of pantothenamides. Importantly we show that the potent antiplasmodial effect of pantothenamides is
attenuated with pantothenate, consistent with the compounds inhibiting parasite proliferation specifically by inhibiting
pantothenate and/or CoA utilization. Additionally, we show that the pantothenamides interact with P. falciparum
pantothenate kinase, the first enzyme involved in converting pantothenate to coenzyme A. This is the first demonstration of
on-target antiplasmodial pantothenate analogues with sub-micromolar potency, and highlights the potential of
pantetheinase-resistant pantothenamides as antimalarial agents.
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Introduction
Every day approximately half of the world’s population is at risk
of contracting malaria, a lethal infectious disease estimated to have
claimed 655 000 lives [1] (if not more [2]) in 2010. New
chemotherapeutic agents are desperately needed to combat
malaria as Plasmodium falciparum, the most virulent of the parasites
that cause the disease in humans, has developed resistance to all
antimalarial agents in clinical use [3].
Plasmodium falciparum has an absolute requirement for exogenous
pantothenate (vitamin B5; Figure 1) [4,5,6], a precursor of the
essential enzyme cofactor coenzyme A (CoA). Analogues of
pantothenate that interfere with the utilization of pantothenate
by P. falciparum have been shown to inhibit growth of Plasmodium
parasites in vitro and in vivo [5,7,8], raising interest in pantothenate
utilization as a potential antimalarial drug target, and pantothe-
nate analogues as the chemical entities to strike this target [6,9].
The structure of pantothenol, one antiplasmodial pantothenate
analogue identified previously, is shown in Figure 1.
Pantothenamides, pantothenate analogues in which the car-
boxyl group of pantothenate is replaced with an amide group
(Figure 1), have been shown to possess antibacterial activity in vitro
[10,11,12,13,14]; Escherichia coli and Staphylococcus aureus are among
the bacteria demonstrated to be susceptible to inhibition by these
compounds. Pantothenamides have been shown to serve as
substrates of pantothenate kinase (PanK), the first enzyme in the
CoA biosynthesis pathway, and as a consequence inhibit PanK-
catalysed pantothenate phosphorylation [13,15,16,17,18]. The
resultant 4’-phosphopantothenamides are further metabolized by
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the CoA biosynthesis pathway of bacteria to yield analogues of
CoA [17]. Such CoA analogues have been shown to be
incorporated by, and inhibit the function of, acyl carrier protein
[16,19], a protein involved in fatty acid biosynthesis that requires
the 49-phosphopantetheine moiety of CoA for activation. Whether
the mechanism that ultimately results in bacteriostasis is inhibition
of CoA biosynthesis [20], fatty acid biosynthesis [19] or another
CoA-utilizing process, or a combination of the above, remains to
be resolved.
In this study, the effect of a series of pantothenamides (see
Figure 2) on the growth of erythrocytic stage P. falciparum parasites
was investigated. We show for the first time that under standard
in vitro culture conditions pantothenamides inhibit parasite growth,
albeit with modest potency. Serendipitously, however, we discov-
ered that the antiplasmodial potency of pantothenamides is
enhanced considerably when the parasite culture medium used
for growth assays (which contains the commonly used serum
substitute Albumax II [21] or human serum) is pre-incubated at
37uC for a prolonged period. Consequently, sub-micromolar
concentrations of pantothenamides that have no effect in freshly
prepared medium inhibit parasite growth effectively in the pre-
incubated medium. We present evidence that links this finding to
the presence in parasite culture medium of pantetheinase activity,
the activity of an enzyme that catalyzes the hydrolysis of
pantetheine (Figure 1) to pantothenate and cysteamine. In
animals, pantetheinase activity is typically linked with the Vanin
proteins [22], soluble or membrane bound proteins that belong to
the nitrilase superfamily, the members of which share an invariant
Glu-Lys-Cys catalytic triad [23]. We show, using an in vitro
primary amine detection assay, that a pantothenamide selected
from the series tested here is hydrolyzed in the presence of
Albumax II, demonstrating Albumax II to be a source of
pantetheinase activity. Furthermore, we show that recombinant
human pantetheinase (Vanin-1) reduces the antiplasmodial
potency of the pantothenamide in the pre-incubated medium
in vitro, and, that the attenuating effect of the pantetheinase is
alleviated by incubation of the pantetheinase-supplemented
medium at 37uC. Together these data are consistent with
pantetheinase-mediated pantothenamide degradation occurring
in medium freshly supplemented with Albumax II or serum under
in vitro culture conditions, lowering the effective pantothenamide
concentration, and thereby masking the sub-micromolar anti-
plasmodial potency of pantothenamides.
Importantly, we demonstrate that the potent antiplasmodial
effect of the pantothenamides in the medium pre-incubated at
37uC is alleviated with pantothenate, and therefore results
specifically from inhibition of pantothenate and/or CoA utiliza-
tion. We also show that all of the pantothenamides in this series
inhibit P. falciparum PanK-catalysed pantothenate phosphorylation
(and hence serve as substrates or inhibitors of P. falciparum PanK).
The data presented here provide additional validation of




The pantothenamides tested were synthesized and purified as
described previously [18]. Each pantothenamide was dissolved in
dimethyl sulfoxide (DMSO) to a final concentration of 400 mM
before being diluted in the solution pertinent to the experiment.
For in vitro growth assays, the concentration of DMSO introduced
into cultures never exceeded 0.05% (v/v), in phosphorylation
assays the DMSO concentration present was 0.025% (v/v), and in
fluorescamine assays the concentration of DMSO never exceeded
0.15% (v/v). Albumax II was purchased from Life Technologies
(Mulgrave, Victoria, Australia), dissolved to a concentration of
20% (w/v) in water, filter sterilized and stored frozen (220uC).
SYBR Safe DNA gel stain (10 0006 stock concentration) was also
from Life Technologies. Recombinant human pantetheinase
(Vanin-1) was purchased from Novoprotein Scientific Inc. (Short
Hills, New Jersey, USA) and was reconstituted to a concentration
of 200 mg/mL in sterile phosphate-buffered saline and stored at
220uC for no longer than 3 weeks before use. [14C]Pantothenate
(55 mCi/mmol) was purchased from American Radiolabelled
Chemicals, Inc., and pantothenol and fluorescamine were from
Sigma-Aldrich.
Cell Culture
Erythrocytic stage P. falciparum parasites (strain 3D7) were
maintained within human erythrocytes in continuous culture
essentially as described previously [24,25]. P. falciparum-infected
erythrocytes were routinely cultured in RPMI 1640 medium
supplemented with 25 mM HEPES, 20 mM D-glucose, 200 mM
hypoxanthine, 24 mg/L gentamycin and Albumax II (0.6%, w/v),
which, hereafter is referred to as Albumax-complete RPMI. For
several days prior to carrying out the assays testing the effect of
compounds on the growth of P. falciparum in medium supplement-
ed with human serum (instead of Albumax II), the parasites were
cultured in the same medium mentioned above, except that
human serum (10%, v/v, pooled from different blood donors) was
used rather than Albumax II. This medium is hereafter referred to
as human serum-complete RPMI.
In vitro Growth Assays
The in vitro antiplasmodial activity of test compounds was
determined using the malaria SYBR Green I-based fluorescence
assay described by Smilkstein et al. [26], with minor modifications.
Briefly, P. falciparum-infected erythrocytes were incubated in
culture medium containing two-fold dilutions of the test
compounds in 96-well microtiter plates. Assays were initiated
Figure 1. Chemical structures of pantothenate and related
compounds. The hydroxy analogue of pantothenate, pantothenol,
inhibits growth of P. falciparum in vitro and in vivo. Amide analogues of
pantothenate, pantothenamides (for which the core structure is
shown), possess antibacterial activity in vitro. Pantetheine, a naturally
occurring pantothenate derivative, is hydrolyzed to pantothenate (and
cysteamine) by the enzyme pantetheinase.
doi:10.1371/journal.pone.0054974.g001
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Figure 2. Effect of pantothenamides on proliferation of P. falciparum and P. falciparum lysate-catalysed [14C]pantothenate
phosphorylation. The 50% inhibitory concentrations (IC50 values) measured against P. falciparum parasites cultured (for 96 h) in Albumax-complete
RPMI containing 1 mM pantothenate, as determined using the SYBR Green I-based growth assay are shown. Assays were performed using Albumax-
Pantothenamides Are Potent Antiplasmodial Agents
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with ring-stage P. falciparum-infected erythrocytes at a hematocrit
and parasitemia of 1%. Wells containing infected erythrocytes in
the presence of chloroquine (0.25–2 mM) served as zero growth
controls and wells containing infected erythrocytes in the absence
of chloroquine or test compounds served as 100% parasite growth
controls. Plates were incubated at 37uC under an atmosphere of
96% nitrogen, 3% carbon dioxide and 1% oxygen for 96 h, before
100 mL from each well was mixed with 100 mL of SYBR Safe
DNA gel stain (0.2 mL/mL) in 20 mM Tris, pH 7.5, 5 mM
ethylenediaminetetraacetic acid (EDTA), 0.008% (w/v) saponin,
0.08% (v/v) Triton X-100, in a second 96-well microtitre plate.
Fluorescence was measured using a FLUOstar OPTIMA multi-
detection microplate reader from BMG LABTECH with excita-
tion and emission wavelengths of 490 and 520 nm, respectively.
The 50% inhibitory concentration (IC50) of each test compound
under each test condition was calculated by fitting the data to a
sigmoidal curve (typically y = a/(1+ (x/x0)b) using nonlinear least
squares regression (SigmaPlot, Systat Software) and averaging the
IC50 estimates from independent experiments.
Preparation of Culture Medium for in vitro Growth
Assays
The antiplasmodial activity of test compounds was assessed in
media that had been subjected to different pre-incubations.
‘‘Fresh’’ medium refers to medium that was stored for a maximum
of 48 h at 4uC, and incubated at 37uC for a maximum of 1 h,
prior to use. ‘‘Aged’’ medium refers to medium that was stored for
a minimum of one week at 4uC and incubated intermittently at
37uC, or medium incubated continuously at 37uC for 40 h soon
after preparation. As indicated at the relevant positions within the
‘‘Results’’ section, for some experiments the fresh medium used
was, more specifically, medium used immediately following
preparation, and the aged medium used was, more specifically,
medium that was incubated at 37uC for 40 h immediately prior to
use.
[14C]Pantothenate Phosphorylation Assays
To assess the effect of the pantothenamides on pantothenate
phosphorylation by P. falciparum PanK, the phosphorylation of
[14C]pantothenate by P. falciparum lysates was measured in the
presence and absence of a single concentration of each
pantothenamide. P. falciparum lysate was prepared from trophozo-
ite stage parasites ‘‘isolated’’ from their host erythrocyte by
treatment with 0.05% (w/v) saponin (essentially as described by
Saliba et al. [27]), and washed (five times) in HEPES-buffered
saline (125 mM NaCl, 5 mM KCl, 20 mM D-glucose, 25 mM
HEPES, 1 mM MgCl2, pH 7.1). Lysates were prepared as
described by van Schalkwyk et al. [28], except that 10 mM
potassium phosphate, pH 7.4 (rather than 10 mM Tris, pH 7.4),
was used to lyse the cells. Aliquots of lysate were stored at 220uC.
The concentration of cell lysates was determined from cell counts
made using an improved Neubauer hemocytometer.
[14C]Pantothenate phosphorylation was assayed using the
Somogyi reagent [29] essentially as described by Saliba et al.
[27], except that pantothenate phosphorylation was terminated by
heat denaturation (rather than acid denaturation) of the protein in
reaction aliquots. Briefly, P. falciparum lysate was added to solutions
(at 37uC) of 50 mM Tris, 5 mM ATP, 5 mM MgCl2, at pH 7.4,
containing [14C]pantothenate (at a final concentration of
0.01 mCi/mL, or 0.2 mM), and a pantothenamide (at a final
concentration of 100 mM) or an equivalent volume of solvent.
Typically, lysate prepared from 5.4–6.56107 parasites was present
in each mL of reaction solution. Zero phosphorylation control
reactions were prepared by adding a corresponding volume of
10 mM potassium phosphate instead of parasite lysate. Following
a ten minute incubation at 37uC (a period during which
pantothenate phosphorylation increased linearly with time in the
absence of inhibitors) 200 mL aliquots of the [14C]pantothenate
phosphorylation reactions were transferred in duplicate to
microcentrifuge tubes, and immediately incubated at 95uC for
10 min to terminate phosphorylation. Terminated reaction
samples were centrifuged at 15 8006g for 10 min to pellet the
denatured protein, before two aliquots of each supernatant
(typically 80 mL) were transferred to new microcentrifuge tubes.
To one aliquot, 500 mL Somogyi reagent was added, and to the
other, 500 mL water was added. The samples were processed for
determination of phosphorylated [14C]pantothenate as described
previously [27].
In vitro Fluorescamine-based Assay
Hydrolysis of compound 12 to pantothenate and isobutylamine
was measured using a modification of a fluorescence-based assay
described previously for the measurement of N-acetyl-1-D-myo-
inosityl-2-amino-2-deoxy-a-D-glucopyranoside deacetylase activi-
ty [30,31]. The assay utilizes fluorescamine (4-phenylspiro-[furan-
2(3H),1-phthalan]-3,39-dione; a non-fluorescent molecule that
reacts with primary amines to form a fluorescent product [32])
for the detection of primary amines. Briefly, recombinant human
pantetheinase (at a final concentration of 100 ng/mL), Albumax II
(at a final concentration 0.6%, w/v), or an equivalent volume of
water, was added to solutions (at 37uC) of 100 mM potassium
phosphate, pH 7.5, 0.5 mM dithiothreitol, 0.01% (w/v) bovine
serum albumin, 0.1% (v/v) DMSO, with or without pantothena-
mide (at a final concentration of 200 mM). At the appropriate time
points, aliquots (30 mL) of the reaction mixtures were removed in
duplicate and mixed with 10 mL 20% (v/v) trichloroacetic acid to
terminate the reaction. Following removal of the precipitated
protein by centrifugation (14 0006g, 15 min), 25 mL of each
supernatant was transferred to the wells of a black 96-well
microtitre plate and 75 mL 1 M borate (pH 9.0) followed by 30 mL
10 mM fluorescamine was added to the wells. The plate was then
complete RPMI prepared within 48 h of the assay, stored at 4uC, and incubated at 37uC for a maximum of 1 h (fresh) or Albumax-complete RPMI
incubated continuously at 37uC for 40 h immediately after preparation (aged). The IC50 values shown for parasites cultured in fresh Albumax-
complete RPMI are averages from between two and eight independent experiments each performed in duplicate or triplicate. Where the IC50 values
determined were below 200 mM, they are presented as the mean 6 SEM from between three and eight independent experiments. The IC50 values
shown for parasites cultures in aged medium are averages from between two and three independent experiments each performed in triplicate.
Where the IC50 values determined were below 200 mM, they are presented as the mean 6 range/2 or SEM as appropriate. The percentage inhibition
of [14C]pantothenate phosphorylation by PanK in P. falciparum lysate caused by pantothenamides (when tested at a concentration of 100 mM) in the
presence of 0.2 mM pantothenate are also shown. The percentage inhibition was calculated from the measured amounts of [14C]pantothenate
phosphorylated during a 10 min incubation in the presence of pantothenamide and in the presence, instead, of the corresponding concentration of
DMSO only. Data are averages 6 range/2 from two independent experiments, each performed in duplicate. A value of 100 indicates complete
inhibition of [14C]pantothenate phosphorylation was observed in both independent experiments. The amount of [14C]pantothenate phosphorylated
by P. falciparum lysate was significantly lower in the presence of all pantothenamides (P,0.0001, ANOVA).
doi:10.1371/journal.pone.0054974.g002
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incubated at 37uC for 10 min before fluorescence was measured
using a FLUOstar OPTIMA multidetection microplate reader
from BMG LABTECH with excitation and emission wavelengths
of 390 and 485 nm, respectively. The fluorescence detected was
converted to the corresponding isobutylamine concentration using
an isobutylamine standard curve. In each experiment, the
isobutylamine standard curve was generated from aliquots
(30 mL) of isobutylamine solutions (0.02–200 mM) processed in
parallel with the reaction aliquots as described above.
Statistical Analysis
To test for a statistically significant difference between the
means of two groups, two-tailed student t tests were performed. To
test for statistically significant differences between the means of
more than two groups, one-way analysis of variance (ANOVA)
was performed. Pairwise comparisons were made post-hoc with
Tukey’s multiple comparisons test (when comparing all means) or
Dunnett’s multiple comparisons test (when comparing all means
with a control mean). P values reported are multiplicity adjusted.
ANOVA was performed using GraphPad 6 (GraphPad Software,
Inc).
Results
Antiplasmodial Activity of Pantothenamides under
Standard in vitro Culture Conditions
A series of 22 previously published [18] pantothenamides was
tested in vitro for antiplasmodial activity against erythrocytic stage
P. falciparum parasites (strain 3D7) in 96 h growth assays initiated
with parasites predominantly in the ring stage. The series of
pantothenamides (see Figure 2 for structures) was composed of 21
secondary amides of pantothenate, each with a different amide
substituent, as well as a lone tertiary amide. The series included
the prototypical pantothenamides N5-Pan and N7-Pan (com-
pounds 1 and 2, respectively). All of the pantothenamides tested
were stereochemically pure, with R-configuration at the chiral
carbon of the 2,4-dihydroxy-3,3-dimethylbutanamide moiety. As
shown in Figure 2, when tested in ‘‘fresh’’ Albumax-complete
RPMI (Albumax-complete RPMI stored at 4uC for a maximum of
48 h, and incubated at 37uC for a maximum of 1 h, prior to use),
ten of the 22 pantothenamides inhibited proliferation of P.
falciparum parasites with IC50 values below 200 mM. With the
exception of compound 2 (N7-Pan; the pantothenamide with the
longest linear alkyl chain), the pantothenamides with simple alkyl
(linear or branched) or alkenyl amide substituents were among the
ten active pantothenamides. Compound 3 (with a phenethyl
substituent) was the only pantothenamide containing a carbocycle
with an IC50 value below 200 mM.
The potency of pantothenamides with acyclic heteroatom-
containing substituents varied. Three pantothenamides with linear
thioether substituents were tested for antiplasmodial activity;
compounds 17 and 18 were among the most active of the series,
while compound 14 had little effect even at a concentration of
200 mM. Compound 17 was also significantly more active than
N5-Pan, the corresponding alkyl pantothenamide (P = 0.02,
ANOVA). Among the four pantothenamides with linear ether
substituents, compound 19 was the most active (P,0.0001,
ANOVA), compounds 21 and 22 were also active, while
compound 15 lacked antiplasmodial activity at the concentrations
tested. The less polar thioether pantothenamides 17 and 18 were
significantly more active (P,0.003, ANOVA) than the corre-
sponding ether pantothenamides 22 and 21, respectively. Com-
pounds 16 and 20 (both with terminal hydroxyl groups in the
substituent) were without effect even at the highest concentration
tested.
Albumax II-complete RPMI contains 1 mM pantothenate, a
concentration close to the normal whole blood pantothenate
concentration [33]. When the ten pantothenamides with IC50
values below 200 mM were tested against P. falciparum parasites in
fresh Albumax-complete RPMI to which 100 mM pantothenate
was added, the IC50 values measured were between 160.1
(compound 13; mean 6 range/2) and 1.760.4 (compound 19;
mean 6 range/2) times higher than those measured against
parasites in Albumax-complete RPMI containing 1 mM pantothe-
nate. The minor attenuating effect (or lack of an effect) of
pantothenate supplementation on the antiplasmodial activity of
the pantothenamides, contrasts with the dramatic attenuating
effect of pantothenate on the antiplasmodial activity of previously
reported antiplasmodial pantothenate analogues such as pantothe-
nol and CJ-15,801 [5,7,8].
Antiplasmodial Activity in Albumax-complete Medium
Pre-incubated at 37uC for a Prolonged Period
During the course of screening pantothenamides for antiplas-
modial activity, it was serendipitously discovered that a prolonged
37uC pre-incubation of the Albumax-complete RPMI used for a
growth assay has a dramatic effect on the antiplasmodial activity of
pantothenamides. As shown in Figure 2, nine of the ten
pantothenamides that inhibit growth of P. falciparum with IC50
values below 200 mM in fresh Albumax-complete RPMI were
found to be more potent in Albumax-complete RPMI incubated at
37uC for 40 h prior to use (‘‘aged’’ Albumax-complete RPMI)
than in fresh Albumax-complete RPMI. When tested in aged
medium, the IC50 values determined for these nine compounds
were between one and three orders of magnitude lower than the
IC50 values determined when the pantothenamides were tested in
fresh medium. Additionally, four of the 12 pantothenamides that
did not inhibit growth of P. falciparum with IC50 values below
200 mM in fresh Albumax-complete RPMI (compounds 2, 9, 16
and 20) did so in aged Albumax-complete RPMI. The effect of
increasing concentrations of three selected pantothenamides
(compounds 3, 12, and 19) on the growth of P. falciparum in fresh
and aged Albumax-complete RPMI is shown in Figure 3A–C. The
activity of pantothenol was, by contrast with the activity of many
of the pantothenamides, comparable in aged and fresh medium
(P = 0.32, unpaired t test; Figure 3D). Hence, the potency of
pantothenamides is selectively enhanced in aged medium.
Among the most potent pantothenamides in aged medium was
the phenethyl substituted pantothenamide, compound 3
(IC50 = 2062 nM; mean 6 SEM; n = 3). One other carbocycle-
bearing pantothenamide (compound 9; a pantothenamide with a
methoxy-substituted benzyl substituent) was also observed to
inhibit parasite growth in aged medium with an IC50 value below
200 mM, but was significantly less potent (P = 0.0009, ANOVA).
When tested in aged medium, an IC50 value below 200 mM was
measured for compound 2 (N7-Pan), however the pantothenamide
remained less active than the pantothenamides with shorter alkyl
amide substituents (compounds 1, 11 and 12). As observed when
the compounds were tested in fresh medium, in aged medium: (i)
compounds 17 and 18 (two thioether substituted pantothena-
mides) were among the most potent pantothenamides, and the
pantothenamide with the shorter thioether substituent lacked
appreciable activity even at 200 mM; and (ii) the activity of the
pantothenamides with ether substituents increased with increasing
chain length, with compound 19 being among the most potent
pantothenamides. Compounds 16 and 20 (both with terminal
hydroxyl groups in the substituent) demonstrated an inhibitory
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effect in aged medium, however, they remained among the least
potent pantothenamides.
Not only did the potency of pantothenamides in fresh and aged
Albumax-complete RPMI differ, the effect of pantothenate
supplementation on pantothenamide potency differed depending
on whether the compounds were tested in fresh or aged medium;
the effect of supplementation with 100 mM pantothenate was
greater when compounds were tested in aged medium than in
fresh. For example, as shown in Figure 4 (closed bars), the IC50
values determined for compounds 12 and 19 against parasites
cultured in aged Albumax-complete medium supplemented with
100 mM pantothenate were 2161 (mean 6 SEM; n = 3) and
2461 (mean 6 range/2; n = 2) times higher, respectively, than the
corresponding IC50 values against parasites cultured in aged
Albumax-complete RPMI containing 1 mM pantothenate; by
comparison, the IC50 values determined for compounds 12 and
Figure 3. Antiplasmodial effect of pantothenamides and pantothenol in fresh and aged Albumax-complete RPMI. The concentration-
response curves show the effect of increasing concentrations of compound 3 (A), compound 12 (B), compound 19 (C), and pantothenol (D) on
proliferation of P. falciparum parasites cultured (for 96 h) in Albumax-complete RPMI containing 1 mM pantothenate, as measured using the SYBR
Green I-based growth assay. Assays were performed using Albumax-complete RPMI stored for a maximum of 48 h at 4uC, and incubated at 37uC for a
maximum of 1 h (fresh; open circles) or Albumax-complete RPMI incubated continuously at 37uC for 40 h immediately after preparation (aged; closed
circles). The data obtained with parasites cultured in fresh Albumax-complete RPMI are from between three and eight independent experiments
performed in duplicate or triplicate and error bars represent SEM. The data obtained with parasites cultured in aged Albumax-complete RPMI are
from between two and three independent experiments performed in duplicate or triplicate and error bars represent range/2 or SEM. For clarity, in D,
the concentration-response curves represented by the closed circles are shown with negative error bars only, and the concentration-response curves
represented by the open circles are shown with positive error bars only. Where not shown, error bars are smaller than the symbol.
doi:10.1371/journal.pone.0054974.g003
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19 against parasites cultured in fresh Albumax-complete RPMI
supplemented with 100 mM pantothenate were only 1.360.2 and
1.760.4 (mean 6 range/2; n = 2) times higher, respectively, than
the corresponding IC50 values against parasites cultured in fresh
Albumax-complete RPMI containing 1 mM pantothenate
(Figure 4, open bars). These data are consistent with the inhibition
of growth in aged medium resulting from inhibition of pantothe-
nate and/or CoA utilization. Pantothenate was found to
antagonize the antiplasmodial activity of pantothenol effectively
in both fresh and aged medium (Figure 4). Taken together, these
data are consistent with (i) the pre-incubation of Albumax-
complete RPMI at 37uC effecting a change in the medium that
specifically and reproducibly enhances the antiplasmodial activity
of pantothenamides; and (ii) pantothenamides acting via an effect
on pantothenate and/or CoA utilization under these conditions.
Inhibition of Pantothenate Phosphorylation
To explore the mechanism of action of pantothenamides, we
investigated whether, like antiplasmodial pantothenate analogues
reported previously [5,7,8], pantothenamides inhibit P. falciparum
PanK-catalyzed pantothenate phosphorylation. As shown in
Figure 2, in the presence of each pantothenamide, the amount
of [14C]pantothenate phosphorylated by PanK present in P.
falciparum lysate during a 10 min period (in which pantothenate
phosphorylation increased linearly with time under control
conditions) was significantly reduced relative to the amount
phosphorylated in the absence of pantothenamides (P,0.0001,
ANOVA). At the pantothenamide concentration tested (100 mM,
a concentration 500-fold higher than the concentration of
pantothenate present in the assay), each of the pantothenamides
inhibited [14C]pantothenate phosphorylation by $94% (Figure 2).
These data are consistent with all of the pantothenamides tested
here interacting with P. falciparum PanK, either as alternate
(competitive) substrates or as inhibitors of its phosphorylating
activity.
Effect of Albumax II-supplementation on the
Antiplasmodial Activity of Pantothenamides in Aged
Culture Medium
The data presented thus far are consistent with there being a
heat-labile component in Albumax-complete RPMI that antago-
nizes the activity of pantothenamides. In an attempt to identify
such a component, the activity of a selected pantothenamide
(compound 12) in aged Albumax-complete RPMI supplemented
immediately prior to the assay with various components of
Albumax-complete RPMI, was investigated. A component of the
medium that was found to antagonize the activity of pantothena-
mides was Albumax II, the lipid-rich bovine serum albumin
preparation used as a serum substitute [21]. As shown in Figure 5A
(open circles), the addition of Albumax II (0.6%, w/v) to aged
Albumax-complete medium reduced the activity of compound 12.
In the presence of the additional Albumax II, compound 12 had
little-to-no effect on parasite growth even at a concentration of
200 mM, a concentration that inhibits parasite growth completely
in aged Albumax-complete RPMI without additional Albumax.
Furthermore, the activity of pantothenol was unaffected by
supplementation with the additional Albumax II (Figure 5B),
consistent with Albumax II specifically influencing the potency of
pantothenamides. To investigate whether the attenuating effect of
Albumax II could be linked to the increased potency of
pantothenamides in Albumax-complete RPMI incubated for a
prolonged period at 37uC, we determined whether the attenuating
effect of the additional Albumax II could be alleviated by
incubating the aged medium to which additional Albumax II
had been added for a further 40 h at 37uC. The pantothenamide
was indeed more potent (.65-fold; Figure 5A, grey circles) when
tested in aged Albumax-complete RPMI supplemented with
Albumax II and aged a second time. The possibility that this
increased potency was due to further inactivation of an
independent component of the aged medium was investigated
by testing the pantothenamide in aged medium incubated for the
same total length of time as the aged Albumax-complete RPMI
supplemented with Albumax II and then incubated. Compound
12 was slightly more active in the Albumax-complete RPMI
subjected to two 40 h incubations at 37uC than in the Albumax-
complete RPMI subjected to a single 40 h incubation (Figure 5A,
closed squares). This demonstrated that a component of the
Albumax-complete RPMI had not been fully depleted/inactivated
after the initial 40 h and hence that the pantothenamide had not
reached a maximum potency in this medium after the initial 40 h
incubation. Nonetheless, the increase in potency was far less than
the increase in potency observed following incubation of the aged
medium supplemented with additional Albumax II, consistent
with the Albumax II being sensitive to heat treatment. Taken
Figure 4. Effect of pantothenate supplementation on pan-
tothenamide and pantothenol potency in fresh and aged
Albumax-complete RPMI. The bars represent the fold-increases in
the IC50 values of compound 12, compound 19 and pantothenol in
Albumax-complete RPMI following supplementation with 100 mM
pantothenate. The fold-increases in IC50 values were calculated by
dividing each IC50 value measured against P. falciparum cultured in the
presence of 100 mM pantothenate by the corresponding IC50 value
measured against P. falciparum cultured in the presence of 1 mM
pantothenate. The fold-increases in IC50 values were determined in
assays performed using Albumax-complete RPMI stored for a maximum
of 48 h at 4uC, and incubated at 37uC for a maximum of 1 h (fresh; open
bar) or Albumax-complete RPMI stored for a minimum of one week at
4uC and incubated intermittently at 37uC, or, soon after preparation,
incubated continuously at 37uC for up to 40 h (aged; closed bar). The
fold-increases in IC50 values are averaged from between two and four
independent experiments in which test compounds were tested in
Albumax-complete RPMI containing 1 mM pantothenate and Albumax-
complete RPMI supplemented with 100 mM pantothenate in parallel.
Each experiment was performed in duplicate or triplicate, and error bars
represent SEM or range/2. Pantothenol bars are shown with a broken
edge to indicate that only a lower limit on the fold-increase in IC50
could be determined. This is because less than 50% inhibition of growth
was observed at the highest pantothenol concentration tested (2 mM).
doi:10.1371/journal.pone.0054974.g004
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together, these data implicate Albumax II as the labile factor in
fresh Albumax-complete RPMI that influences the potency of
pantothenamides.
Antiplasmodial Activity in Human Serum-complete
Medium
To investigate whether the pantothenamide-attenuating prop-
erty of Albumax II was unique to this bovine serum albumin
preparation or whether the property was shared with human
serum, the activity of compound 12 in medium containing human
serum (10%, v/v), rather than Albumax II, was determined. In
human serum-complete RPMI prepared immediately prior to
growth assays (fresh human serum-complete RPMI), compound
12 had no effect on parasite growth even at a concentration of
200 mM, the highest concentration tested (Figure 6A, open circles).
In human serum-complete RPMI that had been incubated at
37uC for 40 h (aged human serum-complete RPMI), however,
compound 12 inhibited proliferation of P. falciparum with an IC50
value of 22610 mM (mean 6 range/2; n = 2; Figure 6A, closed
circles). Pantothenol, on the other hand, inhibited parasite growth
with similar activity in fresh and aged human serum-complete
RPMI (Figure 6B). These data demonstrate that pantothenamide
potency is selectively enhanced in human serum-complete RPMI
following incubation of the medium at 37uC for 40 h, as it is in
Albumax-complete RPMI following incubation, consistent with
Albumax II and human serum having in common a labile
component that decreases pantothenamide potency.
Pantetheinase-mediated Pantothenamide Degradation
in vitro
The activity of pantetheinases, enzymes that catalyze the
hydrolysis of pantetheine to pantothenate and cysteamine, has
previously been detected in human serum [34]. Since pantetheine
is a secondary amide of pantothenate it more closely resembles the
pantothenamides (Figure 1) than pantothenol and other previously
reported [7,8] antiplasmodial pantothenate analogues do. In light
of this, we considered the possibility that pantothenamides in this
series are pantetheinase substrates and that Albumax II may be a
source of pantetheinase activity. To explore this hypothesis we
adapted a fluorescence-based assay used previously to measure N-
acetyl-1-D-myo-inosityl-2-amino-2-deoxy-a-D-glucopyranoside
deacetylase activity [30,31] to measure any breakdown of
compound 12 to pantothenate and isobutylamine (a primary
amine). This assay utilizes fluorescamine, a molecule which is itself
non-fluorescent, but generates a fluorescent product upon reaction
with primary amines. Using an isobutylamine standard curve,
fluorescence measurements were converted to isobutylamine
concentrations. As shown in Figure 7 (closed circles), when
compound 12 (200 mM) was incubated with recombinant human
pantetheinase (100 ng/mL), primary amine was generated, and
the concentration increased approximately linearly with time
before reaching a maximum after ,4 h. The maximum reached
corresponded to an isobutylamine concentration of ,200 mM,
consistent with all of the pantothenamide present having been
hydrolyzed. By contrast, pantothenamide hydrolysis was not
Figure 5. Effect of Albumax II supplementation on pantothenamide and pantothenol potency in aged Albumax-complete RPMI. The
concentration-response curves show the effect of increasing concentrations of compound 12 (A) and pantothenol (B) on proliferation of P.
falciparum parasites cultured (for 96 h) in Albumax-complete RPMI as measured using the SYBR Green I-based growth assay. Assays were performed
using (i) Albumax-complete RPMI incubated immediately after preparation at 37uC for 40 h (aged; closed circles); (ii) aged Albumax-complete RPMI
supplemented with additional Albumax II (0.6%, w/v) immediately prior to the assay (aged+(fresh) Albumax; open circles); (iii) aged Albumax-
complete RPMI supplemented with additional Albumax II (0.6%, w/v) and heated at 37uC for 40 h immediately prior to the assay (aged+(fresh)
Albumax+heat; grey circles); and (iv) aged Albumax-complete RPMI heated at 37uC for 40 h immediately prior to the assay (aged+heat; closed
squares). The data presented in A are averaged from three independent experiments, each performed in triplicate, and error bars represent SEM. The
data presented in B are averaged from two independent experiments, performed in duplicate or triplicate, and error bars represent range/2. For
clarity, in A, the concentration-response curves represented by the closed circles are shown with negative error bars only, and the concentration-
response curves represented by the grey circles are shown with positive error bars only. In B, the concentration-response curves represented by the
closed circles are shown with positive error bars only, and the concentration-response curves represented by the open circles are shown with
negative error bars only. Where not shown, error bars are smaller than the symbol.
doi:10.1371/journal.pone.0054974.g005
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observed when compound 12 was incubated under the same
conditions in the absence of pantetheinase (Figure 7, open circles).
Hence, these data are consistent with pantetheinase mediating the
hydrolysis of pantothenamides in addition to pantetheine. Primary
amine was also generated during incubation of compound 12 with
Albumax II (0.6%, w/v) (Figure 7, grey circles), consistent with
Albumax II (when present at a concentration equivalent to that
present in Albumax-complete medium) mediating hydrolysis of the
pantothenamide. Furthermore, incubation of Albumax II in the
absence of pantothenamide did not result in primary amine
generation (Figure 7, grey squares), which eliminated the
possibility that the amine generated resulted from degradation of
the Albumax II and not the pantothenamide. In the presence of
Albumax II, over one third of the pantothenamide present was
hydrolyzed during a 6 h incubation, and pantothenamide
hydrolysis appeared to reach completion within 24 h.
Pantetheinase-mediated Pantothenamide Degradation
under in vitro Culture Conditions
To establish whether Albumax II-mediated pantothenamide
hydrolysis could explain the reduced potency of pantothenamides
in fresh Albumax-complete RPMI, we compared the activity of
compound 12 in aged Albumax-complete RPMI with and without
recombinant human pantetheinase. As shown in Figure 8 (open
circles), 100 ng/mL recombinant human pantetheinase (when
added at the start of the assay) alleviated the antiplasmodial effect
of compound 12 in aged Albumax-complete RPMI. This result is
consistent with pantetheinase-mediated pantothenamide degrada-
tion occurring under in vitro culture conditions and, in turn,
attenuating the antiplasmodial effect of pantothenamides. Impor-
tantly, the activity of compound 12 in aged Albumax-complete
RPMI supplemented with recombinant human pantetheinase
increased after the medium was incubated at 37uC for 40 h
(Figure 8; grey circles). Moreover, the pantothenamide was more
potent in this medium than in aged Albumax-complete medium
incubated in parallel but to which the recombinant human
pantetheinase was added only after the second incubation at 37uC
(i.e. immediately prior to the assay; Figure 8; grey squares). The
latter provides evidence that the increase in pantothenamide
activity is largely due to inactivation of pantetheinase and not a
result of further inactivation of an independent component of the
medium. Taken together these data demonstrate that the
antagonizing effect of pantetheinase in parasite culture medium
can be alleviated by incubating the medium at 37uC, and are
consistent with inactivation of pantetheinase occurring during the
incubation. Hence, inactivation of Albumax II-derived pantethei-
nase during prolonged incubation at 37uC, can explain the
increase in pantothenamide potency observed when Albumax-
complete medium is incubated for a prolonged period at 37uC.
Discussion
That pantothenamides possess antibacterial activity has been
known for some time [12]. In this study we show for the first time
that pantothenamides also possess antiplasmodial activity. Addi-
tionally, we show there to be a labile serum-derived factor
common to Albumax II and human serum that specifically
antagonizes the antiplasmodial activity of pantothenamides
(Figures 5 and 6) and thereby masks their potency. We
Figure 6. Antiplasmodial effect of a pantothenamide and pantothenol in fresh and aged human serum-complete RPMI. The
concentration-response curves show the effect of increasing concentrations of compound 12 (A) and pantothenol (B) on the proliferation of P.
falciparum parasites cultured (for 96 h) in human serum-complete RPMI as measured using the SYBR Green I-based growth assay. Assays were
performed using human serum-complete RPMI prepared immediately prior to experimentation (fresh; open circles) or human serum-complete RPMI
heated at 37uC for 40 h immediately following preparation (aged; closed circles). The data obtained with parasites cultured in fresh human serum-
complete RPMI are from three independent experiments, each performed in duplicate or triplicate, and error bars represent SEM. The data obtained
with parasites cultured in aged human serum-complete RPMI are from two independent experiments, each performed in duplicate or triplicate, and
error bars represent range/2. For clarity, in B, concentration-response curves represented by the closed circles are shown with positive error bars only,
and the concentration-response curves represented by the open circles are shown with negative error bars only. Where not shown, error bars are
smaller than the symbol.
doi:10.1371/journal.pone.0054974.g006
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demonstrate this factor to be pantetheinase, an enzyme that
hydrolyzes pantetheine to form pantothenate and cysteamine.
This conclusion is based on several findings: (i) that recombinant
human pantetheinase (Vanin-1) also mediates hydrolysis of an
antiplasmodial pantothenamide (compound 12), a finding consis-
tent with earlier reports of secondary amides of pantothenate other
than pantetheine serving as pantetheinase substrates [35,36,37];
(ii) that the pantothenamide is hydrolyzed in the presence of
Albumax II (Figure 7), consistent with Albumax II, like serum,
being a source of pantetheinase activity; and (iii) that the
antiplasmodial potency of the pantothenamide is reduced in the
presence of recombinant human pantetheinase and that this
attenuating effect is alleviated by incubating the pantetheinase-
supplemented culture medium at 37uC (Figure 8). Taken together
these results provide strong evidence that in fresh medium,
pantetheinase-mediated pantothenamide degradation masks the
antiplasmodial potency of pantothenamides. Moreover, we show
that in aged culture medium, pantothenamides inhibit growth of
P. falciparum with potency unparalleled by antiplasmodial panto-
thenate analogues identified previously.
Five pantothenamides were found to inhibit growth of P.
falciparum in aged culture medium with sub-micromolar IC50
values; for one pantothenamide (compound 3), an IC50 value as
low as 20 nM was determined (Figure 2). Furthermore, the finding
that the potency of at least one pantothenamide (compound 12)
was greater in medium incubated for 80 h than in medium pre-
incubated for 40 h (the standard incubation period employed in
this study to ‘‘age’’ medium; Figure 5) is consistent with there
being residual pantetheinase activity in medium pre-incubated for
40 h, and indicates that a maximum pantothenamide potency has
not been reached in this medium. To determine the maximum
(true) potency of pantothenamides, it will be important to test the
pantothenamides under conditions where pantetheinase-mediated
degradation cannot take place. This, however, is not a trivial task.
Serum albumin is required for growth of P. falciparum [38,39] and
so to achieve strictly pantetheinase-free conditions, an albumin
preparation from which all pantetheinase activity has been
removed is needed. Whether there is pantetheinase activity
associated with preparations of human erythrocytes (required for
growth of erythrocytic-stage P. falciparum) will also need to be
Figure 7. Hydrolysis of a pantothenamide in the presence of
recombinant human pantetheinase and Albumax II. The time-
courses show the concentration of isobutylamine (a product of
compound 12 hydrolysis) detected during incubation of compound
12 with recombinant human pantetheinase (100 ng/mL; closed circles),
Albumax II (0.6%, w/v; grey circles), or an equivalent volume of water
(open circles), and during incubation of Albumax II (0.6%, w/v) in the
absence of compound 12 (grey squares). At each time-point, the
amount of primary amine was measured using a fluorescamine-based
fluorescence assay. Fluorescence measurements were converted to
isobutylamine concentrations using a standard curve generated using
isobutylamine samples of known concentration that had been
processed in the same manner as the test samples. The data are from
three or four independent experiments, each performed in duplicate,
and error bars represent SEM. For clarity, the time-courses represented
by the open circles are shown with positive error bars only, and the
time-courses represented by the grey squares are shown with negative
error bars only. Where not shown, error bars are smaller than the
symbol.
doi:10.1371/journal.pone.0054974.g007
Figure 8. Effect of pantetheinase supplementation on the
potency of a pantothenamide in aged Albumax-complete
RPMI. The concentration-response curves show the effect of increasing
concentrations of compound 12 on proliferation of P. falciparum
parasites cultured (for 96 h) in Albumax-complete RPMI as measured
using the SYBR Green I-based growth assay. Assays were performed
using (i) Albumax-complete RPMI incubated immediately after prepa-
ration at 37uC for 40 h (aged; closed circles); (ii) aged Albumax-
complete RPMI supplemented with recombinant human pantetheinase
(100 ng/mL) immediately prior to the assay (aged+pantetheinase; open
circles); (iii) aged Albumax-complete RPMI supplemented with recom-
binant human pantetheinase (100 ng/mL) and heated at 37uC for 40 h
immediately prior to the assay (aged+pantetheinase+heat; grey circles);
and (iv) aged Albumax-complete RPMI heated at 37uC for 40 h before
being supplemented with recombinant human pantetheinase (100 ng/
mL) immediately prior to the assay (aged+heat+pantetheinase; grey
squares). The data are from three independent experiments, each
performed in triplicate, and error bars represent SEM. For clarity, the
time-courses represented by the open circles are shown with negative
error bars only, and the time-courses represented by the grey squares
are shown with positive error bars only. Where not shown, error bars
are smaller than the symbol.
doi:10.1371/journal.pone.0054974.g008
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determined. Based on homology searches conducted using the
human pantetheinase sequences, the parasite genome appears
devoid of putative pantetheinase-encoding genes. This observa-
tion, and the finding that the parasite is sensitive to pantothena-
mide-mediated inhibition, suggests that the parasite is incapable of
pantetheine (and pantothenamide) hydrolysis. An alternative
strategy for determining the true potency of pantothenamides is
to test them in the presence of known pantetheinase inhibitors
[36]. However, as some pantetheinase inhibitors are also reported
to inhibit parasite growth (e.g. [40,41]) (presumably via non-
pantetheinase related mechanisms; e.g. [42]), such a strategy may
prove problematic.
The observed attenuating effect of pantothenate on the
antiplasmodial activity of pantothenamides in aged medium is
consistent with the growth inhibition resulting from inhibition of
pantothenate and/or CoA utilization, whether it be via inhibition
of (i) the uptake of pantothenate; (ii) the biosynthetic conversion of
pantothenate to CoA; or (iii) CoA-utilizing enzymes (by pantothe-
namide-derived CoA analogues). Notably, this is the first report of
compounds that inhibit growth of P. falciparum at sub-micromolar
concentrations by such a mechanism and, as such, this study
provides important further validation of pantothenate and CoA
utilization as potential antimalarial drug targets. Addition of
100 mM pantothenate was observed to alleviate growth inhibition
in the presence of pantothenamides to a much lesser extent than in
aged medium (Figure 4). To reconcile this finding, it is important
to consider that one of the products of pantothenamide hydrolysis
is pantothenate. For this reason, where pantothenamide hydrolysis
has occurred, the pantothenate concentration will have increased
from the initial 1 mM present in the medium. This will not only
attenuate the antiplasmodial effect of the pantothenamides, but
will mean that addition of 100 mM pantothenate will increase the
pantothenate concentration less than 100-fold. We did investigate
the possibility that the antiplasmodial effect observed in fresh
medium in the presence of pantothenamides was due to the
primary amines generated upon pantothenamide hydrolysis,
however, at least for the amines tested (those that should result
from hydrolysis of compounds 12, 17 and 19), little-to-no
inhibition was observed at a concentration of 200 mM (data not
shown).
We showed that all 22 pantothenamides tested inhibit P.
falciparum PanK-catalysed pantothenate phosphorylation, consis-
tent with the pantothenamides either inhibiting or serving as
alternate substrates of P. falciparum PanK. From the data presented
it is not, however, possible to discriminate between these two
possibilities. It has been shown previously that P. falciparum PanK
accepts pantothenol as a substrate for phosphorylation [43]. If
pantothenamides also serve as P. falciparum PanK substrates, it
should be investigated whether the resultant 4’-phosphopantothe-
namides are metabolized by P. falciparum CoA biosynthesis
enzymes downstream of PanK as they are by bacterial CoA
biosynthesis enzymes [17], and whether this has an effect on CoA
levels in the parasite. Inhibition of fatty acid biosynthesis (as a
result of inactivation of acyl carrier protein with pantothenamide
derived CoA analogues) has been implicated as a primary cause of
pantothenamide toxicity in E. coli [19]. As fatty acid biosynthesis is
not required during the pantothenamide-susceptible erythrocytic
stage of P. falciparum development [44,45] it is unlikely that the key
target of pantothenamides in P. falciparum is fatty acid synthesis.
For the SAR generated in this study (Figure 2) to inform future
pantothenamide design, it will be important to determine the
extent to which they reflect (i) relative efficacy against the target,
(ii) relative cell permeabilities (and/or susceptibility to efflux), (iii)
relative rates of pantetheinase-mediated hydrolysis, and (iv)
inactivation by other mechanisms including serum binding. In
light of the demonstration in this study that pantothenamides are
hydrolyzed by serum pantetheinase in vitro, it is likely that they will
also be subject to pantetheinase-mediated hydrolysis in vivo, and
thereby rendered ineffective as antiplasmodial agents in vivo.
Consistent with this, compound 12 had little-to-no effect on
parasite growth at concentrations up to 200 mM in the presence of
human serum (Figure 6A). Therefore to exploit the antiplasmodial
potency of pantothenamides it will be important to consider
strategies for circumventing pantetheinase-mediated hydrolysis
in vivo. This is also crucial for the future development of
pantothenamides as antibacterial agents, as serum stability will
be required for all but topical applications. One strategy is to
develop antiplasmodial (or antibacterial) pantothenamide ana-
logues that are resistant to degradation by pantetheinases by, for
example, using a bioisosteric replacement strategy [46,47] to
replace the key hydrolyzable amide bond. Another strategy for
circumventing pantetheinase-mediated pantothenamide hydrolysis
in vivo is to simultaneously inhibit host pantetheinase. Recently,
however, genetic studies in mice have provided evidence that a
reduction in pantetheinase activity increases susceptibility to
malaria, perhaps as a result of modulation of the inflammatory
response [48]. The design of pantetheinase-resistant pantothena-
mides may therefore be a preferable strategy for circumventing
pantetheinase-mediated degradation.
In conclusion, in this study we present, for the first time,
analogues of pantothenate that inhibit growth of P. falciparum at
sub-micromolar concentrations through inhibition of pantothenate
and/or CoA utilization, and propose the identification of
pantetheinase-resistant pantothenamide analogues as a viable
strategy for the discovery of antimalarial agents.
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ABSTRACT: Pantothenamides are secondary or tertiary amides of pantothenic acid, the vitamin precursor of the essential
cofactor and universal acyl carrier coenzyme A. A recent study has demonstrated that pantothenamides inhibit the growth of
blood-stage Plasmodium falciparum with submicromolar potency by exerting an effect on pantothenic acid utilization, but only
when the pantetheinase present in the growth medium has been inactivated. Here, we demonstrate that small modifications of
the pantothenamide core structure are sufficient to counteract pantetheinase-mediated degradation and that the resulting
pantothenamide analogues still inhibit the in vitro proliferation of P. falciparum by targeting a pantothenic acid-dependent
process (or processes). Finally, we investigated the toxicity of the most potent analogues to human cells and show that the
selectivity ratio exceeds 100 in one case. Taken together, these results provide further support for pantothenic acid utilization
being a viable target for antimalarial drug discovery.
KEYWORDS: Pantothenamide, antimalarial, pantothenic acid, coenzyme A, pantetheinase, drug metabolism
Nearly half the world’s population is at risk of contractingmalaria, a lethal infectious disease that is estimated to
have caused the deaths of more than half a million people in
2010 alone.1,2 Consequently, the search for new antimalarial
agents is an ongoing pursuit that has intensified since the
release of reports that Plasmodium falciparum, the most virulent
of the protozoan parasites that cause the disease in humans, has
become resistant to all chemotherapeutic agents currently in
use.3
One set of targets that has shown promise for antimalarial
drug discovery and development encompasses the processes
and pathways dependent on pantothenic acid (vitamin B5),
which serves as the biosynthetic precursor to the essential
metabolic cofactor and universal acyl carrier coenzyme A
(CoA).4 This is due to P. falciparum showing an absolute
requirement for exogenous pantothenic acid,5 and a sensitivity
to compounds that interfere with its ability to utilize this
vitamin. Structural analogues of pantothenic acid have shown
the most promise in this regard, with many being characterized
as growth inhibitors of the blood-stage parasite.6−8 However,
their exact point of action remains to be elucidated.
The pantothenamides are one class of such pantothenic acid
analogues that we have recently investigated for antiplasmodial
activity.9 These compounds are prepared by transforming the
carboxylic acid group of pantothenic acid to a secondary or
tertiary amide and have previously been studied as antibacterial
agents.10−17 While our initial growth inhibition experiments
seemed to indicate that these analogues only had modest in
vitro antiplasmodial activity against blood-stage P. falciparum,
we found this to be due to their degradation by enzyme(s)
present in the human serum (or the serum substitute, Albumax
II) that is used as a necessary supplement to the parasite culture
medium. The Vanin proteins, which are members of the
nitrilase superfamily, were identified as the probable responsible
agent.9 These proteins have pantetheinase activity, hydrolyzing
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the CoA metabolite pantetheine by means of an invariant Glu−
Lys−Cys catalytic triad to form pantothenic acid and the
antioxidant cysteamine.18,19 However, they tolerate a wide
range of structural modifications on the cysteamine moiety,
thereby explaining their ability to also degrade pantothena-
mides other than pantetheine (Scheme 1).20,21
We found the pantothenamides’ antiplasmodial potency to
be significantly enhanced when growth inhibition experiments
were performed using culture medium that had been preheated
(or aged) to remove most of the pantetheinase activity present,
with five of the compounds tested showing submicromolar IC50
values under these conditions. Among these, N-phenethyl
pantothenamide displayed the highest potency with an IC50 of
20 ± 2 nM,9 comparable to the IC50 of chloroquine when
measured against parasite strains sensitive to the drug.22
Moreover, we found the inhibitory effects of the pantothena-
mides to be attenuated in the presence of increased
concentrations of pantothenic acid, confirming that these
compounds act on pathways or processes dependent on this
vitamin.
The further development of pantothenamides as antiplasmo-
dials is therefore currently hampered by the ubiquitous
presence of Vanin proteins, especially by those found in
serum.19 One approach whereby this shortcoming can be
addressed is to combine pantothenamides with known
pantetheinase inhibitors.23,24 However, such a strategy would
eventually require the separate optimization of the properties of
two compound sets and may result in complications due to
adverse interactions between them, and/or inhibition of the
physiological function of pantetheinases.19 We therefore
decided to investigate an alternative approach in which the
pantothenamides are structurally modified in a manner that
would counteract pantetheinase-mediated degradation without
compromising their antiplasmodial activity.
A previously described series of modified pantothenamides
seemed ideally suited to test such an approach.16 This series
was prepared from pantothenic acid or one of two structural
analogues in which its β-alanine moiety is replaced with either
glycine (to give α-pantothenic acid) or γ-aminobutyric acid (to
give homopantothenic acid). A range of amines representing
four chemical motifs (i.e., primary alkyl amines, primary
heteroatom-containing aliphatic amines, primary amines with
substituents containing aromatic groups, and secondary cyclic
amines) was used to introduce the amide moiety into each of
these acids in parallel. In this manner, three sets of
pantothenamides were formed, referred to as α-pantothena-
mides (α-PanAm), n-pantothenamides (n-PanAm, where n
signifies normal), and homopantothenamides (HoPanAm),
respectively (Tables 1 and S1, Supporting Information).
Importantly, the structural modifications cause a displacement
in the pantothenamide amide bond in the α-PanAm and
HoPanAm series relative to its position in the n-PanAm series
by either the removal or addition of a methylene group. Since
previous studies showed that pantetheinase relies on the
pantothenoyl moiety of its substrate for recognition,20,21 we
expected that this displacement would reduce the scissile amide
bond’s susceptibility to attack by the Cys residue of the
enzyme’s catalytic triad and thereby prevent or reduce the rate
of the pantetheinase-mediated degradation of the α-PanAm and
HoPanAm series relative to that of the n-PanAm series.
We decided to determine whether members of the α-PanAm
and HoPanAm series are more resistant to pantetheinase-
mediated degradation compared to their n-PanAm counterparts
under in vitro conditions. This was tested directly by incubating
four sets of pantothenamides, each with a different type of
amide substituent, in the presence of recombinant human
pantetheinase. The amount of amine released under these
conditions was then determined periodically using a previously
developed fluorescamine-based fluorescence assay (Figure 1).9
After 24 h, the hydrolysis of the n-PanAm compounds was
found to be complete (data not shown), in agreement with our
previous findings.9 However, under the same conditions, the
hydrolysis of members of the α-PanAm and HoPanAm series
was between 5 and 15% complete, except in the case of the
PanAm-2 set where it approached ∼25%. This demonstrates
that displacing the pantothenamide amide bond in the n-
PanAm series confers resistance to pantetheinase degradation.
Next, we set out to determine whether the increased
pantetheinase resistance of the α-PanAm and HoPanAm
members (relative to the corresponding n-PanAm members)
also translated into increased antiplasmodial potency in the
presence of pantetheinase. The inhibitory activity of 47 sets of
α-PanAm, n-PanAm, and HoPanAm compounds was deter-
mined in vitro against intraerythrocytic P. falciparum (strain
3D7) in 96 h growth assays initiated with parasites
predominantly in the ring stage. For these tests, fresh
Albumax-complete RPMI culture medium was used, to ensure
the presence of pantetheinase activity.9 From the IC50 values
obtained in this manner (data for compounds showing IC50
values below 200 μM are given in Table 1; the complete data
set is given in Table S1, Supporting Information), it is clear that
displacement of the scissile amide bond in a n-PanAm
significantly improves its antiplasmodial activity (P < 0.05
and P < 0.01 for α-PanAm and HoPanAm members,
respectively, compared to n-PanAm members; unpaired t
test) as predicted. To confirm that the increased potency of
the α-PanAm and HoPanAm members is due to their resistance
to pantetheinase degradation, the antiplasmodial activity of 11
selected sets of α-PanAm, n-PanAm, and HoPanAm
Scheme 1. Pantothenamides and Their Degradation by the
Enzyme Pantetheinase (Vanin)a
aPantothenamides are amide analogues of pantothenic acid that are
susceptible to degradation by pantetheinase. The native function of
this enzyme is to hydrolyze the CoA metabolite pantetheine to
pantothenic acid and cysteamine (reaction in grey box).
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pantothenamides was tested in aged medium (i.e., medium
subjected to prolonged heat-treatment to reduce the
pantetheinase activity). The results show that, while the
potency of the n-PanAm members improve under these
conditions (consistent with our previous results9), the activity
of the α-PanAm and HoPanAm members determined in the
Table 1. Inhibitory Activity of Selected Pantothenamides on the in Vitro Proliferation of P. falciparum
aInhibition of the proliferation of P. falciparum cultured (for 96 h) in either fresh (i.e., freshly prepared) or aged (i.e., heat-treated to reduce
pantetheinase activity) Albumax-complete RPMI containing 1 μM pantothenic acid (see Supporting Information for details). Values represent the
mean ± SEM (or range/2) from at least two independent experiments, each performed in triplicate. bND, not determined. cValues taken from ref 9.
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presence and absence of pantetheinase is comparable (P > 0.05;
unpaired t test). Taken together, these results confirm that the
structural modification of pantothenamides is a viable approach
to confer resistance to pantetheinase degradation while at the
same time preserving antiplasmodial activity.
A comparison of the IC50 values determined for the various
pantothenamides in fresh medium reveals several interesting
trends (Figure 2). First, while the α-PanAm members show
variable antiplasmodial potencies, the majority of inhibitory
HoPanAm members have IC50 values below 10 μM, with the
most potent compound (HoPanAm-38) having an IC50 value of
1.1 ± 0.1 (mean ± SEM; n = 4). This highlights the elongation
of the β-alanine moiety of the n-PanAm series as the preferred
structural modification to counteract pantetheinase degradation
while maintaining antiplasmodial activity. Second, there does
not seem to be a clear structure−activity relationship between
the α-PanAm, n-PanAm, and HoPanAm series from the
perspective of an analysis that focuses on the amide substituent.
This would not be unexpected if all three series interacted with
the same target since the shortening or elongation of the β-
alanine moiety by one methylene unit would displace the amide
substituent relative to the pantoyl moiety that all three hold in
common. Therefore, one might predict that compounds that
have a similar but opposite modification in the amide
substituent would counteract these effects and should show
some correlation in potency. A case in point is the phenethyl-
substituted n-PanAm-29 that shows potent (20 ± 2 nM; mean
± SEM; n = 3)9 activity in aged medium. Displacement of the
phenyl group of n-PanAm-29 (as in the case of n-PanAm-30)
leads to a complete loss of activity (IC50 > 200 μM); in
contrast, the corresponding HoPanAm-30, which has an
extension that returns the phenyl group to the same relative
position as in n-PanAm-29, has an IC50 value of 4.7 ± 0.5 μM
(mean ± range/2; n = 2). Similar examples can be found
among the alkyl-substituted pantothenamides (Table 1, entries
3 and 4), suggesting that all three series of pantothenamides
interact with the same target(s).
We next set out to confirm that the α-PanAm and HoPanAm
members are on-target and, like n-PanAm members, affect
processes in P. falciparum dependent on pantothenic acid.9 This
was done by investigating the antimalarial activity of these
compounds in the presence of excess pantothenic acid (100
μM, compared to the 1 μM that is normally present in culture
medium). Concentration−response assays were conducted in
fresh culture medium with 25 compounds selected on the basis
of their antiplasmodial activity and structural diversity (Table
2). A significant increase (P < 0.01, unpaired t test) in IC50
values was observed for nearly all the compounds tested, with
potency reduced by >95-fold in one case. The only exceptions
were three α-PanAm members with aromatic substituents (α-
PanAm-36, -37, and -38) that showed significant but small (P ≈
0.01) or negligible shifts (P > 0.1). While the exact basis for this
difference is not clear, for the other α-PanAm and HoPanAm
members tested these results indicate that these compounds,
like the n-PanAm pantothenamides, exert their inhibitory
effects by affecting targets dependent on pantothenic acid. This
conclusion is strengthened further by the fact that the
HoPanAm members, which in general showed the highest
potency in fresh medium (Table 1), also showed the largest
fold shifts when the concentration of pantothenic acid was
Figure 1. Pantetheinase-mediated hydrolysis of the α-PanAm, n-
PanAm, and HoPanAm series of pantothenamides. Four sets of α-
PanAm, n-PanAm, and HoPanAm compounds (see Table 1 for
structures) were treated with recombinant human pantetheinase. After
24 h, the amount of amine released was determined by means of a
fluorescamine-based fluorescence assay. Values represent the mean
from three independent experiments, each performed in duplicate; the
error bars represent SEM. Asterisks above the bars indicate the
significance of the difference between the values determined for the
respective α-PanAm and HoPanAm series members and the n-PanAm
in a given set (** P < 0.005; *** P < 0.001, one way ANOVA). Note
that, since the fluorescence intensity of fluorescamine−amine
conjugates is dependent on the structure of the amine, the
fluorescence measurements are not necessarily comparable between
the different sets.
Figure 2. Structure−activity relationship analysis of the inhibitory
activity of selected pantothenamides on the in vitro proliferation of P.
falciparum determined in fresh medium. Graphical representation of
the data given in Table 1, highlighting the differences between the
activities of the α-PanAm, n-PanAm, and HoPanAm members, and the
influence of the structure of the amide substituent (structural group
descriptions are given above the graph) on potency. Symbols touching
the top of the graph represent compounds with IC50 values > 200 μM.
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increased. A discussion on the possible identity of these targets
is provided in the Supporting Information.
We finally also explored the potential utility of the 10 most
potent α-PanAm and HoPanAm members identified in this
study as antimalarial drugs by investigating their toxicity to
mammalian cells. This was done by determining their
concentration−response profiles against Jurkat cells (a human
leukemic T-cell line). The toxicity results (Table 3) show that
although no obvious trend was apparent for these compounds,
the selectivity indexes (the ratio of the IC50 values measured
against Jurkat cells to the IC50 values for the inhibition of P.
falciparum growth) of HoPanAm-3, -15, -18, -29, and -37
ranged from 40 to >100, indicating that at least these
pantothenamides should be considered for in vivo antimalarial
activity studies in a mouse model of malaria.
In conclusion, we have demonstrated in this study that
antiplasmodial pantothenamides can be structurally modified to
counteract their susceptibility to degradation by pantetheinase
while at the same time maintaining their on-target anti-
plasmodial activity. The good selectivity for parasite growth
inhibition (compared to human cell inhibition) of the most
potent pantetheinase-resistant pantothenamides identified
lends further support for continued focus on these antivitamins
as potential new antimalarials.
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